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Abstract 
Inflammation is a complex and highly organised immune response to microbes and 
tissue injury. Recognition of noxious stimuli by pathogen recognition receptor 
families including Toll-like receptors results in the expression of hundreds of genes 
that encode cytokines, chemokines, antimicrobials and regulators of inflammation. 
Regulation of TLR activation responses is controlled by TLR tolerance which 
induces a global change in the cellular transcriptional expression profile resulting in 
gene specific suppression and induction of transcription. In this thesis the plasticity 
of TLR receptor tolerance is investigated using an in vivo, transcriptomics and 
functional approach to determine the plasticity of TLR tolerance in the regulation of 
inflammation. Firstly, using mice deficient in the negative regulator of TLR gene 
transcription, Bcl-3 (Bcl-3
-/-
) in a model of intestinal inflammation, we investigated 
the role of Bcl-3 in the regulation of intestinal inflammatory responses. Our data 
revealed a novel role for Bcl-3 in the regulation of epithelial cell proliferation and 
regeneration during intestinal inflammation. Furthermore this data revealed that 
increased Bcl-3 expression contributes to the development of inflammatory bowel 
disease (IBD).  
Secondly, we demonstrate that lipopolysaccharide tolerance is transient and recovery 
from LPS tolerance results in polarisation of macrophages to a previously un-
described hybrid state (RM). In addition, we identified that RM cells have a unique 
transcriptional profile with suppression and induction of genes specific to this 
polarisation state. Furthermore, using a functional approach to characterise the 
outcomes of TLR tolerance plasticity, we demonstrate that cytokine transcription is 
uncoupled from cytokine secretion in macrophages following recovery from LPS 
xi 
 
tolerance. Here we demonstrate a novel mechanism of regulation of TLR tolerance 
through suppression of cytokine secretion in macrophages. We show that TNF-α is 
alternatively trafficked towards a degradative intracellular compartment. These 
studies demonstrate that TLR tolerance is a complex immunological response with 
the plasticity of this state playing an important role in the regulation of 
inflammation. 
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1. General Introduction 
1.1 Inflammation 
Inflammation is a complex and tightly regulated immunological response to 
pathogen invasion and tissue injury largely controlled by cells of the innate and 
adaptive immune system. Innate immune cells such as macrophages are central 
mediators of inflammatory responses through recognition of microbial pathogens 
and host tissue injury by different pathogen recognition receptor (PRR) families [1]. 
Following pathogen or injury recognition, production of soluble inflammatory 
mediators including cytokines, chemokines, enzymes, vasoactive peptides and 
amines, complement components and lipid mediators orchestrates leukocyte 
recruitment and migration to inflammatory tissue sites. This in turn activates 
cytotoxic and tissue remodelling innate and adaptive immune cells which ultimately 
clear infection, promote tissue repair and the resolution of inflammation [2]. While a 
robust microbicidal inflammatory response is critical to fighting infection, prolonged 
responses can have devastating tissue destructive effects. Excessive or uncontrolled 
inflammation can result in a pleiotropic range of chronic inflammatory and 
autoimmune diseases in addition to cancer, heart disease and diabetes. Thus a 
physiological adjustment of inflammatory responses is critical to promoting tissue 
homeostasis and resolution of inflammation post inflammatory challenge [2, 3]. 
1.2 Pathogen recognition 
Pathogen recognition is central to innate immunity and mediated through germ-line 
encoded pathogen recognition receptors found on both immune and non-immune 
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cells. These receptors include Toll-like receptors (TLRs), RIG-I-like receptors 
(RLRs), nucleotide-binding oligomerization domain (NOD-like) receptors (NLRs) 
and C-type lectin receptor (CLRs) families which recognise a vast repertoire of 
microbial pathogen associated molecular patterns (PAMPS) and tissue derived 
danger associated molecular patterns (DAMPS) [1, 4-6]. PRRs can be soluble or 
membrane bound however they are limited in number in contrast to the number of 
stimuli that they recognise. Soluble PRRs include pentraxins, collectins, ficolins and 
complement which recognise and bind to foreign molecules which are then cleared 
by opsonic mediated phagocytosis by host phagocytic cells [7]. Membrane bound 
PRRs directly bind microbes or tissue injury signals and can be found at both the cell 
surface and intracellular compartments. Furthermore PRRs have the ability to 
discriminate between different microbial species including bacteria, viruses, 
parasites and fungi. This further extends to discrimination between RNA and DNA 
viruses, gram negative and gram positive bacteria in addition to bacterial flagellin  in 
order to mediate tailored and stimulus specific immune responses [1, 6] (Table 1.1 
and Figure 1.1)  
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Figure 1.1: Pathogen recognition receptors 
C-type lectins (DC-SIGN, Dectin-1, siglecs) and scavenger receptors (CD36, mannose receptor - MR, 
scavenger receptor A - SR-A, macrophage receptor with collagenous structure - MARCO) and 
complement receptors (CR3). TLRs, NLRs, RLRs, opsonic receptors (Fc receptors). Surface 
receptors; activating receptors - EGF-TM7 (epidermal growth factor seven transmembrane receptor), 
TREM-1 (triggering receptor expressed on myeloid cells – 1), inhibitory receptors - CD200. [8] 
 
 
1.3 Toll-like receptors  
Toll-like receptors (TLRs) are the most extensively studied and widely characterised 
family of PRRs. TLRs are evolutionary conserved type 1 transmembrane proteins 
homologus to the protein TOLL in Drosophila [9]. TOLL was originally found to be 
important for dorso-ventral polarity in drosophila embryonic development with its 
cytoplasmic domain later found to be important in anti-fungal responses [10]. This 
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cytoplasmic Toll/interleukin-1 (IL-1) receptor (TIR) domain region of TOLL shares 
amino acid homology with the interleukin 1 receptor (IL-1R) and is important for 
NF-κB activation. It was in 1997 that the mammalian homologue hTOLL (TLR4) 
was cloned and shown to be involved in NF-κB activation and inflammatory gene 
expression [11]. 
Discovery of the human TOLL homologue has since led to the discovery of 12 TLRs 
in mice and 10 in humans. Structurally, TLRs contain an ectodomain rich in leucine 
repeats which recognises a variety of PAMPs and DAMPS, a transmembrane 
domain and cytoplasmic TIR domain which mediates downstream signalling and 
transcriptional events. TLR1, TLR2, TLR4, TLR5 and TLR6 are embedded in the 
plasma membrane at the cell surface and recognise microbial components expressed 
on their surface. TLRs are the most extensively studied PRR in innate immunity 
which recognise a variety of fungal (mannan), viral (envelope proteins, RNA and 
DNA), bacterial (lipopolysaccharide (LPS), lipotechoic acids, peptidoglycan and 
DNA) and host DAMPS (heat shock proteins and fibrinogen) (Table 1.1). TLR4 
primarily recognises LPS, an outer membrane cell wall component of gram negative 
bacteria. TLR4 also recognises mannan, heat shock proteins and fibrinogen. TLR2 is 
important for detection of gram positive bacteria. It recognises peptidoglycan (PGN) 
and lipotechoic acid, lipoarabinomannan and zymosan from mycobacterium and 
fungi in addition to hemagglutinin protein from measles virus. TLR2 can form 
heterodimers with TLR1 and TLR6 to detect microbial triacylated and diacylated 
lipoproteins respectively. TLR5 specifically recognises flagellin while its closely 
associated murine family member TLR11 recognises uropathogenic bacteria and 
profilin like molecules (Table 1.1) [1, 12, 13].   
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TLR3, TLR7, TLR8 and TLR9 specifically recognise RNA and DNA viruses; 
therefore these TLRs are strategically located within cytosolic compartments such as 
endosomes and lysosomes to detect nucleic acids from virally infected cells. TLR7 
and TLR8 are closely related and recognise single stranded RNA (ssRNA) viruses 
such as Influenza A and HIV while TLR9 recognises unmethlyated CpG DNA 
motifs found in viruses and bacteria but not in mammals. TLR3 specifically 
recognises double stranded RNA (dsRNA) viruses and signals through a distinct 
signally pathway from all other TLRs to mediate robust antiviral responses (Table 
1.1) [1, 12, 13].  
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Table 1.1: Pathogen Recognition Receptors and ligands 
Source PAMP TLR PRR 
Bacterial Triacyl Lipopeptides TLR1/TLR2  
 Diacyl Lipopeptides TLR6/TLR2  
 LPS TLR4  
 Lipotechoic acid TLR2 NOD1/NOD2 
 Peptidoglycan TLR2 NOD1/NOD2 
 Flagellin TLR5  
 DNA TLR9 AIM2 
 Lipoarabinomannan TLR2  
 Porins TLR2  
 Uropathogenic bacteria TLR11  
Viral dsRNA TLR3 RIG-I, MDA5, LGP2 
 ssRNA TLR7 & TLR8 RIG-I, MDA5, LGP2 
 DNA TLR9 AIM2 
 Envelope proteins TLR4  
 Hemagglutinin TLR2  
Fungal Profilin like molecules TLR11  
 Glycoinositolphospholipids TLR4  
 Mannan TLR2/4  
 Zymosan TLR2/6 Dectin1 
 Phospholipomannan TLR2  
 Hemozoin TLR9  
Host HSP TLR4  
 Fibrinogen TLR4  
 
 
1.4 Lipopolysaccharide and TLR4 signalling  
Lipopolysaccharide (LPS) is a complex glycolipid of gram negative bacteria and an 
extremely potent activator of innate immune responses towards microbial infections. 
TLR4 recognition of LPS requires a number of co-factors to facilitate effective 
recognition and activation. LPS is transported in the blood by LPS binding protein 
(LBP), a soluble plasma carrier protein that binds the glycosylphosphatidylinositol 
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linked protein, CD14. The interaction between CD14 and LBP facilitates the 
recognition of LPS by the TLR4 - myeloid differentiation factor 2 (MD2) complex 
thereby conferring TLR4 responsiveness to LPS [14-17]. Park et al demonstrated 
that successful TLR4 activation requires five of the six LPS lipid chains to bind the 
hydrophobic region of MD2 [18]. This intricate interaction results in stabilisation of 
the LPS-TLR4-MD2 complex, dimerisation and activation of the receptor complex 
and subsequent downstream TLR signalling [18].  
1.5 MyD88 dependent pathway 
TLR inducible immunological responses are tailored according to specific TLR 
activation signals by PAMPs or DAMPs. TLR3 TLR7, TLR8 and TLR9 recognise 
viral RNA and DNA and drive anti-viral immunity though induction of interferon 
response genes. TLR1/TLR2, TLR6/TLR2 and TLR5 mainly mount pro-
inflammatory cytokine responses. All TLRs except TLR3 exclusively signal through 
an adaptor protein MyD88, which leads to a robust activation of pro-inflammatory 
cytokine production through activation of NF-κB and mitogen activated protein 
(MAP) kinase gene expression. In addition TLR4 is the only TLR that can utilise 
both MyD88 dependent and independent pathways further emphasising the robust 
immunological potential of TLR4 signalling responses towards infection [12, 13, 
19].  
Activation of all TLRs signalling events requires the recruitment of a combination of 
TIR domain adaptor proteins. These include MyD88, TRIF, TIRAP (MAL), TRAM 
and the recently identified adaptor protein SARM [20]. The activated TLR signalling 
complex recruits MyD88 to the plasma membrane through TIR domain interactions 
facilitated by the bridging adaptor molecule TIRAP. MyD88 interacts through death 
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domain interactions with IRAK4 leading to its activation. IRAK4 phosphorylates 
IRAK1 and IRAK2, both of which detach from this adaptor group and form a new 
complex with TRAF6, an E3 ubiquitin ligase and an E2 ubiquitin enzyme complex 
composed of Ubc13 and Uev1. This E2 complex is responsible for mediating K63 
mediated poly-ubiquitination of TRAF6 and generation of a free unconjugated 
polyubiquitin chain which leads to recruitment of another complex comprising of 
TAK1, TAB1, TAB2 and TAB3. TAK1 is an IKK kinase and therefore 
phosphorylates specific serine residues on IKKβ in the IKK complex involved in 
NF-κB activation. Activated IKKβ phosphorylates and targets the predominant IκB 
protein IκBα for proteosomal degradation by triggering K48 polyubiquitination. 
Degradation of IκBα allows movement of the transcription factor NF-κB into the 
nucleus to promote the transcription of pro-inflammatory mediators. In addition, 
TAK1 phosphorylates MAP kinase 6 which in turn leads to activation of JNK and 
p38 stress response pathways and subsequent activation of the transcription factor 
AP1 [12, 13, 21] (Figure 1.2). 
Deficiencies in these signalling adaptor molecules results in altered immunological 
responses and subsequently increased susceptibility to microbial infections. MyD88 
and TIRAP deficient
 
mice display reduced NF-κB inducible pro-inflammatory gene 
expression in response to LPS activation [22, 23]. Furthermore, MyD88 deficiency 
renders mice highly susceptible to the development of intestinal inflammation and 
colitis [24]. Similarly, IRAK4 deficiency leads to defective IL-1 and TLR signalling 
[25, 26]. Interestingly, deficiency in MyD88 identified a MyD88 independent 
pathway downstream of TLR4 which led to the induction of type 1 interferons and 
delayed NF-κB gene expression [27]. 
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1.6 MyD88 independent pathway 
The MyD88 independent TLR signalling pathway employs the adaptor and TIR 
domain protein TRIF. TRIF dependent signalling is utilised by TLR3 to activate 
interferon gene expression tailored specifically towards viral infection. However 
TRIF signalling is not exclusively employed by TLR3 as TLR4 can also signal 
though TRIF independently of MyD88 to mediate both pro-inflammatory and 
interferon responses. Activated TLR3 can directly interact with TRIF through its TIR 
domain, however TLR4 requires an additional bridging adaptor protein, TRAM to 
mediate TLR4 interactions with TRIF. TRIF interacts with TRAF3 and TRAF6 in 
addition to RIP1 through its RIP homotypic interaction motif (RHIM). A complex 
comprising of TRAF6, RIP1, pellino and TRADD is required for activation of the 
IKK kinase TAK1, which in turn leads to activation of the IKK complex and 
subsequently NF-κB and MAP kinase activation. TRIF signalling also gives rise to 
the induction of interferon response genes through the transcription factor IRF3. 
TRAF3 is responsible for activating TBK1 and IKKi which are responsible for 
phosphorylation of IRF3 and IRF7 and subsequent transcription of type 1 interferons 
[1, 12, 13, 21] (Figure 1.2). Deficiencies in TRIF signalling can lead to significant 
impairment in anti-viral responses through repression of IRF3 and IFNβ production 
[28]. 
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Figure 1.2: TLR signalling pathways 
MyD88 dependent and MyD88 independent (TRIF) TLR signalling pathways are utilised by different 
TLRs. TLR4 uses both pathways to activate pro-inflammatory cytokines through NF-κB and stress 
response pathways (p38 and JNK). Interferon inducible genes are activated by both NF-κB and IRF3 
[9]. 
 
1.7 Negative regulation of TLR induced inflammation 
TLR signalling induces a rapid yet tailored and robust immune response towards a 
broad repertoire of stimuli. However uncontrolled and excessive TLR signalling can 
have devastating pathological consequences. Excessive TLR signalling and 
subsequent transcription of cytokines and chemokines can result in induction of 
unregulated cellular recruitment of innate immune cells such as neutrophils, TNF-α 
induced cellular apoptosis in addition to excessive production of reactive oxygen and 
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nitrogen species all which can result in tissue and organ damage. This necessitates 
the need for strict control of TLR signalling responses to maintain immune 
homeostasis. To limit host tissue damage, TLR inflammatory responses are 
controlled by a number of molecular processes that include inhibition of signal 
transduction and repression of gene transcription (Table 1.2 and Figure 1.3) [29-32].  
1.7.1 Negative regulators of TLR signalling 
Soluble decoy receptors target the early stages of TLR signalling by altering TLR 
activation and therefore represent one of the first lines of negative regulation of TLR 
signalling [31]. sTLR4 has been proposed to directly attenuate TLR activation and 
downstream signalling events by blocking the interaction between TLR4 and the 
accessory proteins MD2 and CD14 [33, 34]. In support of this, sTLR2 and sTLR4 
have been shown to reduce NF-κB activation and pro-inflammatory gene expression 
[29].  ST2 is a type 1 transmembrane bound glycoprotein and negative regulator of 
both TLR4 and IL-1R1 signalling which sequesters the adaptor proteins MyD88 and 
TIRAP preventing their recruitment to the activated TLR complex. Moreover, ST2 
deficient mice were found to be hyperresponsive towards repeated challenges with 
LPS and failed to develop LPS tolerance, a protective regulatory response towards 
repeated challenges with LPS [35, 36]. Similar to ST2, the orphan receptor SIGIRR 
(TIR8) has been demonstrated to prevent adaptor protein recruitment to the TLR 
receptor with increased MyD88 dependent NF-κB activation measured in SIGIRR 
deficient mice [37]. SIGIRR is a negative regulator of both TLR and IL-1R1 
signalling but it is only the TIR domain of SIGIRR that has been shown to be 
specific for interaction with IRAK1 and TRAF6 in TLR signalling [38].  
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In addition to SIGIRR and ST2 there are many more negative regulators which affect 
adaptor protein recruitment to the TLR adaptor protein complex. IRAK-M is an 
inducible intracellular negative regulator of both IL-1 and TLR signalling which 
inhibits IRAK1 and IRAK4 dissociation from MyD88 by preventing them from 
forming a complex with TRAF6, required for downstream activation of TLR 
signalling. IRAK-M
-/- 
mice and macrophages are hyperresponsive towards both 
TLR/IL-1 stimulation and display a defect in LPS tolerance similar to that of ST2 
deficient mice [39]. Reduced IRAK-M expression in germ-free mice highlighted the 
importance of IRAK-M in regulation of intestinal immune responses towards the 
intestinal microbial community [40]. Furthermore a number of conditions including 
asthma and cystic fibrosis have been associated with a loss of function mutations for 
IRAK-M which further supports its role as an important upstream negative regulator 
of TLR signalling [41, 42]. In addition, the TLR and IL-1 signalling negative 
regulator Tollip directly interferes with IRAK1 inhibiting its phosphorylation and 
kinase activity [43, 44]. Similarly, MyD88s has been demonstrated to inhibit the 
phosphorylation of IRAK1 by IRAK4 thereby inhibiting downstream signalling and 
NF-κB activation [45, 46]. Sterile-alpha and armadillo-motif containing protein 
(SARM) represents another negative regulator of the MyD88 independent TLR 
pathway. SARM is a TIR domain adaptor protein which inhibits the essential adaptor 
protein TRIF with its mechanism unknown [20].  
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Table 1.2: Negative regulators of TLR signalling 
Site Negative regulator Target  
Signalling ST2 MyD88, TIRAP  
 SIGIRR IRAK1, TRAF6  
 IRAK-M IRAK1, IRAK4 MyD88  
 TOLLIP IRAK1  
 MyD88s IRAK1/IRAK4  
 sTLR2/sTLR4 TLR receptor complex  
 SARM TRIF  
 A20 TRAF6  
 USP4 TRAF6  
 CYLD TRAF6/TRAF7  
 SHP2 TRIF/TBK1  
 SOCS1 TIRAP, MAPK, p38, JNK  
 PDLIM2 p65  
 TRIM30α/TRIM38 TAB2/TAB3/TRAF6  
 IL10, TGFβ IRAK1, IRAK4, ↑negative regulators  
 IL1RA IL1R signalling  
 TGF-β ↑ SHIP1  
 PI3K  TLR9 signalling  
 ATG16L ROS, IL1 signalling  
 IRF4/IRF5 MyD88  
 TIPE2 Activating protein 1 (NF-Kb)  
    
Transcription Bcl-3 p50 homodimers  
 IκBNS NF-κB target genes  
 Nurr1 p65 bound promoters  
 Ahr Pro-inflammatory gene expression  
 Micro-RNAs Repress transcription  
 ATF3 chromatin  
    
 
Phosphorylation and ubquitination events play an important role in shaping a tailored 
TLR induced response following pathogen recognition. Therefore it is not surprising 
that post-translational modifications play a central role in negative regulation of TLR 
signalling [30]. The deubiquitinating enzyme A20 is a TLR inducible negative 
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regulator of both MyD88 dependent and independent TLR induced responses 
through removal of K63 linked polyubiquitin chains on activated TRAF6 [47]. A20 
also regulates TLR3 signalling by preventing IRF3 dimerisation [48] in addition to 
negatively regulating TNF signalling [49] and NOD2 signalling [50] through 
removal of K63 polyubiquitin chains on RIP proteins. Furthermore, A20 has been 
associated with a number of inflammatory diseases, with A20 deficiency in 
enterocytes and dendritic cells implicated in the development of spontaneous 
inflammation including colitis [51, 52]. Additionally loss of function polymorphisms 
are associated with rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE) [53, 54]. 
Similarly to A20, ubiquitin specific peptidase 4 (USP4) negatively regulates TLR 
signalling by removing ubiquitin chains from TRAF6 and a deficiency in USP4 
leads to an increase in pro-inflammatory cytokines upon LPS and IL-1 stimulation 
[55]. Moreover while the deubiquitinylating enzyme cylindromatosis protein 
(CYLD) has been identified as a negative regulator of NF-κB and the IκB protein 
Bcl-3, it also plays a role in negatively regulating TLR2 signalling by 
deubiquitinating TRAF6 and TRAF7 [56, 57]. In addition Src homology 2 domain-
containing protein tyrosine phosphatase 2 (SHP2) has been shown to be a negative 
regulator of TRIF dependent pathways by targeting TBK1. This was supported by 
SHP2 knockdown studies in macrophages which resulted in increased IFN-β 
production [58].  
Suppressor of cytokine signalling 1 (SOCS1) is an important negative regulator of 
TLR signalling due to its multiple targets of regulation. SOCS1
-/- 
mice are 
hypersensitive to LPS stimulation and produce more IFN-γ than their WT 
counterparts [31, 32]. This has been associated with influencing susceptibility to 
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endotoxin shock [59, 60]. SOCS1 inhibits the JAK-STAT pathway and suppresses 
NF-κB activation by targeting the adaptor protein TIRAP in addition to binding to 
the NF-κB member p65 targeting them for ubiquitination and subsequent 
degradation [61]. Furthermore, SOCS1 also regulates stress response MAP kinase, 
JNK and p38 pathways [61]. Moreover, deficiencies in TAM (Tyro3, Axl and MER) 
receptors have been shown to lead to a reduction in SOCS1 expression and 
subsequently an increase in cytokine secretion [62]. In addition, TRIM30α was 
identified as an important negative regulator of TLR signalling with both in vitro and 
in vivo studies emphasising its importance in protection against endotoxin shock 
[63]. TRIM30α negatively regulates TLR signalling by targeting TAB2 and TAB3 of 
the TAK1-TAB2-TAB3 complex for degradation and therefore inhibiting the 
activation of NF-κB [63]. Furthermore the TRIM38 family member has also been 
shown to act as a negative regulator of TLR signalling by targeting TRAF6 for 
proteosomal degration following its poly-ubquitination by TRIM38 [64]. 
Negative regulation of TLR signalling can be brought about through the expression 
of soluble mediators including IL-10, TGF-β and IL-1RA. TGF-β and IL-10 are anti-
inflammatory mediators of TLR signalling and deficiencies in IL-10 or TGF-β 
renders mice more susceptible to developing colitis [65]. IL-10 reduces pro-
inflammatory gene expression resulting from degradation of IRAK1 and IRAK4 in 
addition to altering macrophage antigen presentation capacity [66]. Furthermore IL-
10 expression leads to an increase in a number of negative regulators of TLR 
signalling including IL-1RA, SOCS3 and Bcl-3 in addition to increased activity of 
STAT3 and PI3K pathways [32, 67, 68]. TGF-β alters pro-inflammatory gene 
expression by altering NF-κB activation and leading to an increase of an additional 
negative regulator SHIP1 with SHIP1
-/- 
macrophages defective in endotoxin 
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tolerance [69]. Moreover TGF-β has been shown to play an important role in 
dampening MyD88 dependent TLR signalling pathways by inducing the 
ubiquitination and subsequent degradation of MyD88 [70]. Furthermore, deficiency 
in IL-1RA rendered mice highly susceptible to endotoxin shock with altered IL-1R 
signalling decreasing pro-inflammatory cytokine production [71]. 
In addition to the expression of soluble mediators, components of other cellular 
signalling pathways play a role in regulating TLR responses. The induction of PI3K 
has been shown to play a role in negative regulation in response to TLR9 signalling 
[29].  A loss of Atg16L1, a component of the autophagy pathway is associated with 
increased risk of inflammatory bowel disease in addition to elevated production of 
reactive oxygen species and IL-1 signalling suggesting it plays a regulatory role in 
response to TLR signalling [72]. Furthermore competition between the transcription 
factors IRF4 and IRF5 for the adaptor protein MyD88 represents another level of 
complexity to negative regulation of TLR signalling with IRF4 affecting IRF5 
transcription [30, 73]. In addition TIPE2 was identified as a negative regulator of 
TLR signalling though caspase 8 activity with TIPE2 deficiency resulting in a state 
of cellular hyperresponsiveness [74]. The large number of negative regulators and 
the extent of different modes of negative regulation demonstrate the complexity of 
the TLR signalling pathway and the necessity to tightly control TLR responses to 
generate an appropriate tailored immune response. 
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Figure 1.3: Negative regulators of TLR signalling 
Negative regulators of MyD88 and TRIF dependent TLR pathways through inhibition of TLR signal 
transduction and TLR inducible gene transcription mechanisms. Adapted from Kondo et al, 2011[30] 
 
1.7.2 Negative regulators of TLR gene transcription 
Transcriptional analysis of TLR4 induced gene expression reveals a large number of 
LPS inducible genes which can be divided into different subgroups dependent on 
their function. The array of functions ranging from pro-inflammatory, anti-
inflammatory, anti-microbial, tissue remodelling, wound repair and metabolic 
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suggests that these genes are differentially regulated dependent upon their 
requirements for immunological or normal physiological responses [75]. 
Transcriptional regulation of TLR signalling involves a number of mechanisms 
including the expression of negative regulators affecting transcription, in addition to 
gene specific regulation at individual promoters by chromatin remodelling and 
histone modifications [29, 30, 32, 61, 75].  
1.7.2.1 Transcriptional factors 
The negative regulator Nurr1 was shown to be involved in terminating NF-κB 
responses in microglia cells of the central nervous system (CNS) in a negative 
feedback system. Nurr1 was shown to be recruited to p65 on inflammatory gene 
promoter sites which in turn led to the recruitment of a CoREST repression complex 
resulting in termination of NF-κB transcriptional responses [76]. The aryl 
hydrocarbon receptor (AhR) transcription factor is a LPS inducible transcriptional 
negative regulator of TLR induced responses with AhR deficiency in mice resulting 
in increased susceptibility to LPS induced lethal shock. Furthermore AhR
-/-
 
macrophages are hyperresponsive following LPS stimulation resulting in increased 
production of TNF-α and IL-6 pro-inflammatory cytokines [77]. Moreover 
transcriptional regulation by AhR was shown to require the transcription factor 
STAT1, with deficiency in STAT1 and AhR leading to further increased IL-6 
production. It has been demonstrated that the activity of the IL-6 promoter was 
affected by an inhibitory complex composed of NF-κB, STAT1 and the Ah Receptor 
in TLR4 stimulated macrophages resulting in decreased LPS induced IL-6 gene 
expression [77].  
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1.7.2.2 MicroRNAs 
MicroRNAs (miRNA) represent another level of complexity to transcriptional 
regulation of TLR signalling. miRNAs are short (22nt) non-coding evolutionarily 
conserved molecules which regulate a number of biological processes post 
transcriptionally [78]. miRNAs have been shown to play a role in regulating immune 
responses. miR-146a, miR-155 and miR-132/-212 are induced upon TLR activation 
and lead to the repression of pro-inflammatory gene transcription in a negative 
feedback loop [78]. miR-146a inhibits IRAK1 and TRAF6 thus inhibiting NF-κB 
activation and pro-inflammatory gene expression. miR-146a deficiency has 
demonstrated NF-κB dysregulation. Mice deficient in miR-146a are hyperresponsive 
and polymorphisms have been identified in inflammatory conditions including 
rheumatoid arthritis. [30, 79].  
More recently, a bioinformatics target scan approach revealed miR-132 and miR-212 
(miR-132/-212) as miRNAs that target IRAK4. This revealed that miR-132/-212 was 
induced by peptidoglycan, Pam3CSK4 and flagellin in a cREB dependent manner 
where it promoted tolerance to TLR stimulation. miR-132/-212 was shown to be 
induced rapidly upon TLR stimulation and to target the adaptor protein kinase 
IRAK4 [80]. In addition, miR-21 was identified as another negative regulator of 
TLR4 signalling where it was shown to target the tumour suppressor PDCD4 thereby 
inhibiting pro-inflammatory gene expression and promoting the expression of IL-10 
[81]. Furthermore miR-155 plays a dual role in the regulation of TLR immune 
responses. While miR-155 positively regulates TLR induced responses by repressing 
SHIP1 [82], it plays a crucial role in negatively regulating TLR responses by 
targeting TAB2, IKKι and MyD88 [83, 84]. 
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1.7.2.3 Chromatin remodelling 
Chromatin remodelling plays an essential role in regulating TLR induced gene 
transcription by modifying DNA containing chromatin structures making promoter 
regions of DNA accessible or inaccessible to the transcriptional machinery. Histone 
modifications are the principal epigenetic modifications associated with chromatin 
remodelling in response to LPS signalling. Histone proteins which package 
chromatin structures are subject to addition or removal of acetylation, methylation, 
phosphorylation and ubiquitination markers by a number of different enzymes 
including histone acetlytransferases, demethylases, kinases and methyltransferases. 
The addition or removal of histone modifications determines the accessibility of 
promoter regions to transcription factors and additional transcriptional machinery 
[85]. Regulation of TLR induced responses during LPS tolerance was recently 
shown be regulated by chromatin remodelling with the inhibitory histone 
methylation mark H3K27 observed on pro-inflammatory genes. This inhibitory 
histone modification prevented pro-inflammatory gene promoter accessibility to the 
transcriptional machinery resulting in repression of gene expression [75, 85]. ATF3 
is a member of the CREB/ATF family of transcription factors with ATF3
-/-
 
macrophages displaying increased gene expression of IL-6 and IL-12p40 following 
TLR4 stimulation with LPS. ATF3 has been shown to bind to acetylation sites 
within chromatin structures resulting in recruitment of the histone deacetylase 
HDAC1. ATF3 negatively regulates gene expression by facilitating an alteration in 
the chromatin conformational structure resulting in an inhibition of access of 
activating transcription factors to gene promoter sites [86, 87].  
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1.7.2.4 Additional transcriptional regulators of TLR gene transcription 
PDLIM2, a PDZ and LIM domain protein targets the p65 NF-κB subunit for 
proteosomal degradation thereby negatively regulating NF-κB activation. PDLIM2-/- 
mice displayed increased NF-κB activation and are hyperresponsive towards TLR 
stimulation. PDLIM2 binds to p65 in the nucleus and promotes K48-linked 
polyubiquitination resulting in sequestering of p65 to PML nuclear bodies followed 
by subsequent degradation [88]. IκBNS is a member of the IκB inhibitory proteins 
which negatively regulates gene expression of pro-inflammatory genes including IL-
6 and IL-12p40 but not TNF-α or IRF3 target genes. IκBNS deficient mice are 
susceptible to endotoxin shock and intestinal inflammation with IκBNS deficient 
macrophages displaying increased NF-κB activation. Therefore IκBNS represents a 
selective transcriptional negative regulator of NF-κB target genes [89].  
1.8 B cell Leukemia-3 in inflammation and immunity 
B cell leukemia-3 (Bcl-3) is an atypical member of the IκB family which regulates 
NF-κB transcription [90]. Bcl-3 is predominantly nuclear in localisation and is not 
degraded upon activation of the IKK complex. Bcl-3 selectively binds the REL 
homology domain region of p50 and p52 homodimers through its ankyrin repeat 
domain thereby modulating NF-κB gene transcription. Bcl-3 was originally 
identified in a subset of chronic lymphocytic leukaemia (B-CLL) patients containing 
a recurring t(14:19) chromosomal translocation [91, 92]. As a result Bcl-3 has since 
been implicated in cell survival and tumorigenesis [93-96]. Increased expression of 
NF-κB subunits in addition to Bcl-3 was observed in breast cancer tumours and 
epithelial cancer cells [97, 98]. Additionally, a loss of function mutation in the 
CYLD gene which negatively regulates Bcl-3 expression is associated with benign 
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skin tumours, cylindromas [56, 99]. Bcl-3 has been shown to play an important role 
in cell survival. Bcl-3 deficient T cells demonstrated reduced survival while over-
expression of Bcl-3 increased T cell survival [100-102]. Bcl-3 is a regulator of cyclin 
D1 and is important in cell cycle regulation. Over-expression of Bcl-3 has been 
shown to shorten the G1 phase of cell cycle in breast cancer epithelial cells which 
coincided with elevated cyclin D1 expression levels [96]. Bcl-3 also regulates 
HDM2, an inhibitor of p53 induced apoptosis by promoting its expression [103]. 
Bcl-3 has also been shown to play a critical role in immunological development, the 
negative regulation of autoreactive thymocytes and altering T cell responses [104, 
105]. Bcl-3 deficient mice revealed impaired differentiation of naïve T helper cells 
into Th2 immune cells as a result of a lack of the transcription factor GATA3 
expression and subsequent induction of IL-4 [106]. In addition, Bcl-3 deficient mice 
were found to display defects in lymphoid organogenesis including a defective 
follicular dendritic cell network, reduced germinal centre formation and secondary 
lymphoid organ development including reduced numbers of Peyer’s patches and 
defective lymph node structure. [104, 107, 108]. Bcl-3 has recently been shown to 
play a regulatory role by limiting granulopoiesis under inflammatory conditions with 
Bcl-3 deficient myeloid progenitors demonstrating increased granulocyte 
proliferation and differentiation [109]. Furthermore, Bcl-3 deficiency in 
haematopoietic cells led to increased susceptibility of mice to develop diabetes. In 
this study Bcl-3 was shown to play a regulatory role in autoimmune diabetes by 
limiting pro-inflammatory cytokine and chemokine gene expression [110]. 
Bcl-3 is an important negative regulator of TLR and NF-κB induced responses. Bcl-
3 is essential for induction of TLR tolerance and Bcl-3
-/- 
mice and macrophages are 
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hyperresponsive to TLR stimulation and are defective in LPS tolerance. Furthermore 
Bcl-3 deficiency revealed increased susceptibility of mice to endotoxin shock 
resulting from uncontrolled pro-inflammatory gene expression at the transcriptional 
level. Bcl-3 negatively regulates NF-κB gene expression by stabilising inhibitory 
p50 homodimers at κB promoter sites of pro-inflammatory genes by inhibiting p50 
ubiquitination and subsequent proteasomal degradation. This in turn prevents 
activating NF-κB heterodimers (p65/p50) from occupying NF-κB gene promoter 
sites and promoting transcription [111]. Additionally Bcl-3 deficiency in mice led to 
increased susceptibility to microbial infections with Klebsiella pneumoniae, 
Streptococcus pneumoniae and Listeria monocytogenes [68, 108, 111, 112]. Thus, 
Bcl-3 plays an important role in inflammation, immunological development and cell 
cycle however it is critical in negatively regulating TLR signalling and TLR induced 
gene expression. 
1.9 LPS Tolerance – historical and physiological perspective 
Paul Beeson first identified the novel phenomenon of LPS tolerance as a 
physiological adaptation following inflammatory challenge in the 1940’s. Beeson 
demonstrated that rabbits displayed a reduction in fever following repeated 
challenges with typhoid vaccine and induced a state of tolerance towards repeated 
exposure [113]. This was one of the first pieces of evidence that the inflammatory 
response adapts to limit the deleterious consequences of excessive inflammation. 
This was later repeated with endotoxin (LPS) which demonstrated similar 
suppressed responses to the typhoid vaccine findings. Beeson defined this 
physiological immune adaption as endotoxin tolerance. He postulated that the cells 
of the reticuloendothelial system were involved in promoting tolerance towards 
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endotoxin with this state later demonstrated to be transferrable from one animal to 
another [114-116]. In support of this pioneering work, patients recovering from 
polynephritis, malaria, typhoid and paratyphoid fever displayed reduced fever 
responses when challenged with endotoxin [117]. Furthermore reports suggested this 
protective phenomenon was used in fever therapies over 100 years ago to treat 
neurological related illnesses such as depression [118].  
Following Beesons pioneering work, Freudenberg and Galanos demonstrated that a 
pre-stimulation with LPS protected mice against lethal doses of LPS even when LPS 
responsiveness was increased upon galactosamine treatment [119]. Importantly, they 
elegantly demonstrated that monocytes and macrophages were responsible for 
mediating tolerance towards LPS [119]. This work indicated that innate immunity 
played a pivotal role in regulating inflammation by inducing a state of 
unresponsiveness or tolerance towards repeated exposure to inflammatory signals 
such as LPS. However, the molecular events leading to this essential protective 
phenomenon remained to be elucidated at this time with the lack of identification of 
a recognition receptor playing a central role. This work did however pave the way 
for extensive research into pathogen recognition by the immune system first 
postulated by Charles Janeway [4]. Following the discovery of PRRs, genetic studies 
identified TLR4 as the LPS receptor [120]. This data was supported by the findings 
of the spontaneous mutation in the LPS
D
 gene which encodes for TLR4, in the 
C3H/HeJ mouse colony which rendered them insensitive to LPS [120]. In addition 
TLR4 deficient mice were found to be unresponsive to LPS thus confirming TLR4 
as the LPS receptor [19]. 
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1.10 LPS Tolerance – transcriptional regulation 
Since the discovery of TLRs, extensive study of the intricate regulation of TLR 
signalling pathways has led to significant developments in elucidating the molecular 
mechanisms involved regulating TLR signalling in addition to induction of LPS 
tolerance. LPS tolerance is defined as a state of altered responsiveness in cells such 
as macrophages as a result of a global change in the cellular transcriptional profile 
from that of a pro-inflammatory to anti-inflammatory resolving state. Prior to 
transcriptomics analysis of LPS tolerance, TLR4 signalling studies revealed LPS 
tolerance as a state of hyporesponsiveness or refractoriness towards repeated 
challenges with LPS. It was proposed that induction of this state of reduced 
responsiveness resulted in suppression of TLR signalling and NF-κB inducible 
expression of pro-inflammatory cytokines including TNF-α. These studies defined 
LPS tolerance as an essential suppressed inflammatory state resulting from inhibition 
of adaptor protein recruitment and TLR receptor desensitisation mediated through 
induction of multiple negative regulators (Table 1.2) [121-125].  
Recently, a transcriptomics profiling study identified two classes of LPS responsive 
genes; those that are suppressed during LPS tolerance, so-called tolerisable (Class T) 
genes and those whose expression is maintained or even increased during LPS 
tolerance, so called non-tolerisable genes (class NT). Pro-inflammatory genes 
including TNF-α and IL-6 were found to be rapidly tolerised upon prolonged LPS 
exposure while anti-microbial peptides, tissue remodelling factors, mediators of 
phagocytic activity and genes promoting the resolution of inflammation were 
induced during this state. Upon further examination it was found that chromatin 
modification plays a central role in regulation of LPS tolerance gene expression. 
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Selective histone deacetylation and chromatin remodelling of tolerisable genes 
reduced promoter access and Pol II recruitment preventing gene transcription. In 
contrast acetylation of histones and Pol II recruitment remained intact on NT gene 
promoters [75].  
This pivotal finding revealed that TLR induced gene transcription is required to 
suppress transcription of tolerisable genes in addition to promoting expression of NT 
genes. Furthermore, this data confirmed that LPS tolerance is a gene specific 
regulatory mechanism which results in altered gene expression of different 
functional groups rather than global suppression of TLR induced gene expression, 
LPS signalling and receptor desensitisation. In support of this study, it was later 
confirmed that NF-κB specific motifs within promoters of genes specified TLR 
induced gene repression. Furthermore the interaction between the NF-κB motifs and 
the NcoR repressosome was found to be essential in the induction of TLR tolerance 
[126]. This study showed that NF-κB sites were significantly enriched within 
promoter regions of TLR4 induced tolerisable genes. However these sites were not 
enriched in non-tolerisable gene promoters. Interestingly mutations in these NF-κB 
motifs resulted in an inability of tolerisable genes to be suppressed during LPS 
tolerance. Mutation in NF-κB motifs converted LPS tolerisable genes into non-
tolerisable genes. In addition, inserting NF-κB motifs into promoter sites on non-
tolerisable genes converted them into tolerisable genes. Both these studies provide 
molecular insight into the physiological adaption of the inflammatory response 
towards TLR challenge with LPS tolerance inducing a global shift in the 
transcriptional profile of macrophages from a pro-inflammatory to anti-inflammatory 
pro-resolution state [75]. 
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1.11 Macrophage activation response upon microbial challenge  
Macrophages are key components of the innate immune system and are central 
mediators of inflammation and disease. Macrophages also play important 
physiological roles involving tissue repair and remodelling, phagocytosis of cellular 
debris and apoptotic cells in addition to having essential metabolic functions [127]. 
Macrophages can be divided into two populations; inflammatory and tissue resident 
macrophages both of which are members of the mononuclear phagocyte system 
(MPS) [128]. The MPS was originally described by Van Furth and colleagues in the 
early 1970’s where they described the MPS as comprising of different cell types 
(monocytes, macrophages and dendritic cells) which are all derived from a common 
bone marrow progenitor cell [129]. Macrophages can be further divided into two 
subgroups based on whether they are tissue resident or recruited to different 
anatomical sites under inflammatory cues. Macrophages can be found at a variety of 
anatomical tissue sites including the lungs, spleen, intestines and the CNS with each 
site determining specific macrophage environmental characteristics and biological 
functions [130-132] (Figure 1.4). Recently, significant insight has been provided into 
macrophage origins independent of the haematopoietic stem cell (HSC). The resident 
macrophage population of the CNS, microglia cells, have recently been shown by 
fate mapping studies to originate from the yolk sac [132]. Furthermore a number of 
additional resident macrophage populations including pleural macrophages, 
Langerhans cells and Kupffer cells have been shown to proliferate independently of 
the bone marrow through the primitive yolk sac macrophage lineage [133]. 
Tissue resident macrophages are one of the first activators of inflammation at sites of 
infection as they detect pathogens through their pathogen recognition receptors. This 
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initiates a local inflammatory response characterised by production of cytokines and 
chemokines which instigate leukocyte recruitment and migration to the site of 
infection. Inflammatory macrophages are not terminally differentiated but are 
recruited from the GR1
+ 
CX3CR1
Low
 pool of circulating monocytes in the blood. 
Upon recruitment and migration of monocytes to sites of infection, they differentiate 
into inflammatory macrophages where they perform pro-inflammatory and cytotoxic 
activities to fight and clear infection. In addition these cells have pro-resolution 
properties and function to restore tissue homeostasis. Thus macrophages play a dual 
role in fighting infection and restoring tissue homeostasis post infection [127, 134]. 
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Figure 1.4: Macrophage origins and tissue resident macrophage populations 
Differentiation of the haematopoietic stem cell (HSC) in response to monocytes/macrophage colony 
stimulating factor leads to commitment to the monocyte lineage. Monocytic cells exit the bone 
marrow and enter circulation giving rise to two populations, resident monocytes (GR1 negative, 
CX3CR1 high) and inflammatory monocytes (GR1 positive, CX3CR1 low) which migrate into tissue 
to become resident and inflammatory macrophage populations. Recent evidence suggests that 
microglia cells originate from the yolk sac rather from the haematopoietic lineage described above 
[130, 132]. Adapted from Murray and Wynn, 2011 [130]. 
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1.12 Macrophage activation and plasticity 
Macrophages are highly plastic and adaptable professional phagocytes which play 
important roles in a wide range of biological activities. This is reflected in the 
emerging spectrum of macrophage activation states based around the M1 pro-
inflammatory and M2 anti-inflammatory classification system.  
1.12.1 Classical macrophage activation (M1) 
Classical activation of macrophages results primarily in a pro-inflammatory 
microbicidal state. Macrophages are polarised into classically activated M1 
phagocytes following stimulation with TNF-α or a TLR ligand such as LPS in 
addition to a second signal, interferon-gamma (IFN-γ), produced by natural killer 
(NK) cells and Th1 cells in response to infection. Upon activation M1 macrophages 
produce type 1 interferons including IFN-β which can signal in an autocrine manner 
and replace the short lived cellular immune source (NK cell and Th1 cells) of IFN-γ 
in addition to further enhancing M1 polarisation. Classical macrophage activation 
results in production of pro-inflammatory cytokines such as TNF-α, IL-6, IL-1, IL-
12, and IL-23 leading to recruitment of both innate and adaptive immune cells 
including the expansion of Th17 helper cells. This results in a robust inflammatory 
response towards pathogenic infection and tissue injury. In addition to production of 
pro-inflammatory mediators of inflammation, M1 macrophages play an important 
role in antigen presentation and activation of Th1 immune responses against 
infection. Furthermore, these cells are critical for destruction and elimination of 
intracellular and phagocytosed pathogens through production of reactive oxygen and 
nitrogen species [127, 130, 135-138]. 
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Defects in nitric oxide (NO) production can lead to the inability of macrophages to 
effectively kill and clear intracellular pathogens such as Mycobacterium tuberculosis 
[127]. Furthermore a defect in the membrane bound enzyme complex NADPH 
oxidase involved in superoxide production has been found in chronic granulomatous 
disease (CDH) patients rendering them susceptible to infections [139]. In addition, 
combined stimulation of macrophages with IFN-γ and a TLR ligand is essential to 
lead to full activation and effective clearance of intracellular bacteria. A single signal 
can render macrophages less efficient at clearing infection. Leishmania species and 
Mycobacterium tuberculosis are two intracellular pathogens that can interfere with 
IFN-γ signalling, effectively dampening the immune response and enhancing their 
survival. Thus a combination of M1 polarisation stimuli is required for effective 
killing and clearance of intracellular pathogens [127].  
Recently, transcriptional profiling has been used to define macrophage polarisation 
in combination with surface markers [140]. Classically activated M1 macrophages 
have a unique transcription factor signature. Macrophages deficient in the 
transcription factor IRF5 displayed impaired pro-inflammatory (M1) cytokine 
expression suggesting IRF5 is an essential M1 polarisation factor [141]. In addition, 
classically activated macrophage markers including IL-12, inducible nitric oxide 
synthase (iNOS) activity and antigen presentation are all regulated by JAK-STAT 
signalling with STAT1 playing an important role [142, 143]. While classically 
activated M1 macrophages are essential in fighting and clearing bacterial infections, 
they have strong potential to inflict host tissue and organ damage. Thus strict 
regulation of M1 responses through induction of negative regulatory pathways and 
TLR tolerance is important.  
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Figure 1.5: Macrophage activation states 
Macrophages can be polarised into a spectrum of activation states with the main polarisation states 
illustrated. M1 macrophages are primarily pro-inflammatory and activated by bacterial infections. M2 
macrophages are anti-inflammatory cells strictly polarised by IL-4, IL-13 and parasitic infection. 
Many hybrid macrophage populations exist in the emerging spectrum of macrophage polarisation 
which encompasses multiple anti-inflammatory M2-like states. These include, tumour associated 
macrophages, regulatory macrophages, endotoxin tolerant macrophages. Illustration adapted from 
Biswas and Mantovani, 2010 [135]. 
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1.12.2 Alternative macrophage activation (M2) 
Alternatively activated macrophages (M2) have a unique transcriptional and 
biological signature initiated by IL-4 and IL-13 which are produced by immune cells 
of the Th2 adaptive immune response including basophils, eosinophils and mast 
cells. Furthermore, parasitic infections are powerful drivers of M2 polarisation and 
Th2 immunity. Two additional cytokines, IL-21 and IL-33 have also been implicated 
in M2 macrophage polarisation. IL-21 drives increased expression of the IL-4 
receptor (IL-4R) promoting M2 macrophage polarisation [127, 144, 145]. Wound 
healing and tissue remodelling are key biological functions of M2 macrophages 
which are reflected in increased arginase activity. IL-4 drives a shift from iNOS 
enzyme activity to that of increased expression of arginase 1 activity in M2 cells. 
Arginase 1 facilitates wound healing responses by converting L-arginine to L-
ornithine, a polyamine and proline (collagen) precursor, which is required for 
generation of the extracellular matrix in tissue remodelling, repair and parasite 
capture [127, 138]. M2 macrophages are highly phagocytic and uniquely express the 
mannose receptor MRC1 (CD206) [144]. In addition to reduced reactive oxygen 
species mediated microbicidal activities, M2 cells have reduced ability to kill 
intracellular pathogens such as mycobacteria [146].  
In contrast to the pro-inflammatory profile of M1 macrophages, gene expression of 
TNF-α, IL-6 and IL-12 is greatly suppressed in M2 cells. However M2 macrophage 
activation induces the expression of anti-inflammatory mediators IL-10, TGF-β and 
VEGF in addition to a number of unique markers YM1 (CHI3L3), FIZZ1 (RELM-
α), CCL17, CCL22 and CCL24 which are potent inducers of Th2 responses [127]. 
IRF4, STAT6 and PPARγ transcription factors play a central role in M2 macrophage 
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polarisation [140]. IL-4 stimulation of macrophages from a myeloid specific 
knockout of the IL-4 receptor (IL-4RA) fail to polarise towards the M2 alternative 
state emphasising the importance of IL-4 signalling in M2 macrophage polarisation 
[147, 148]. While STAT1 plays an important role in M1 pro-inflammatory gene 
expression STAT6 regulates the transcription of M2 specific genes including Arg1, 
MRC1, FIZZ1 and YM1. In addition, PPAR-γ is involved in M2 polarisation and 
uses STAT6 as a co-factor. IL-4 induction via STAT6 in addition to PI3K and IRF4 
has been shown to be an important pathway involved in M2 polarisation [140]. 
Recently IRF4 and the histone demethylase JMJD3 have been shown to be involved 
in polarisation of M2 macrophages in response to chitin, a component found in the 
cell walls of fungi and parasites [149]. Additionally mice which lack CREB 
promoter binding sites in C/EBPβ displayed specific suppression in M2 associated 
genes in addition to defects in wound healing following muscle injury suggesting 
that the transcription factors CREB  and CEBPβ are essential for M2 polarisation 
and gene expression [150].  
One of the hallmarks of bacterial infections is the recruitment and migration of 
inflammatory M1 macrophages to sites of infections. In contrast to this, recent 
evidence has suggested that M2 macrophages are not recruited from the circulation 
Rather resident macrophages proliferate locally and polarise towards an M2 
alternatively activated state upon parasitic infection [151]. In summary, M2 
macrophages are anti-inflammatory macrophages specifically activated by IL-4/IL-
13 cytokines in addition to parasitic infections. These cells have unique biological 
functions including tissue remodelling and mounting Th2 immune responses as a 
result of a unique transcriptional profile distinct from that of pro-inflammatory M1 
macrophages.  
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1.12.3 Regulatory Macrophages and Hybrid activation states 
Due to the highly plastic and adaptable nature of macrophages it is difficult to 
designate all macrophage polarisation states to the M1 and M2 classification system. 
Rather M1 and M2 represent two contrasting states in the emerging spectrum of 
macrophage activation. Furthermore this classification fails to account for the many 
hybrid macrophage populations which display overlapping and unique activation 
properties largely influenced by the variety of environmental specific stimuli they 
encounter in vivo [127, 135] (Figure 1.5).  
Regulatory macrophages are immune regulatory cells that display both anti-
inflammatory and pro-inflammatory features through suppression of some pro-
inflammatory genes including TNF-α, IL-6 and IL-12 and increased production of 
IL-10 and TGF-β. In addition, these cells are highly phagocytic, antigen presenting 
macrophages however unlike M2 macrophages, these cells do not perform wound 
healing or tissue remodelling functions. Immune complexes in conjunction with TLR 
activation polarise macrophages into a regulatory state. In addition, other stimuli 
including glucocorticoids, prostaglandins and apoptotic cells have been implicated in 
regulatory macrophage polarisation. While regulatory macrophages are distinct from 
both M1 and M2 macrophages, these cells share some overlapping anti-
inflammatory properties with M2 cells [127]. These three macrophage populations 
represent the main groups in the emerging spectrum of macrophage polarisation 
however many hybrid macrophage activation states exist owing to the large number 
of activation stimuli that macrophages encounter in vivo. Tumour associated 
macrophages, intestinal macrophages, placental macrophages,  Kupffer cells and 
LPS tolerised macrophages are described as representing hybrid macrophage 
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populations which share overlapping M1/M2 and regulatory properties while 
expressing distinct features unique to their polarisation state and microenvironment. 
[135, 152-156].  
Intestinal macrophages represent a unique macrophage population that does not 
belong to either the M1 or M2 groups. Intestinal macrophages display some feature 
of M2 activation including increased phagocytic capacity and reduced pro-
inflammatory responses. Importantly, while intestinal macrophages display M2-like 
characteristics they are not M2 cells as the M2 polarising cytokines IL-4, IL-13 and 
IL-33 are in low abundance in the intestine [157]. Rather the intestinal 
microenvironment, composed of a variety of antigens and the microbial community, 
influences the polarisation of intestinal macrophages towards a hybrid M2-like 
immune regulatory state [131, 157]. LPS tolerant macrophages have been shown to 
display anti-inflammatory [158] properties including reduced bactericidal activity 
and increased phagocytic capacity. Furthermore pro-inflammatory responses are 
suppressed while anti-microbial peptides and pro-resolution factors are induced 
during this state [36, 153, 154]. Importantly, LPS tolerant macrophages are not M2 
cells. M2 polarisation is mediated by IL-4 and the IL-13 pathway and is therefore 
distinct from LPS tolerance and TLR4 signalling [144, 152]. LPS tolerant 
macrophages display a hybrid regulatory phenotype which shares some features of 
M2 polarisation similar to that of intestinal macrophages. These different 
populations possess unique biological functions dependent on their specific 
environment; however they share many anti-inflammatory M2-like features.  
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1.13 Macrophage TLR tolerance 
TLR tolerance is an essential immune homeostatic response in macrophages. As 
previously mentioned, LPS tolerance induces a global change in the gene expression 
profile of macrophages with suppression of pro-inflammatory genes including IL-6 
and TNF-α, and up-regulation of anti-microbial peptides, anti-inflammatory 
cytokines and chemokines in addition to pro-resolution factors. Thus LPS tolerance 
induces a switch in macrophage polarisation from that of a M1 pro-inflammatory 
state to that of an anti-inflammatory activation state. LPS tolerant macrophages share 
some M2 properties including reduced cytotoxic and antigen presenting capacity but 
maintain increased phagocytic activity [36, 42, 135, 152-154] (Figure 1.6). 
The plasticity of macrophages can have different outcomes depending on the local 
environmental requirements and activation stimuli that macrophages encounter. 
While an LPS tolerant state may limit excessive inflammation, maintenance of this 
state can have devastating consequences in cases of septic shock, cystic fibrosis and 
cardiovascular complications. Monocytes isolated from patients of these groups 
displayed reduced responsiveness towards ex vivo challenges with LPS as 
determined by pro-inflammatory cytokine production [159]. These cells remained 
locked in an LPS tolerant state and contributed to patient mortality due to the 
inability to respond to secondary infection. Interestingly patients who recovered 
from sepsis displayed responsiveness towards LPS upon LPS challenge ex vivo [159, 
160]. Furthermore, monocytes isolated from cystic fibrosis patients also displayed a 
tolerant-like state with patient mortality linked to secondary infections [42]. In 
addition monocytes isolated from patients with acute coronary syndrome displayed 
an LPS tolerant phenotype [161]. This suggests that prolonged TLR tolerance is a 
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pathophysiological immunosuppressive state rather than a protective physiological 
immune response. 
 
 
 
Figure 1.6 LPS tolerised macrophage 
LPS tolerant macrophages are anti-inflammatory cells. Pro-inflammatory cytokines, antigen 
presenting markers and iNOS activity all illustrated in red are classical M1 features which are 
suppressed (-) in LPS tolerant macrophages. Increased expression of negative regulators of TLR 
signalling, anti-microbial peptides, anti-inflammatory cytokines and enhanced mediators of 
phagocytosis illustrated in blue are all inducible (+) properties of LPS tolerant macrophages . Adapted 
from Biswas SK, 2009 [36] 
 
39 
 
TLR and microbial tolerance is also central to maintaining environment specific 
homeostasis. The gastrointestinal tract is home to the largest microbial community in 
humans, which does not lead to robust activation of the immune system. While 
multiple factors are involved in the regulation of the complex interplay between the 
host immune response and the intestinal microbial community, macrophages 
significantly contribute to this by adopting an anti-inflammatory tolerant state 
towards the local environmental stimuli which include the intestinal microbiota. This 
environment is enriched in the M2-like polarising cytokines IL-10 and TGF-β which 
contribute to generating an anti-inflammatory tolerant environment in the gut [131]. 
Furthermore these cells produce reduced amounts of pro-inflammatory cytokines 
upon TLR challenge [162]. In addition, the resident liver macrophage population, 
Kupffer cells adopt a unique tolerant-like phenotype specific to the liver 
microenvironment where they are exposed to numerous gut derived and 
environmental toxins under the normal physiologic conditions. Upon LPS challenge, 
induction of both pro-inflammatory and immunmodulatory responses control 
inflammation in this environment including increased arginase activity which 
inhibits TNF-α expression by Kupffer cells [163-165]. These two macrophage 
populations reside in environments where maintenance of tolerance is a 
physiological protection mechanism. Alcoholic liver disease, viral infections and 
inflammatory bowel disease (IBD) are all associated with a loss in the normal 
environmental tolerogenic state [158, 165-169]. Thus macrophage plasticity is 
central to their physiological and immunological functions. While maintenance of 
the resident macrophage population in anti-inflammatory tolerant states may be 
essential to certain environments, prolonged or inappropriate tolerance could have 
devastating consequences to the host post infection clearance.  
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1.14 Aims of thesis 
Since the discovery of TLRs, extensive research has lead to the characterisation of 
the acute response to TLR activation. Furthermore, the necessity for strict control of 
these responses is evident by the numerous mechanisms of negative regulation of 
TLR signalling and TLR induced gene expression including TLR tolerance. The first 
aim of this study was to investigate the role of Bcl-3 in inflammation in the gut, an 
environment colonised by a large microbial community. Recently, a single 
nucleotide polymorphism (SNP) associated with reduced Bcl-3 gene expression has 
been identified as a potential risk factor for Crohn’s disease [170]. Bcl-3 is an 
important anti-inflammatory factor and therefore we postulated that Bcl-3 may play 
a protective role in the gut to prevent intestinal inflammation. To test this theory, an 
in vivo approach was utilised to model intestinal inflammation using mice deficient 
in Bcl-3 [108] as illustrated in Chapter 3. An acute model of inflammation using the 
dextran sodium sulphate model of murine colitis was used in these studies as it has 
been shown to be highly reproducible, of short duration, technically straightforward 
and mimics aspects of human IBD [65, 171-174].  
The second aim of this thesis was to investigate the transcriptional plasticity of TLR 
tolerance. Chapter 4 sets out to use a transcriptomics approach to investigate the 
plasticity of LPS tolerance in macrophages. The aim of this chapter was to first 
design a model of recovery from LPS tolerance in macrophages. Once the model was 
established microarray profiling and subsequent downstream bioinformatics analysis 
generated a gene expression profile of macrophages that recovered from LPS 
tolerance.  
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The final aim of this thesis was to characterise the functional outcomes of TLR 
tolerance plasticity. Chapter 5 represents a continuation of the previous chapter 
which provided transcriptional analysis of TLR tolerance and is based on an 
observed uncoupling of cytokine transcription and secretion in macrophages 
following TLR tolerance Here, cytokine secretion is examined in recovered 
macrophages by flow cytometry, cytokine intracellular trafficking by 
immunofluorescence, inhibitor studies and cytokine secretion by ELISA. In 
summary, this thesis utilised both in vivo and molecular approaches to provide in-
depth analysis and characterisation of TLR tolerance plasticity. 
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2. Materials and Methods 
2.1 Materials  
All reagents were stored and prepared according to the manufacturer’s guidelines. 
 
2.1.1 Reagents 
 Bovine serum albumin (BSA) (Sigma Aldrich Ltd. Dublin, Ireland) 
 Bafilomycin A (Sigma) 
 BD GolgiPlug (BD Biosciences, NJ, USA) 
 Ca074me (Calbiochem/Merck KGaA, Darmstadt, Germany) 
 Dextran Sodium Sulfate (DSS) 45 kDa (TdB Consultancy, Uppsala, Sweden) 
 Dulbecco’s modified eagles medium (DMEM) (Sigma Aldrich) 
 DPX mounting medium (Sigma Aldrich) 
 Ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich) 
 Eosin (Sigma Aldrich) 
 Goat serum (Dako Diagnostics, Dublin, Ireland) 
 Harris haemotoxylin (Sigma Aldrich) 
 Heat-inactivated foetal calf serum (FCS) (Gibco, Life Technologies, NY, 
USA) 
 Histochoice clearing agent (Sigma Aldrich) 
 Hoechst (Invitrogen, Life Technologies, USA) 
 Human Tissue Array (Crohn’s/Colitis) (Origene, Rockville, MD, USA) 
 IL-1β (Peprotech, London, UK) 
 L-Glutamine (Sigma Aldrich) 
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 Lipopolysaccharide K12 Ultrapure (LPS) (Invivogen, Toulouse, France) 
 MDL28170 (Sigma) 
 Monensin (Biolegend, San Diego, CA, USA) 
 Non essential amino acids (Sigma) 
 OCT compound  (Tissue-Tek, Sakura, Finetek, USA) 
 Pam3CSK4 (Invivogen) 
 Paraformaldehyde (Sigma Aldrich) 
 PBS (Sigma Aldrich) 
 Penicillin/Streptomycin (Sigma) 
 Pepstatin A (Sigma) 
 Prolong gold antifade reagent (Molecular probes/ Invitrogen) 
 Rat serum (Sigma Aldrich) 
 SYBR safe DNA gel stain (Invitrogen) 
 Trypan blue (Sigma Aldrich) 
 Tween  (Sigma Aldrich) 
 Lightcycler 480 Probes Master mix (Roche Applied Sciences, West Sussex, 
UK) 
 5X Transcriptor Buffer (Roche) 
 Deoxyribonucleotide triphosphate - dNTPs (Roche) 
 Nuclease free water (Sigma) 
 RNAse inhibitor (Roche) 
 Random primers (Roche) 
 Rneasy mini RNA isolation kit (Qiagen, Manchester, UK) 
 Taqman gene expression  assays (Life technologies, USA) 
 Transcriptor reverse transcriptase enzyme (Roche) 
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2.1.2 Mice 
 Bcl-3
-/-
C57BL/6 (B6) mice were generated as described previously [108, 111]. Bcl-
3
-/-
C57BL/6 (B6) male mice were generously provided for establishment of 
homozygous breeding by Professor Y. Chen (University of Pennsylvania, 
Philadelphia, Pennsylvania, USA). Wild-type (WT) C57BL/6 mice were purchased 
from Harlan laboratories, UK at 6 - 8 weeks of age. Atg16L1
-/- 
female mice [175] (6 
– 8 weeks) were provided by Dr Silvia Melgar for generation of bone marrow 
derived macrophage experiments. Bcl-3
-/- 
and WT littermate controls were group 
housed in individually ventilated cages (IVC’s), (OptiMice, Animal Care Systems, 
UK) with WT C57BL/6 mice housed in conventional mouse housing units under 
specific pathogen free (SPF) conditions. Standard housing and environmental 
conditions were maintained (temperature 21°C, 12 hours light and 12 hours darkness 
with 50% humidity). Animals were fed sterile standard pellet diet and water ad 
libitum. Animal husbandry and experimental procedures were approved by the 
University College Cork Animal Experimentation Ethics Committee (AEEC). 
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Table 2.1: Antibody Table 
Target Species Clone Host Conjugate Source 
CD80 Mouse B7-1 Hamster FITC eBiosciences 
CD86 Mouse GL1 Rat APC BD Biosciences 
F4/80 Mouse BM8 Rat APC eBiosciences 
F4/80 Mouse BM8 Rat PE eBiosciences 
CD11b Mouse M1/70 Rat PE BD Biosciences 
TNF Mouse MP6-XT22 Rat PEcy7 BD Biosciences 
CCR3 Mouse 83103 Rat AF647 BD Biosciences 
CD16/CD32 Mouse 2.4G2 Rat N/A BD Biosciences 
TNF Mouse Polyclonal Rabbit N/A Abcam 
GM130 Mouse 35 Mouse N/A BD Biosciences 
LAMP1 Mouse 1D4B Rat N/A Santa Cruz 
p65 Mouse Polyclonal C20 Rabbit N/A Santa Cruz 
p105/p50 Mouse Polyclonal C19 Goat N/A Santa Cruz 
RELB Mouse Polyclonal C19 Rabbit N/A Santa Cruz 
cREL Mouse Polyclonal Rabbit N/A Santa Cruz 
ERK 1/2 Mouse p44/p42 Rabbit N/A Cell signalling 
Phospho ERK 1/2 Mouse Thr202/Tyr204 Rabbit N/A Cell signalling 
p38 Mouse Polyclonal Rabbit N/A Cell signalling 
Phospho p38 Mouse Thr180/Tyr182 Rabbit N/A Cell signalling 
IRF5 Mouse 10T1 Mouse N/A Abcam 
IRF4 Mouse H140 Rabbit N/A Santa Cruz 
HDAC Mouse H-51 Rabbit N/A Santa Cruz 
Β-actin Mouse AC-74 Mouse N/A Sigma 
Bcl-3 Mouse + (H) C14 Rabbit N/A Santa Cruz 
Secondary Rat Whole Ab Goat Alexa 594 Molecular Probes 
Secondary Rabbit Whole Ab Gorat Alexa 594 Molecular Probes 
Secondary Mouse Whole Ab Goat Alexa 488 Molecular Probes 
Secondary Rat Polyclonal Goat HRP Dako Diagnostics 
Secondary Rabbit Polyclonal Rabbit HRP Dako Diagnostics 
Secondary Mouse Polyclonal Rabbit HRP Dako Diagnostics 
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Table 2.2: Oligonucleotide Primers and Universal probe Library probes 
Gene Name NCBI reference Forward (5’-3’) Reverse (5’-3’) UPL probe  
18s NR_003278.3 aaatcagttatggttcctttggtc gctctagaattaccacagttatccaa 55 
IL6 NM_031168.1 tctaattcatatcttcaaccaagagg tggtccttagccactccttc 78 
TNF-α NM_001278601.1 tcttctcattcctgcttgtgg ggtctgggccatagaactga 49 
IL1β NM_008361.3 tgtaatgaaagacggcacacc tcttctttgggtattgcttgg 78 
CXCL10 NM_021274.2 gctgccgtcattttctgc tctcactggcccgtcatc 3 
CXCL1 NM_008176.3  agactccagccacactccaa tgacagcgcagctcattg 83 
NFIL3 NM_017373.3 gttacagccgccctttcttt gagcctttcatgggttatcg 32 
IL10 NM_010548.2 cagagccacatgctcctaga gtccagctggtcctttgttt 41 
IFNA5 NM_010505.2 gccttaaccctcctggtaaaa tcctgtgggaatccaaagtc 51 
BCL3 NM_033601.3 gaacaacagcctgaacatgg tctgaccgttcacgttgg 18 
IL17A NM_010552.3 cagggagagcttcatctgtgt gctgagctttgagggatgat 28 
IL22 NM_016971.2 tttcctgaccaaactcagca ctggatgttctggtcgtcac 49 
CCL5 NM_013653.3 tgcagaggactctgagacagc gagtggtgtccgagccata 110 
IL33 NM_001164724.1 cacattgagcatccaaggaa aacagattggtcattgtatgtactcag 51 
BCL3 N/A cggaagtgcttgacattgg gtattgaccgattccttgcg N/A 
IL2 N/A catacagaaggcgttcattg tacctgtgtggcagaaagc N/A 
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2.2 Methods 
2.2.1 Genotyping 
Bcl-3
-/-
 and WT littermate control mice were ear clipped and genotyped upon 
weaning to confirm their genetic status. DNA was extracted by incubating the ear 
clip sample in a solution containing 0.2mM EDTA and 25mM NAOH for 45 
minutes at 99ºC. The reaction was neutralised by addition of an equal volume of 
40mM Tris-CL (pH 5). Bcl-3
 
deficiency was confirmed by measuring expression of 
the Bcl-3 targeting cassette construct which results in Bcl-3 becoming functionally 
inactive [108]. Homozygous Bcl-3
-/- 
mice contain two copies of the Bcl-3 construct 
in comparison to the one copy for heterozygotes. WT mice contain no copy of the 
Bcl-3 cassette. Primers were designed to measure expression of the Bcl-3 construct 
compared with the IL-2 promoter control (Table 2.2). The genetic status of each 
mouse was determined by measuring the ratio of the Bcl-3 targeting construct to the 
IL-2 promoter followed by visualisation of amplified DNA on a 2% agarose gel 
containing SYBR safe DNA gel stain (Invitrogen). WT mice contain only the IL-2 
promoter with heterozygotes containing both the Bcl-3 construct and the IL-2 
promoter in a 1:1 ratio. All Bcl-3 deficient homozygous mice have a 2:1 Bcl-3 
construct: IL-2 promoter ratio. All Bcl-3
-/- 
and WT littermate controls were 
genotyped prior to breeding and experimental usage. 
2.2.2 DSS induced colitis – an acute model of colonic inflammation 
Mice were administered dextran sodium sulphate (DSS) (45 kDa) ad libitum in their 
drinking water to induce colitis as previously described [176]. 1%, 2% and 2.5% 
DSS solutions were prepared freshly and administered on a daily basis for six days 
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followed by administration of water only from day six to eight to induce acute 
disease. Body weight, stool consistency and posture/fur texture were recorded daily 
to determine the daily disease activity index (DAI). DAI scoring was assessed 
blinded with a maximum score of 10 as previously described [176, 177]. DAI 
scoring combined scoring from weight loss (% change) 0 – 4, stool consistency 0 – 4 
and posture/fur texture 0 – 2 (Table 2.3). Mice were sacrificed at day 8 with colons 
removed from anus to caecum and washed in PBS. Colons were measured, cut 
longitudinally and divided into the distal and proximal colon segments. Both 
proximal and distal colons were weighed and processed for histology, protein and 
gene expression analysis according to sample requirements. Distal colon samples 
were further divided into three segments with one snap frozen in liquid nitrogen for 
protein analysis. For histological analysis a segment of distal colon was rolled in a 
“swiss roll”, embedded in optimal cutting temperature (OCT) compound (Tissue-tek) 
and snap frozen with liquid nitrogen. The final distal colon segment was transferred 
in to 1ml of RNA later (Sigma) and snap frozen with liquid nitrogen. All samples 
were stored at -80ºC until required for analysis 
Table 2.3: Daily disease activity Index scoring system (DAI) 
Score Weight loss Stool consistency Fur/posture 
0 No change No change No change 
1 1-3% weight loss Minor change Mildly hunched 
2 3-6% weight loss Loose stool Hunched & reduced movement 
3 6-9% weight loss Loose stool & rectal bleeding - 
4 >9% weight loss Diarrhoea & rectal bleeding - 
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2.2.3 Colon histology 
2.2.3.1 Tissue Sectioning 
Distal colons (3cm) were cut longitudinally into three sections with one rolled in a 
“swiss roll” for histological analysis as described in section 2.2.2. Frozen sections 
were cut using a Leica CM1900 cryostat (Leica Microsystems, Ireland) and allowed 
to air dry prior to staining. Alternatively, frozen sections were stored at -80ºC until 
required for tissue staining. 
2.2.3.2 Haematoxylin and Eosin tissue staining 
Frozen distal colonic sections (6μm) were fixed in an ice cold acetone/ethanol 3:1 
solution and stained with haematoxylin and eosin according to standard histological 
staining procedures. Briefly, distal colon sections were stained with Harris 
haematoxylin for 10 minutes, washed in running tap water for 5 minutes and 
differentiated in 1% acid alcohol for 30 seconds. Sections were then stained with 
eosin for 30 seconds prior to dehydration steps through increasing ethanol 
concentrations. Sections were then incubated with histochoice clearing reagent 
(Sigma), allowed to air dry followed by mounting with DPX mounting media 
(Sigma). Stained sections were allowed to dry overnight prior to histological 
analysis. Stained sections were analysed using an Olympus BX51 camera and Cell F 
software (Olympus, Germany). Images captured are representative of greater than 
seven fields of view at 20X magnification per mouse. Histological scoring was 
performed in a blinded fashion. Scoring of tissue damage was quantified as 
previously described with a maximum combined score of 12 [177, 178] as follows: 0 
– no infiltration, no injury, no crypt damage; 1 - minor infiltration, mucosal injury, 
damage at crypt base; 2 – moderate infiltration (foci formation), mucosal and sub 
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mucosal injury, damage at crypt base and centre; 3 – severe infiltration, transmural 
injury, only epithelium intact; 4 – loss of whole crypt and epithelium (Table 2.4). 
 
Table 2.4: Colon histological scoring (H&E) 
Injury Cell infiltration Extent of Injury Crypt Damage 
0 No change No change No Change 
1 Minor Mucosal Base 
2 Moderate (Foci formation) Mucosal & Submucosal Base and centre 
3 Severe (loss of architecture) Transmural Only epithelium intact 
4 - - Crypt and epithelium loss 
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2.2.4 Cell culture 
2.2.4.1 L929 cell culture  
The L929 fibroblast cell line NCTC clone 929 [L cell, L-929, derivative of Strain L] 
(ATCC® CCL-1™) was cultured to provide a source of the growth factor M-CSF 
used for the differentiation of macrophages from bone marrow. Murine L929 
fibroblasts were seeded in tissue culture flasks with Dulbecco’s Modified Eagles 
Medium (DMEM), 10% foetal bovine serum (FBS), 1% penicillin/streptomycin and 
1% L-glutamine (Sigma) and grown to confluency in a T175 tissue culture flask.  
Cells were maintained at 37ºC in a humidified environment with 5% CO2. Confluent 
L929 fibroblasts were incubated with 50ml of L929 culture media for a further 7 
days to allow for production and secretion of M-CSF by the cells. After 7 days the 
supernatants were removed and filter sterilised, aliquoted and stored at -80°C until 
required. L929 fibroblasts were passaged by mechanical disruption using a cell 
scraper and re-seeded in a T175 tissue culture flask. Every 7 days after the cells 
reached confluency supernatants were removed and stored as described. L929 
fibroblast cell line stocks were cryopreserved in FCS supplemented with 10% 
DMSO at a cell density of 2 x 10
6
/ml.  
2.2.4.2 Murine bone marrow isolation  
Bone marrow was isolated from female C57BL/6 and Atg16L1
-/- 
mice at 6 - 8 weeks 
old for generation of primary bone marrow derived macrophages (BMDM) in vitro. 
Mice were sacrificed by cervical dislocation with both hind legs removed at the hip 
joint. Excess tissue was removed from the femur and tibia bones and then cleaned in 
1X sterile PBS and 70% ethanol. Using a 21 gauge needle and syringe bone marrow 
was isolated by flushing ice cold sterile PBS through the femur and tibia bones and 
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collected in a 50 ml falcon tube. Isolated bone marrow was re-suspended to generate 
a single cell suspension and passed through a 70μM cell strainer to remove any 
debris. The bone marrow suspension was washed twice in BMDM culture media 
(DMEM, 10% FBS, 1% penicillin/streptomycin, 1% L-glutamine, 1% non-essential 
amino acids), and centrifuged at 4°C at 300 x g for 5 minutes. Bone marrow was 
cryopreserved in foetal calf serum (FCS) supplemented with 10% DMSO until 
required for use.  
2.2.4.3 Bone Marrow derived Macrophage (BMDM) differentiation  
Bone marrow was cultured following isolation or from cryopreserved stocks in 
BMDM culture media supplemented with 30% L929 conditioned media for seven 
days. The cells were cultured on sterile non tissue culture treated petri dishes. On day 
3 BMDM differentiation media was removed and replaced with fresh differentiating 
BMDM culturing media with any non-adherent cells removed at this stage. Adherent 
monocytes/macrophage progenitors differentiated into BMDMs by day 7. 
Differentiated BMDMs were removed from the petri dishes by incubating the cells 
with 5mM EDTA in sterile PBS at 37°C for 5 minutes. Cells were collected and 
washed twice in BMDM culture media at 4°C for 5 minutes at 300 x g, re-suspended 
in BMDM culture media and transferred to tissue culture treated dishes for 
downstream experimental use. The purity of BMDMs was assessed by flow 
cytometry and was typically greater than 95% F4/80 positive. 
2.2.4.4 Peritoneal Macrophage isolation 
Peritoneal macrophages were isolated from C57BL/6 female mice (6 – 8 weeks). 
Macrophages were recruited to the peritoneal cavity by administration of 1ml of 
sterile 4% thioglycollate to mice via intraperitoneal injection. Three days post i.p 
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injection recruited macrophages were isolated by peritoneal lavage. Mice were 
euthanized using CO2 to ensure the peritoneal cavity remained intact. Briefly, 10ml 
of ice cold sterile PBS was injected into the peritoneal cavity. The peritoneal cavity 
was gently massaged to allow cells to be collected and withdrawn from the cavity. 
Collected cells from three mice were pooled, passed through a 70μM cell strainer 
(BD Biosciences) and centrifuged at 4°C for 5 minutes at 300 x g. Isolated peritoneal 
cells were plated in tissue culture dishes overnight to allow for adherence of 
macrophages. Non-adherent cells were removed prior to experimental use. The 
purity of the population was measured by flow cytometry using CD11b and F4/80 
double positive staining. 
2.2.5 LPS Tolerance Recovery Model 
BMDM were differentiated for 7 days in BMDM differentiating media, removed 
from petri dishes and washed in BMDM culture media as described in section 
2.2.4.3. Cells were quantified using trypan blue exclusion dye and a Neubauer 
haemocytometer counting chamber. Roughly 2 x 10
8 
BMDMs were derived from the 
femurs and tibias of three C57BL/6 mice at 6 - 8 weeks of age. BMDMs were seeded 
at various densities in tissue culture dishes for experimental treatment. 
LPS tolerance was induced in BMDMs by stimulating cells for 8 hours with 
100ng/ml ultrapure LPS-EK (K12) (Invivogen). After 8 hours the media was 
removed and the cells were washed twice with sterile PBS. The cells were allowed to 
rest and recover in fresh BMDM culture media for a further 16 hours before a second 
stimulation with LPS was given. These cells were described as being LPS tolerised 
macrophages (T). Recovery from LPS tolerance (R – recovered macrophage) was 
achieved by inducing LPS tolerance in BMDMs as described, however the period of 
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rest and recovery with the fresh culture media extended beyond 16 hours to that of 
64 to 136 hours (2 to 4 days) before they received a second challenge with LPS. All 
data including transcriptional profiling experiments were performed on macrophages 
rested for three days prior to re-stimulation (Recovery – R) as determined by 
recovery time optimisation experiments. Additional analysis of recovery from LPS 
tolerance on day 2 and day 4 is specified within the text where appropriate. The 
acute LPS response group (A) received a single LPS stimulation for 1, 4, 8 or 24 
hours depending on protein or gene expression analysis requirements. Macrophages 
that received no stimulation with LPS were described as Naïve macrophages (N). 
LPS tolerant and recovered macrophages received a second challenge of LPS for 1, 
4, 8 or 24 hours depending on protein or gene expression analysis requirements.  
2.2.6 Gene expression analysis 
2.2.6.1 RNA isolation 
BMDMs were washed twice in cold 1X PBS and removed from tissue culture dishes 
by mechanical disruption using a cell scraper. The cell suspension was centrifuged at 
4°C for 5 minutes at 300 x g with RNA isolated using the RNeasy mini RNA 
isolation kit (Qiagen) according to the manufacturer’s guidelines. Briefly, 
supernatants were discarded and the cell pellet was lysed in RLT lysis buffer 
containing 10% β-mercaptoethanol (Sigma). The lysates were homogenised using 
Qiashredders (Qiagen) and total RNA was extracted using the RNeasy mini kit with 
an optional DNase step included using the RNase free DNase kit (Qiagen). 
Distal colon tissue samples were stored at -80ºC in RNA-later to preserve RNA 
integrity. Samples were thawed on ice, removed from RNA-later and transferred to 
magNALyser green bead tubes (Roche) and homogenised using the magNALyser 
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homogeniser three times for 15 seconds at 6500 x g (Roche). Colonic tissue was 
homogenised in RLT lysis buffer (Qiagen) with homogenised samples centrifuged 
for 5 minutes at 4°C at 200 x g.  RNA was isolated using the RNeasy mini kit 
according to the manufacturer’s guidelines. RNA purity and quantification was 
measured using a nanodrop ND1000 spectrophotometer (Thermo Scientific) and 
stored at -80°C until required. All work was performed under nuclease free 
conditions. 
2.2.6.2 Complementary DNA (cDNA) Synthesis: RT-PCR 
1μg total RNA was used to synthesise complementary DNA (cDNA) with random 
hexamer primers using Transcriptor Reverse Transcriptase (Roche). Briefly, the 
reverse transcription reaction mix was incubated for 10 minutes at 25°C to allow 
efficient annealing of random primers. This was followed by incubating the reaction 
at 55°C for 30 minutes. The reaction mix was finally incubated at 85°C for a final 5 
minutes to inactivate the enzyme (Table 2.5). Synthesised cDNA was diluted with 
nuclease free water in a 1:5 dilution. Two negative controls were included in each 
RT-PCR reaction. A no RT control (reverse transcriptase enzyme) was included 
which contained RNA and all the reaction mix except the enzyme. A second 
negative control contained the reverse transcriptase enzyme however RNA was not 
included to determine non specific DNA amplification. cDNA was stored at -20°C 
until required for experimental use. 
2.2.6.3 Quantitative/ Real Time PCR (qRT-PCR) 
Gene expression was measured by quantitative real time PCR (qRT-PCR) using the 
LightCycler 480® (Roche) in combination with the Universal Probe Library system 
(Roche) (Table 2.6). Primers sequences and corresponding probes can be found in 
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Table 2.2. Gene expression was measured from triplicate wells with mRNA levels 
made relative to the housekeeper gene 18s ribosomal RNA (rRNA). Human tissue 
arrays (Crohn's/Colitis cDNA Array, Origene) were used to measure Bcl-3 
expression. Gene expression was measured using the LightCycler 480 system in 
combination with Taqman gene expression assay for Bcl-3 (Applied Biosystems). 
Gene expression changes were calculated using the 2
-CT
 method [179] and 
represented as relative mRNA. 
Table 2.5: cDNA synthesis – Reaction master mix 
cDNA Master Mix Volume (1 reaction) 
5X Transcriptor Buffer 5μl 
RT enzyme (500 Units) 0.5μl 
RNase Inhibitor (2000 Units) 0.5μl 
Random primers (200ng/μl) 3μl 
dNTP mix (10mM each) 1μl 
Nuclease free water Max 10μl – sample dependent 
1μg Total RNA Volume – sample dependent 
Total Volume 20μl 
 
Table 2.6: qRT-PCR reaction master mix 
qRT-PCR Master Mix Volume (1 reaction) 
Lightcycler® 480 Enzyme mix 5μl 
Forward primer (10mM) 0.5μl 
Reverse primer (10mM) 0.5μl 
Probe (UPL) (10mM) 0.1μl 
Nuclease free water 1.9μl 
cDNA (1:5 dilution) 2μl 
Total volume 10μl 
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2.2.7 Microarray profiling 
Total RNA was isolated using the RNeasy mini kit (Qiagen) with all samples DNase 
treated as described in section 2.2.6.1. RNA quantification and purity were measured 
using the Nanodrop ND1000 spectrophotometer (Thermo Scientific). Triplicate 
biological replicate samples submitted for microarray profiling met all sample 
submission criteria (Beckman Coulter Genomics, NC, USA). Briefly, 200ng of total 
RNA was fluorescently labelled with Cy3 nucleotides. Labelled RNA (cRNA) was 
hybridised to Agilent mouse 8 x 60K microarrays (Agilent-028005). Hybridised 
arrays were washed and scanned and data extrapolated for downstream 
bioinformatics analysis. Each experiment is representative of BMDM derived from 
bone marrow pooled from three mice.  
2.2.8 Bioinformatics 
All data processing was carried out using Bioconductor packages [180] in the R 
software environment with the data background corrected using Limma package 
[181]. The data was then corrected for batch effects using the ComBat script [182]. 
The corrected data was then normalised between arrays using quantile normalisation 
[181]. Differentially expressed genes were found using the Limma package [181]. 
These genes were then corrected for multiple testing using the Benjamini-Hochberg 
method. Data was corrected with an adjusted p-value cut off of p<0.05 and a 1.5 fold 
change. Further bioinformatics analysis was performed using DAVID [183] to 
perform gene ontology and pathway analysis. Gene expression changes and gene 
expression trends were visualised by hierarchical and K means clustering using 
Genesis software [184]. Gene expression profiling was independently validated by 
real time quantitative PCR (qRT-PCR). Gene expression profiling data (GSE47783) 
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has been deposited in the National Center for Biotechnology Information Gene 
Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bxoxxisyouyoulw&acc=GS
E47783). Transcriptional profiling of Crohn’s disease and Ulcerative Colitis tissue 
was performed using a dataset of sigmoid biopsy patient samples published by 
Costello et al. (GEO dataset ID GDS1330) [185] (Crohn’s disease n = 10, Ulcerative 
Colitis n = 10, normal controls n = 11). 
2.2.9 Western blotting 
Cells were initially washed in ice cold PBS to remove any remaining stimuli 
followed by removal of cells from tissue culture treated dishes using a cell scraper. 
Cells were transferred into ice cold PBS and washed twice by centrifugation at 300 x 
g for 5 minutes at 4°C. Total protein was isolated from both BMDMs and distal 
colonic tissue samples by lysing the cell pellet or tissue sample in radio-
immunoprecipitation assay (RIPA) buffer (150 mM NaCl, 50 mM Tris-Cl, pH 7.4, 
1% NP-40, 0.25% sodium deoxycholate, 1mM Na3VO4, 1mM EDTA)  
supplemented with a protease and phosphatase inhibitor cocktail (Sigma). Cells were 
lysed for 30 minutes on ice followed by centrifugation at 14000 x g for 10 minutes to 
remove cellular debris. Supernatants were removed and stored at -20ºC until 
required.  
Cytoplasmic and nuclear proteins were isolated from cells using the nuclear extract 
kit (Active Motif, Carlsbad, CA, USA). Briefly, cells were washed with 5ml of an 
ice-cold PBS/Phosphatase inhibitor solution and removed from the dishes by 
mechanical disruption using a cell scraper. Cytoplasmic protein was isolated by re-
suspending the cell pellet in a 1X hypotonic solution for 15 minutes on ice followed 
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by addition of detergent. The cell suspension was centrifuged at 4°C for 30 seconds 
at 14000 x g. Supernatants containing cytoplasmic proteins were removed and stored 
at -80°C. The pellet was re-suspended in a nuclear lysis solution for 30 minutes 
shaking gently followed by centrifugation of the nuclear lysates at 4°C for 10 
minutes at 14000 x g. Supernatants containing nuclear protein were removed and 
stored at -80°C.  
Distal colon tissue samples were washed in PBS and snap frozen with liquid 
nitrogen. Tissue samples were thawed and transferred to magNA Lyser green bead 
tubes (Roche) and homogenised using the Magna lyser instrument three times for 15 
seconds at 6500 x g (Roche) in RIPA lysis buffer supplemented with a protease and 
phosphatase inhibitor cocktail (Sigma). Homogenised tissue lysates were centrifuged 
at 14000 x g for 10 minutes to remove cellular debris. Distal colon lysates were 
stored at -20ºC until required for use. 
Protein concentration quantification was measured for all protein samples using the 
Bio-Rad protein assay solution (Bio Rad, Hertfordshire, UK) with absorbance 
measured at 595nm using an absorbance plate reader. 30μg of protein from each 
sample was resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to methanol activated polyvinyl difluoride (PVDF) membrane (Millipore 
Billerica, MA, USA) and incubated for antibodies of interest according to 
manufacturer’s guidelines (Table 2.1). Membranes were incubated with horseradish-
peroxidise (HRP) labelled secondary antibodies (1:1000) for 1 hour at room 
temperature. Membranes were analysed by electrochemiluminescence detection 
using Super Signal® West Dura Extended Duration kit (Thermo Scientific, USA). 
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2.2.10 Electrophoretic mobility shift assay (EMSA) 
Nuclear protein was isolated as described above using the nuclear extract kit (Active 
Motif). NF-κB consensus double stranded oligonucleotides    
(5’AGTTGAGGGGACTTTCCCAGG-3’) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). 10μg of nuclear protein was incubated with the 
NF-κB consensus probe for 15 minutes at room temperature in a 25μl binding 
reaction containing 1μg/μl Poly dI:dC (Roche), Ficoll (Sigma), DTT, orange G and 
10X EMSA buffer (10mM HEPESKOH (pH7.9), 50mM KCL, 2.5mM MgCl2, 1mM 
DTT, 40μg/ml BSA). The reaction was resolved in the dark on a 5% non-denaturing 
polyacrylamide gel running at 300 Volts for 3 hours at 4°C in 0.5X TBE buffer. The 
gel was visualised using the Odyssey Infrared Imager system and Odyssey software 
(Li-Cor Biosciences, USA). 
2.2.11 Cytokine and Chemokine secretion 
2.2.11.1 ELISA/MSD 
BMDM were plated in 96 well flat bottom tissue culture plates at a cell density of 
0.6 x 10
5
 / well. Each time point was performed in triplicate with supernatants 
removed at specific time points for cytokine and chemokine measurement; TNF-α (8 
hours), IL-6, IL-12p70, CXCL1, RANTES and IL-10 (24 hours). For secretion 
experiments, BMDMs were re-stimulated with LPS for 8 or 24 hours in the presence 
or absence of additional inflammatory ligands including IL-1β (10ng/ml), 
Pam3CSK4 (100ng/ml), CpG (1μM), IFN-γ (50ng/ml) and CD40L (10μg/ml). 
BMDMs were also re-stimulated in the presence or absence of Bafilomycin A (1μM) 
in addition to intracellular enzymatic inhibitors including pepstatin A (10μM), 
ca074me (10μM) and MDL28170 (10μM) for 8 hours during LPS re-stimulation for 
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inhibitor experiments. Secretion was measured using murine Meso Scale Discovery 
(MSD) tissue culture single spot plates in conjunction with the 
electrochemiluminescence system Sector 2400 imager from Meso Scale Discovery 
(Gaithersburg, MD). Cytokine and chemokine secretion was measured in pg/ml.  
2.2.11.2 Cytokine antibody array 
BMDM were seeded in 6 well plates at 2 x 10
6
/ well. Supernatants after 24 hours 
LPS re-stimulation were removed following experimental treatment (24 hours) and 
stored at -80ºC until required. Supernatants were incubated on mouse cytokine arrays 
for 32 cytokines (Ray Biotech, Inc, USA) according to manufacturer’s guidelines 
Cytokine arrays were visualised and captured using electrochemiluminescence HRP 
detection (Appendix 2).  
2.2.12 Flow cytometry 
2.2.12.1 Surface staining 
Macrophages were surface stained with a panel of antibodies (Table 2.1) with 
expression measured using the C6 Accuri Flow cytometer (BD Bioscience). 
Macrophages were removed from tissue culture dishes following experimental 
conditions and washed three times in ice cold staining buffer composed of 1X PBS, 
0.5% BSA, 1% FBS and 0.1% sodium azide (Sigma). Cells were incubated with 
CD16/CD32 (Fc Block - 1μg/106 cells) antibody for 15 minute to block non-specific 
binding of antibodies to the Fc receptors on macrophages. Cells were surface stained 
in the dark on ice for 30 minutes, washed in staining buffer three times and re-
suspended in running buffer (1X PBS, 1mM EDTA, 0.5% BSA) prior to analysis on 
the flow cytometer. Data was controlled for using isotype and by fluorescence minus 
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one (FMO) controls. Data was analysed using FCS express flow cytometry software 
(De Novo Software, Los Angeles, CA). 
2.2.12.2 Intracellular staining 
To stain for intracellular cytokines, macrophages were initially stimulated in 
combination with Golgi plug (Brefeldin A) at 1μg/106 cells (BD Bioscience). To 
stain for TNF-α intracellularly, cells were stimulated for 8 hours with LPS and 
Brefeldin A. Cells were removed from tissue culture treated dishes and washed in 
staining buffer as described above. Cells were also incubated with Fc block to block 
non-specific binding to the Fc receptors. Following surface staining (if applicable), 
cells were fixed and permeablised using the Cytofix/Cytoperm
TM
 kit (BD 
Biosciences) according to the manufacturer’s guidelines. Briefly cells were fixed and 
permeabilsed for 20 minutes in the dark on ice with FIX/Perm buffer, washed twice 
in 1X FIX/Perm wash buffer and incubated with the intracellular cytokine antibody 
for 30 minutes on ice in the dark. After intracellular staining, the cells were washed 
three times in 1X FIX/Perm wash buffer and re-suspended in flow cytometry 
running buffer prior to analysis. Data was controlled for using isotype and by 
fluorescence minus one (FMO) controls. Mean fluorescence intensities were 
calculated from three independent experiments. Data was analysed using FCS 
express flow cytometry software (De Novo Software). 
2.2.13.3 Assessment of phagocytosis 
BMDM were seeded at 5x10
5 
per well in a 24 well plate with cells treated according 
to experimental requirements. The phagocytic capacity of cells was measured using 
pHrodo E.coli bioparticles (molecular probes). Briefly, pHrodo E.coli bioparticles 
were incubated with each macrophage group for 3 hours in the dark at 37°C 
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according to the manufacturer’s protocol. After incubation, the bioparticles were 
removed and the cells were vigorously washed in ice cold PBS three times. 
Phagocytosis was measured by flow cytometry using the FL2/PE channel of the 
Accuri C6 flow cytometer (BD Biosciences).  
2.2.14 Immunofluorescence staining 
2.2.14.1 Distal Colon tissue Immunofluorescence staining 
Frozen colonic sections (6μm) were fixed in an ice cold acetone/ethanol 3:1 solution 
and incubated with blocking buffer (10% rat/mouse/goat serum, 5% fish gelatine, 
0.05% Tween-20, 1% BSA, 0.1% sodium azide) for 45 minutes at room temperature. 
Distal colon sections were incubated with directly conjugated anti mouse antibodies 
specific to the protein of interest (Table 2.1) and counterstained with Hoechst 1μg/ml 
(Molecular Probes). Stained tissue sections were mounted with Prolong Gold 
antifade mounting medium (Molecular probes) and visualised using a fluorescence 
microscope (Olympus BX51, Olympus, Germany). Fluorescence images were 
captured using Cell F software (Olympus). Images captured are representative of 
greater than seven fields and 10 fields of view at 20X and 40X magnification 
respectively per mouse. Quantification was performed on greater than 10 fields of 
view per tissue section at 100X magnification. Quantification was performed on all 
mice per group. 
2.2.14.2 TUNEL 
The extent of apoptosis in distal colonic tissue was measured by terminal 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling 
(TUNEL). Frozen distal colon sections (6μm) were thawed at room temperature and 
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initially incubated with 3% hydrogen peroxide (Sigma)  and a 4% DEPC (Sigma) 
solution to eliminate background fluorescence from both peroxidase and 
endonuclease enzyme activity in the tissue. The colon sections were incubated for 
one hour in a reaction using Terminal Deoxynucleotidyl Transferase (Promega) and 
Fluorescein 12 - dUTP (Roche) at 37ºC. Nuclei were counterstained with Hoechst 
1μg/ml (Molecular Probes). Stained distal colon sections were imaged and analysed 
using a fluorescence microscope (Olympus BX51, Olympus, Germany) and Cell F 
software (Olympus). Images captured are representative of greater than seven fields 
of view at 20X magnification per mouse. Quantification of TUNEL positive cells 
was performed in a blinded manner on greater than 10 fields of view per tissue 
section at 100X magnification. Quantification was performed on all mice per group. 
2.2.14.2 BMDM Immunofluorescence staining 
BMDM were seeded in 12 well tissue culture dishes with inserted sterile glass 
coverslips at a density of 0.8 x 10
6 
per well. BMDM were allowed to adhere 
overnight prior to experimental treatment. For immunofluorescence inhibitor 
experiments, BMDMs were re-stimulated with LPS for 1.5 hours in the presence or 
absence of intracellular enzymatic inhibitors including pepstatin A (1μM), ca074me 
(10μM) and MDL28170 (10μM). BMDMs were also re-stimulated with Bafilomycin 
A (1μM) and monensin (2μg/106 cells) for 1.5 hours during LPS re-stimulation for 
immunofluorescence analysis. At the experimental endpoint, cells were fixed in 3% 
paraformaldehyde for 15 minutes followed by quenching of free aldehyde groups 
using 50mM ammonium chloride (NH4Cl) for an additional 15 minutes. BMDMs 
were permeabilsed in permeabilisation buffer (PBS, 2% BSA, 0.05% saponin. 
Primary antibody and secondary antibody (Table 2.1) incubation steps were carried 
65 
 
out in a humidified chamber in the dark at room temperature. Cells were incubated 
with anti-TNF-α (1:200) and anti-GM130 (1:4000) for 1 hour and washed twice in 
permeabilisation buffer. Coverslips were then incubated with anti rabbit and anti 
mouse secondary antibodies (1:400) in addition to the DAPI nuclear stain for an 
additional hour at room temperature. All antibodies were diluted in 5% FBS/PBS. 
Coverslips were mounted onto glass slides with mowiol and dried over night prior to 
imaging. Fluorescence images were captured using a Nikon Digital Sight DS Fi1C 
camera (Nikon) and NIS element software (Nikon). Images captured are 
representative of greater than 10 fields of view / sample at 100x magnification. 
Quantification was performed in a blinded manner on greater than 10 fields of view 
per sample at 100X magnification. Quantification of GM130 and TNF-α co-
localisation is represented as percentage co-localisation per field of view at 100X 
magnification. Quantification was performed on triplicate experiments. 
2.2.15 Statistical analysis 
Statistical analysis was determined using one-way ANOVA/ two-way ANOVA with 
post hoc analysis (Tukey’s post hoc test and Bonferroni post hoc test). qRT-PCR 
expression data was calculated using the 2
-CT
 [179]
 
followed by unpaired and 
Mann Whitney U Test or one–way ANOVA with Tukey’s post hoc test to compare 
differences between groups. Statistical analysis was performed using GraphPad 
software, (San Diego, CA, USA). Data is represented by mean ± SEM with p<0.05 
considered statistically significant. 
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3. Bcl-3 deficiency protects against DSS-induced 
colitis in the mouse 
3.1 Abstract 
Bcl-3 is a member of the IκB family of proteins and is an essential negative regulator 
of Toll-like receptor induced responses. Recently, a single nucleotide polymorphism 
associated with reduced Bcl-3 gene expression has been identified as a potential risk 
factor for Crohn’s disease. Here we report that in contrast to the predictions of SNP 
analysis, patients with Crohn’s disease (CD) and Ulcerative Colitis (UC) 
demonstrate elevated Bcl-3 mRNA expression relative to healthy individuals. To 
further explore the potential role of Bcl-3 in inflammatory bowel disease (IBD) we 
used the dextran-sodium sulphate (DSS) induced model of colitis in Bcl-3
-/- 
mice. 
We found that Bcl-3
-/-
 mice were less sensitive to DSS-induced colitis compared to 
wild type controls and demonstrated no significant weight loss following treatment. 
Histological analysis revealed similar levels of oedema and leukocyte infiltration 
between DSS treated wild type and Bcl-3
-/-
 mice but showed that Bcl-3
-/-
 mice 
retained colonic tissue architecture which was absent in wild type mice following 
DSS treatment. Analysis of the expression of the pro-inflammatory cytokines IL-1β, 
TNF-α and IL-6 revealed no significant differences between DSS-treated Bcl-3-/- and 
wild type mice. Analysis of intestinal epithelial cell proliferation revealed enhanced 
proliferation in Bcl-3
-/-
 mice which correlated with preserved tissue architecture. Our 
results reveal that Bcl-3 has an important role in regulating intestinal epithelial cell 
proliferation and sensitivity to DSS induced colitis which is distinct from its role as a 
negative regulator of inflammation. 
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3.2 Introduction 
The nuclear factor (NF)-κB transcription factor family controls the inducible 
expression of more than 500 genes, including cytokines, chemokines and regulators 
of cell survival and proliferation [186, 187]. The dual role of NF-κB as a key 
regulator of inflammation and cell survival makes it a critical factor in the 
pathogenesis of chronic diseases such as inflammatory bowel disease (IBD). 
Increased NF-κB activation is observed in the mucosa of IBD patients and the 
requirement for NF-κB for the expression of pro-inflammatory cytokines supports a 
contributory role for NF-κB in IBD [188, 189]. Indeed, in the IL-10-/- mouse model 
of colitis, increased activation of NF-κB in myeloid cells is critical for the 
development of disease, while mice lacking CYLD or A20, two important negative 
regulators of NF-κB, show increased sensitivity to dextran-sodium sulphate (DSS)-
induced colitis [51, 189-191]. Moreover, the pharmacological inhibition of NF-κB 
by anti-sense oligonucleotides or inhibitory peptides can prevent DSS-induced colitis 
in mice [192].
 
Genetic studies have identified an equally important role for NF-κB in maintaining 
the homeostasis of the intestinal epithelium. Mice lacking NF-κB essential 
modulator (NEMO) in intestinal epithelial cells (NEMO
IEC
) develop spontaneous 
and severe colitis resulting from elevated intestinal epithelial cell apoptosis [189, 
193]. A similar phenotype is observed in mice lacking both the IKKα and IKKβ 
subunits in intestinal epithelial cells (IKKα\βIEC) and mice lacking the NF-κB 
subunit RelA in intestinal epithelial cells are hypersensitive to DSS-induced colitis 
[189, 194]. Toll-like receptors (TLRs) are the key sensors of microbial products in 
innate immunity and are critical in initiating NF-κB activation in intestinal epithelial 
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cells. Thus, mice lacking MyD88, a key component downstream of a number of 
TLRs, are also hyper-responsive to DSS-induced colitis [24, 195]. Together these 
studies indicate that while NF-κB activity is critical for inflammation in IBD, NF-κB 
activity in the epithelium is critical for tissue homeostasis and its inhibition can have 
severe consequences including the development of IBD. Thus a further 
understanding of the regulation of NF-κB during inflammation in the intestine and 
the contribution of components of the NF-κB pathway to inflammation and epithelial 
proliferation in the mucosa, are critical for the development of effective therapies for 
IBD. 
Bcl-3 is a member of the IκB family of proteins as determined by sequence 
homology and the presence of ankyrin repeat domains which mediate interaction 
with NF-κB dimers [108, 196, 197]. Bcl-3 is largely a nuclear protein and only binds 
homodimers of the p50 or p52 NF-κB subunits [197]. Interestingly, these two 
subunits lack a transactivation domain and thus have generally been regarded as 
repressors of NF-κB transcription when present in the homodimeric form. Bcl-3 is an 
essential negative regulator of TLR induced responses. Bcl-3
-/-
 macrophages and 
mice are hyper-responsive to TLR stimulation and are defective in 
lipopolysaccharide tolerance [111]. Recently, a single nucleotide polymorphism 
(SNP) associated with reduced Bcl-3 gene expression has been identified as a 
potential risk factor for Crohn’s disease [170]. However, the role of Bcl-3 in IBD has 
not been investigated to date. 
In this chapter the regulation of gut homeostasis by Bcl-3 is analysed using a murine 
acute model of intestinal inflammation. Measurements of Bcl-3 mRNA in patient 
groups with Crohn’s disease (CD), Ulcerative Colitis (UC) and healthy control 
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individuals reveal elevated Bcl-3 expression associated with IBD, in contrast to the 
predictions of the SNP analysis [170]. To further explore the potential role of Bcl-3 
in IBD we used the DSS-induced model of colitis in Bcl-3
-/- 
mice. Considering the 
previously described anti-inflammatory role of Bcl-3 as a negative regulator of 
cytokine expression and an inducer of TLR tolerance [111], we were surprised to 
find that Bcl-3
-/-
 mice were less sensitive to DSS-induced colitis. Measurement of the 
inflammatory response in the colon by analysis of the expression levels of pro-
inflammatory cytokines and the recruitment of T-cells, neutrophils, macrophage and 
dendritic cells, revealed no significant differences between DSS-treated Bcl-3
-/-
 and 
wild type mice. Analysis of intestinal epithelial cell death and proliferation revealed 
increased proliferation and regeneration of the epithelium in Bcl-3
-/-
 mice identifying 
Bcl-3 as an important factor in regulating epithelial cell turnover and sensitivity to 
colitis. Our study suggests that Bcl-3 may be an effective target for promoting 
regeneration of the epithelium in the colon. 
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3.3 Results 
3.3.1 Elevated Bcl-3 mRNA is found in the colon of IBD patients 
To assess the role of Bcl-3 in IBD the Bcl-3 mRNA expression levels were initially 
analysed from a previously published study which identified a large number of genes 
associated with inflammatory bowel diseases [185]. In that study, transcriptional 
profiles were generated from biopsies taken from the sigmoid colon of patients with 
Crohn’s disease (CD) (n = 10) and ulcerative colitis (UC) (n = 10) and those of 
normal controls (n = 11). Bioinformatics analysis of this dataset revealed that Bcl-3 
mRNA expression levels were significantly increased in both CD (p<0.01) and UC 
(p<0.05) (Figure 3.1A). The elevated Bcl-3 mRNA levels in CD and UC were 
unexpected considering a SNP in the BCL3 locus predicted reduced expression of 
Bcl-3 mRNA was associated with in CD [170].  
To confirm this analysis Bcl-3 mRNA expression was measured by real time 
quantitative PCR (qRT-PCR) in an additional, independent patient cohort of 21 CD, 
21 UC and 6 normal control colon tissue samples. Importantly, this independent 
analysis of Bcl-3 mRNA expression also revealed a statistically significant increase 
in Bcl-3 gene expression in Crohn’s disease tissue samples relative to normal healthy 
controls (p<0.05) (Figure 3.1B). Moreover, the magnitude of increase of Bcl-3 
mRNA levels in CD and UC relative to normal controls was similar in these tissue 
samples and in those contained in the previous microarray analysis. However, 
although an increase in Bcl-3 mRNA expression was observed in UC tissue samples, 
this did not meet statistical significance. To gain an insight into the association of 
elevated Bcl-3 mRNA with sites of inflammation in CD, Bcl-3 mRNA expression 
levels were further investigated in tissue samples of the ileum and colon from CD 
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patients and from normal patient control samples. Real time PCR (qRT-PCR) 
analysis of Bcl-3 mRNA in CD ileum and colon tissue revealed increased Bcl-3 
mRNA expression in colon tissue samples of Crohn’s disease relative to normal 
controls (Figure 3.1C). Increased Bcl-3 mRNA expression was not observed in ileum 
tissue of CD tissue samples suggesting that elevated Bcl-3 mRNA levels may be 
associated with specific anatomical regions of the intestine (Figure 3.1C). No 
difference was seen in Bcl-3 expression levels between rectal and colon UC tissue 
(Figure 3.1D). Taken together, these data demonstrate a strong correlation between 
increased Bcl-3 mRNA expression and colitis in human IBD. 
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Figure 3.1: Bcl-3 expression in inflammatory bowel disease. 
 
(A) Bcl-3 mRNA levels in normal (N, n = 11), Crohn’s disease (CD, n = 10) and ulcerative colitis 
(UC, n = 10) colon tissue. Data extracted from the NCBI GEO dataset GDS1330. (B-D) Real time 
PCR (qRT-PCR) analysis of Bcl-3 gene expression relative to normal controls (Human inflammatory 
bowel disease (IBD) tissue array library) (B) Bcl-3 mRNA levels in Crohn’s disease (CD, n = 21) and 
ulcerative colitis (UC, n = 21) tissue samples relative to normal (N, n = 6) controls (p<0.05 *). (C) 
Increased Bcl-3 expression in Crohn’s disease colon (C) tissue relative to normal control tissue (N). 
(D) Differences in Bcl-3 gene expression between colon (C) and rectal (R) UC tissue samples were 
found to be not statistically significant. Data is expressed as means ± standard error of the mean 
(SEM). Statistical significance was determined using Mann Whitney U Tests. N = Normal, C = 
Colon, I = Ileum, R = Rectal, CD = Crohn’s Disease, UC = ulcerative colitis. 
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3.3.2 DSS colitis experimental design  
In order to investigate further the potential role of Bcl-3 in IBD, the murine model of 
dextran-sodium sulphate (DSS) induced colitis was performed using male Bcl-3
-/- 
and wild-type littermate controls as described in chapter 2. Briefly, Bcl-3
-/-
 and wild-
type (WT) litter mate controls were group housed with administration of DSS in 
their drinking water. Three concentrations of DSS (1%, 2% and 2.5%) were tested to 
determine the optimal DSS concentration to induce disease. Fresh DSS solutions 
were administered daily to the mice for six days (D0 – D6) followed by removal of 
DSS and replacement with water only for a further two days. Disease scoring was 
performed daily on each group with weight loss, stool consistency and fur/posture 
individually measured to calculate the daily disease activity index (DAI). On day 8, 
mice were sacrificed for further downstream tissue analysis. Colons were weighed, 
measured and divided into different sections for tissue processing. Tissue samples 
were further processed according to sample requirements (Figure 3.2).  
3.3.3 Bcl-3
-/- 
and WT litter mate controls - genotype confirmation 
Bcl-3
-/-
 and WT littermates were genotyped to confirm their genetic status prior to 
experimental use. Bcl-3
-/-
 expression was analysed by measuring expression of the 
Bcl-3 targeting neocassette construct which results in Bcl-3 becoming functionally 
inactive [108]. Homozygous Bcl-3
-/- 
mice contain two copies of the Bcl-3 construct 
in comparison to the one copy for heterozygotes. WT animals contain no copy of the 
Bcl-3 neocassette as determined by analysing the PCR amplified DNA by agarose 
gel electrophoresis. Expression of the Bcl-3 construct was compared with the IL-2 
promoter with the genetic status of each mouse determined by measuring the ratio of 
the Bcl-3 construct to the IL-2 promoter. WT mice contain only the IL-2 promoter 
74 
 
with heterozygotes containing both the Bcl-3 construct and the IL-2 promoter in a 
1:1 ratio. All Bcl-3 deficient homozygous mice were found have a 2:1 ratio, when 
comparing the Bcl-3 construct with the IL-2 promoter. Following confirmation of 
the genetic status, validated WT and Bcl-3 deficient mice were used in the DSS 
colitis experiment (Figure 3.3). 
 
 
Figure 3.2: DSS colitis experimental design 
Bcl-3
-/- 
and WT litter mate control male mice (10 -12 weeks) were fed a daily solution of DSS (1%, 
2% and 2.5%) in their drinking water for 6 days. DSS was removed and replaced with water only for 
two days prior to experimental endpoint. Daily disease scoring was measured by the daily disease 
activity index scoring system (DAI). Colons were removed at experimental endpoint, opened 
longitudinally and divided into different sections for tissue processing. Colon weight and length were 
influenced by experimental treatment (untreated, DSS treated). The distal colon was determined using 
a 3cm cut off from the base of the colon. Samples were processed according to specific sample 
requirements. 
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Figure 3.3: Genotype confirmation of Bcl-3
-/-
 and WT litter mate control mice 
Bcl-3
-/- 
and WT litter mate controls were all genotyped prior to DSS experimental trial. Data is 
representative of total mice used for DSS trial. N = negative control (no template control), +/+ = Wild 
type control (WT), -/- = Bcl-3
-/- 
(KO – knockout) and +/- = Heterozygous (Het). Amplified PCR 
products for the Bcl-3 construct (209 base pairs) and IL-2 promoter control (170 base pairs) were ran 
on a 2% agarose gel containing SYBR safe DNA gel stain. 
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3.3.4 Bcl-3
-/-
 mice are protected against DSS-induced colitis 
To assess the optimal concentration of DSS required to induce colitis in Bcl-3 
deficient mice, we administered three doses of DSS for six days followed by 
replacement of DSS with water until day eight. Administration of a 1% DSS solution 
did not have a significant effect on either WT or Bcl-3
-/- 
DSS groups when compared 
with healthy untreated groups as determined by DAI score. In contrast a 2.5% DSS 
dose induced a significant change in DAI score for both WT and Bcl-3
-/-
 DSS groups 
when compared to untreated healthy control mice (Day 4; p<0.05, Day 5 – Day 8; 
p<0.001). Interestingly no difference in DAI score was observed between WT and 
Bcl-3
-/- 
2.5% DSS groups suggesting that both Bcl-3
-/- 
and WT mice develop a 
similar colitis phenotype based on DAI scoring analysis (Figure 3.4). 
 Within four days of beginning 2% DSS administration both Bcl-3
-/-
 and WT mice 
developed characteristic symptoms associated with DSS-induced colitis. This data 
suggests that the 2% dose of DSS was sufficient to induce colitis in WT and Bcl-3
-/- 
mice (Day 5 – 8; p<0.001). However when rectal bleeding, diarrhoea, hunched 
posture, and weight loss of 2% DSS treated and untreated mice were analysed, the 
DAI score revealed that Bcl-3
-/-
 mice developed a significantly less severe form of 
DSS-induced colitis when compared with WT DSS treated mice (Day 7; p<0.01, 
Day 8; p<0.001) (Figure 3.4). Importantly, the reduced disease observed in the Bcl-
3
-/-
 mice (2% DSS group) was not a consequence of reduced DSS intake, since water 
consumption was equivalent between groups during the experiment (Figure 3.5).  
Furthermore breakdown analysis of the DAI scoring revealed a large difference in 
weight loss between the WT and Bcl-3
-/- 
2% DSS group. By day eight following 
DSS treatment WT mice had lost greater than 12% of their body weight (Day 6; 
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p<0.01, Day 7; p<0.001, Day 8; p<0.001) (Figure 3.6A). In contrast, DSS treated 
Bcl-3
-/-
 mice did not demonstrate any significant loss of body mass when compared 
to untreated Bcl-3
-/-
 mice up to 8 days following the initial DSS treatment. 
Differences between the WT and Bcl-3
-/-
 2% DSS groups were found to be 
statistically significant at day 7 (p<0.05) and day 8 (p<0.001) (Figure 3.6A). WT and 
Bcl-3
-/- 
mice treated with 2% DSS demonstrated rectal bleeding and alterations in 
stool consistency between day 5 to day 8 relative to their respective healthy 
untreated groups (p<0.001) (Figure 3.6B). However, stool consistency in the 2% 
DSS treated Bcl-3
-/- 
group began to resolve between day 6 and day 8 when compared 
with the WT 2% DSS group (Day 8; p<0.001). This difference in stool consistency 
correlated with the difference in weight loss between the 2% DSS groups with WT 
mice severely losing weight between day 6 to day 8 in comparison to Bcl-3
-/- 
mice. 
In addition treatment with 2% DSS lead to an alteration in fur and posture of both 
WT and Bcl-3
-/- 
2% DSS treated mice when compared with healthy untreated 
controls (Day 4 – 8; p<0.001) however no significant difference was observed 
between these DSS groups (Figure 3.6C). 
The 1% DSS dose did not lead to any weight loss or difference in stool consistency 
when compared with healthy untreated mice (Figure 3.7A-B). A minor change in fur 
and posture score was observed in the 1% DSS groups relative to healthy untreated 
controls however this was not found to be statistically significant (Figure 3.7C). This 
was consistent with the low DAI score for the 1% DSS group (Figure 3.4). The 2.5% 
dose of DSS led to the development of colitis in both WT and Bcl-3
-/- 
mice. Despite 
a robust induction of inflammation as determined by DAI score, the 2.5% DSS dose 
resulted in no difference in weight loss, stool consistency and fur/posture between 
WT and Bcl-3
-/- 
groups. This indicated that this dose exceeded the minimal DSS dose 
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required to induce colitis in these mice (Figure 3.8). Taken together, individual 
scoring analysis of weight loss, stool consistency and fur/posture score revealed that 
the 2% DSS dose was the optimal concentration of DSS to induce colitis in both WT 
and Bcl-3
-/-
 mice. Importantly, this also resulted in a differential response between 
WT and Bcl-3 deficient mice towards DSS. Therefore the 2% DSS concentration 
was used for all subsequent analyses of the role of Bcl-3 in acute colitis unless 
otherwise stated. This data demonstrates clearly that Bcl-3 contributes to colitis with 
WT mice developing a more severe disease in comparison to Bcl-3
-/- 
mice when 
administered 2% DSS. 
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Figure 3.4: Bcl-3
-/- 
mice develop a milder colitis phenotype when administered a 2% DSS dose 
WT and Bcl-3
-/- 
mice were administered DSS for 6 days followed by water for an additional 2 days. 
Weight loss (A), stool consistency (B) and fur/posture (C) were measured each day to determine the 
DAI score for each DSS dose group. Statistical significance in DAI scores were calculated over time 
by Two-way ANOVA with Bonferroni post hoc test with p<0.001 (***), p<0.01 (**) and p<0.05 (*) 
(n = 7/group). 
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Figure 3.5: WT and Bcl-3
-/- 
mice – Daily DSS consumption 
WT and Bcl-3
-/- 
mice were administered DSS for 6 days followed by water for an additional 2 days. 
Average daily DSS consumption was measured in each group every day during DSS consumption. 
Statistical significance in DSS consumption was calculated over time by Two-way ANOVA with 
Bonferroni post hoc test (ns – not statistically significant). (n = 7/group). 
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Figure 3.6: DSS administration (2%) induces a milder colitis phenotype in Bcl-3
-/-
 mice 
WT and Bcl-3
-/- 
mice were administered 2% DSS for 6 days followed by water for an additional 2 
days. Weight loss (A), stool consistency (B) and fur/posture (C) were measured each day to determine 
the DAI score. Statistical significance in weight loss (% change), stool consistency and fur/posture 
scores were calculated over time by Two-way ANOVA with Bonferroni post hoc test with p<0.001 
(***), p<0.01 (**) and p<0.05 (*) (n = 7/group). 
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Figure 3.7: 1% DSS administration is not sufficient to induce the colitis phenotype in Bcl-3
-/-
 
and WT mice 
WT and Bcl-3
-/- 
mice were administered 1% DSS for 6 days followed by water for an additional 2 
days. Weight loss (A), stool consistency (B) and fur/posture (C) were measured each day to determine 
the DAI score. Statistical significance in weight loss (% change), stool consistency and fur/posture 
scores were calculated over time by Two-way ANOVA with Bonferroni post hoc test with p<0.001 
(***), p<0.01 (**) and p<0.05 (*) (n = 7/group). 
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Figure 3.8: 2.5% DSS administration leads to an equivalent colitis phenotype in both WT and 
Bcl-3
-/-
 mice 
WT and Bcl-3
-/- 
mice were administered 2.5% DSS for 6 days followed by water for an additional 2 
days. Weight loss (A), stool consistency (B) and fur/posture (C) were measured each day to determine 
the DAI score. Statistical significance in weight loss (% change), stool consistency and fur/posture 
scores were calculated over time by Two-way ANOVA with Bonferroni post hoc test with p<0.001 
(***), p<0.01 (**) and p<0.05 (*) (n = 7/group). 
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3.3.5 Macroscopic analysis of colon tissue in DSS treated WT and Bcl-3
-/- 
mice 
 
Macroscopic analysis of colon tissue was performed on day eight following 
termination of the experiment. WT 2% DSS-treated mice demonstrated significant 
shortening of the colon when compared to untreated healthy controls (p<0.05; Figure 
3.9A). Surprisingly, a similar degree of colon shortening was observed in 2% DSS 
treated Bcl-3
-/-
 mice when compared to untreated healthy Bcl-3
-/-
 controls (Figure 
3.9A). Moreover, the significantly increased colonic weight of 2% DSS treated WT 
mice relative to untreated controls was also observed in 2% DSS treated Bcl-3
-/-
 mice 
(p<0.05; Figure 3.9B). Thus, although the macroscopic inflammation of colonic 
tissue was similar in both 2% DSS treated WT and Bcl-3
-/-
 mice, the clinical indices 
of the DSS-induced colitis, in particular weight loss, were significantly reduced in 
Bcl-3
-/-
 mice. 
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Figure 3.9: Macroscopic analysis of colon tissue in DSS treated WT and Bcl-3
-/- 
mice 
Differences in (A) colon length and (B) distal colon weight between in both WT and Bcl-3
-/-
 mice was 
relative to healthy untreated controls and found to be statistically significant (p<0.05). Data is 
expressed as mean ± SEM. Statistical significance was determined using Mann Whitney U Tests with 
p<0.05 (*) (n = 7/group). 
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3.3.6 Bcl-3
-/-
 mice show reduced tissue pathology following DSS treatment 
To further investigate the differences in DSS-induced colitis (2% DSS) between WT 
and Bcl-3
-/-
 mice histological examination of distal colon tissue sections from 
untreated and DSS treated WT and Bcl-3
-/-
 mice was performed (Figure 3.10A). No 
differences were observed between untreated WT and untreated Bcl-3
-/-
 distal 
colonic tissue samples by haematoxylin and eosin (H&E) staining. Both WT and 
Bcl-3
-/-
 mice displayed normal epithelial architecture with intact goblet cells and 
crypts with no discernible inflammatory influx. DSS treatment of WT mice induced 
a dramatic alteration in the colonic mucosal tissue with extensive oedema, large 
cellular infiltrates and a severe loss of tissue organisation with destruction of crypts 
and loss of goblet cells. Although histological analysis revealed similar levels of 
oedema and cellular infiltrates in Bcl-3
-/-
 mice there was significantly less 
destruction of the tissue architecture following DSS treatment (Figure 3.10A). 
Quantitative histopathology analysis of the distal colon tissue from DSS treated Bcl-
3
-/-
 mice revealed significantly reduced epithelium damage and loss of tissue 
architecture compared to WT mice (Figure 3.10B). However, there were no 
significant differences in the extent of inflammation, the degree of cellular 
infiltration and oedema between DSS-treated WT and Bcl-3
-/-
 mice. This histological 
analysis provides insight into the reduced weight loss and overall clinical disease 
score observed in DSS-treated Bcl-3
-/-
 mice relative to WT mice, which would 
appear to result from an intact or regenerated epithelium rather than reduced 
leukocyte infiltration in Bcl-3
-/- 
mice. 
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Figure 3.10: Reduced histological damage in Bcl-3
-/- 
mice following DSS induced colitis (Figure legend – Next page) 
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Figure 3.10: Reduced histological damage in Bcl-3
-/- 
mice following DSS induced colitis 
(A) Representative H&E of untreated (control) and DSS treated wild type (WT) and Bcl-3
-/-
 mice. (B) 
Histological sections were scored for cellular infiltration, extent of injury and epithelium/crypt 
damage. DSS induced cellular infiltration, extent of injury, and epithelium and crypt damage scores 
were increased in WT and Bcl-3
-/-
 mice relative to untreated controls. Statistical significance was 
determined using the Mann Whitney U test with p<0.05 (*), p<0.01 (**) and p<0.001 (***). DSS 
treated WT mice showed greater crypt and epithelium damage relative to DSS treated Bcl-3
-/-
 mice 
(p<0.01). Data is representative of greater than 7 fields of view per tissue section at 20X 
magnification (n = 7 per group). 
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3.3.7 DSS induces similar levels of cytokines in the colon of Bcl-3
-/-
 and WT mice 
Although histological analysis showed similar levels of oedema and leukocyte 
infiltration in DSS treated WT and Bcl-3
-/-
 mice, it is possible that the inflammation 
may be qualitatively different between these groups. In order to characterise the 
inflammation associated with DSS-induced colitis in Bcl-3
-/-
 mice we next measured 
inflammatory gene expression in distal colon tissue from untreated and DSS treated 
WT and Bcl-3
-/-
 mice by qRT-PCR. Surprisingly, although Bcl-3 has previously been 
described as a negative regulator of Toll-like receptor induced pro-inflammatory 
gene expression, we found no significant difference in the expression of TNF-α, IL-
6, CXCL1 and IL-1β between DSS-treated WT and Bcl-3-/- mice (Figure 3.11A). 
Measurement of distal colon Bcl-3 protein expression by immunofluorescence was 
unsuccessful using commercially available antibodies (Figure 3.12A) however 
previous studies have demonstrated Bcl-3 mRNA expression in intestinal epithelial 
cells [198, 199]. In support of this we measured increased Bcl-3 mRNA in DSS 
treated WT mice when compared to untreated controls (Figure 3.12B). This suggests 
that although Bcl-3 is inducible upon DSS challenge, its loss does not appear to lead 
to a hyperresponsive immune response. 
 Recent studies have identified a protective role for the cytokines IL-17A and IL-22 
[200-202] in DSS colitis by inducing anti-bacterial peptide expression and epithelial 
cell regeneration in the colon. To assess any role for these cytokines in the observed 
resistance of Bcl-3
-/- 
mice to DSS induced colitis and maintenance of intestinal 
epithelium we next measured their expression in the colon of WT and Bcl-3
-/-
 mice. 
In line with previous reports, the expression of both IL-17A and IL-22 is robustly 
induced by DSS treatment in WT mice, however no significant differences in the 
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expression of these cytokines was found between DSS treated WT and Bcl-3
-/-
 mice 
Figure 3.11B).  
We next analysed the cellular composition of the leukocyte infiltrates in DSS-treated 
WT and Bcl-3
-/-
 mice using immunofluorescence microscopy and antibodies against 
the cell surface markers F4/80 (macrophage), CD3 (T cell), Ly6G (neutrophil) and 
CD11c (dendritic cells) (Figure 3.13A). Quantitative analysis of tissue sections 
demonstrated recruitment of macrophages, neutrophils and to a lesser degree T cells 
and dendritic cells to the distal colon of DSS treated mice. No significant differences 
in the recruitment of these cell types were found between WT and Bcl-3
-/-
 mice 
(Figure 3.13B). These data demonstrate that the inflammatory component of DSS-
induced colitis is similar between WT and Bcl-3
-/-
 mice and suggest that the reduced 
susceptibility of Bcl-3
-/-
 mice to DSS induced colitis may result from altered 
epithelial responses to treatment. 
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Figure 3.11: Inflammatory cytokine expression in mucosal tissue of DSS-treated Bcl-3
-/- 
mice 
Distal colon tissues were analysed for changes in immune gene expression relative to the 
housekeeping gene 18s rRNA. (A) Increased pro-inflammatory gene expression was found in the DSS 
group of WT and Bcl-3
-/-
 mice relative to untreated control groups (p<0.05). (B) Increased IL-17A 
and IL-22 gene expression in DSS treated WT and Bcl-3
-/-
 mice relative to untreated controls. Data is 
represented as relative mRNA expression as determined by the 2
-CT 
method. Statistical significance 
was calculated using Mann Whitney U Tests (p<0.05 *). Data expressed as mean ± SEM (n = 7).
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Figure 3.12: Inducible gene expression in DSS induced colitis (Figure Legend – next page) 
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Figure 3.12: Inducible gene expression in DSS induced colitis 
(A) Immunofluorescent staining for Bcl-3 protein expression in distal colon frozen sections (6μm) at 
40X magnification. (B) Inducible Bcl-3 gene expression in WT DSS treated mice measured by qRT-
PCR. Data is represented as relative mRNA expression as determined by the 2
-CT 
method. Statistical 
significance was calculated using Mann Whitney U Tests (p<0.05 *). Data expressed as mean ± SEM 
(n = 7) U = untreated, D = DSS. 
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Figure 3.13: Analysis of inflammatory cell infiltration during colitis in Bcl-3
-/- 
mice (Figure Legend – next page) 
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 Figure 3.13: Analysis of inflammatory cell infiltration during colitis in Bcl-3
-/- 
mice 
(A) Immunofluorescent staining of 6μm distal colon section at 40X magnification for macrophages 
(F/480), dendritic cells (CD11c), T cells (CD3) and neutrophils (Ly6G). (B) Quantification of F4/80, 
CD3, Ly6G and CD11c positive cellular populations was performed on seven fields of view per 
section. Data is representative of scoring of all sections per treatment group (n =7). Statistical 
significance was determined using Mann Whitney U Tests with p<0.05 (*), p<0.01 (**) and p<0.001 
(***). 
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3.3.8: Increased epithelial cell proliferation in DSS treated Bcl-3
-/-
 mice 
Since DSS induces epithelial cell damage to initiate colonic inflammation and colitis 
we next measured cell death in the colon of WT and Bcl-3
-/-
 mice using terminal 
dUTP nick end labelling (TUNEL) of tissue sections followed by fluorescence 
microscopy analysis. In both untreated WT and untreated Bcl-3
-/-
 mice we observed 
a small number of TUNEL positive nuclei in the top of the crypts representing the 
normal turnover of epithelial cells in this tissue (Figure 3.14A). However, following 
DSS treatment we observed a dramatic increase in TUNEL positive cells in both WT 
and Bcl-3
-/-
 mice. Quantitative analysis of TUNEL staining demonstrated no 
significant differences in the number of cells undergoing apoptosis in both groups 
(Figure 3.14B). Immunoblot analysis of caspase-3 cleavage in colonic tissues also 
demonstrated a significant increase in apoptosis in WT and Bcl-3
-/-
 mice following 
DSS treatment (Figure 3.14C). Densitometric analysis of cleaved caspase-3 levels 
normalised to β-actin level revealed no significant difference between WT and Bcl-3-
/-
 mice (Figure 3.14D). Analysis of the mRNA levels of the apoptotic regulators 
PUMA, Bcl-XL, cIAP1/2 and NOXA by qRT-PCR also revealed no significant 
differences in gene expression between WT and Bcl-3
-/-
 mice (Figure 3.14E). 
Next the extent of epithelial cell proliferation was assessed in tissue sections using 
the cell proliferation marker Ki67. Immunofluorescence microscopy analysis of 
untreated WT and Bcl-3
-/-
 mucosal colonic tissue revealed equivalent numbers of 
Ki67 positive cells at the base of the crypts (Figure 3.15: A and Figure 3.15: B). 
Ki67 staining was largely absent in WT mucosal tissue following DSS treatment and 
coincided with the extensive destruction and loss of tissue architecture (Figure 3.10). 
In contrast, widespread and strong Ki67 staining was found throughout the crypts of 
97 
 
colonic tissue taken from DSS-treated Bcl-3
-/-
 mice, indicating significantly 
enhanced proliferation of Bcl-3
-/-
 epithelial cells following treatment (Figure 3.15: A 
and Figure 3.15: B). Taken together these data suggest that Bcl-3
-/-
 mice develop less 
severe clinical and histopathological colitis due to an increase in epithelial 
proliferation, which leads to regeneration of the damaged epithelium. Our data also 
demonstrate that this regeneration occurs despite the presence of on-going 
inflammation in the colonic mucosa. 
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Figure 3.14: Analysis of cell death during colitis in Bcl-3
-/- 
mice (Figure Legend – next page)
99 
 
Figure 3.14: Analysis of cell death during colitis in Bcl-3
-/- 
mice 
(A) TUNEL stained distal colon 6μm sections. Arrows indicate TUNEL positive cells. Quantification 
of TUNEL positive cells was performed on seven fields of view per tissue section at 20X 
magnification (n = 7 per group). Statistical significance was calculated using Mann Whitney U Tests 
with p<0.05 (*), p<0.01 (**) and p<0.001 (***).White bars represent 200μM scale bar. 
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Figure 3.14: Analysis of cell death during colitis in Bcl-3
-/- 
mice 
(C) Western blotting for inactive (32kDa) and active (17kDa) caspase-3 in distal colon tissue of 
control and DSS treated WT and Bcl-3
-/-
 mice. (C) qRT-PCR analysis of PUMA, Bcl-XL, cIAP1/2 
and NOXA mRNA in distal colon tissue of control and DSS treated WT and Bcl-3
-/-
 mice. Data is 
represented as relative mRNA expression as determined by the 2
-CT 
method. Statistical significance 
was calculated using Mann Whitney U Tests with p<0.05 (*), p<0.01 (**) and p<0.001 (***). Data 
expressed as mean ± SEM (n = 7). White bars represent 200μM scale bar.
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Figure 3.15: Elevated epithelial cell proliferation in DSS treated Bcl-3
-/- 
mice (Figure Legend – next page)
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Figure 3.15: Elevated epithelial cell proliferation in DSS treated Bcl-3
-/- 
mice  
(A) Ki67 immunofluorescence staining of 6μm distal colon sections. Data is representative of greater 
than seven fields of view per tissue section at 20X (n = 7 per group). (B) Quantification of Ki67 
positive cells was performed on seven fields of view per tissue section at 20X (n = 7 per group). 
Statistical significance was determined using Mann Whitney U Tests with p< 0.001 (***), p<0.01 (*) 
and p<0.05 (*). 
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3.4 Discussion 
This study investigated the expression of Bcl-3 in human IBD and also the role of 
Bcl-3 in DSS-induced colitis in the mouse. We found that Bcl-3
-/-
 mice develop less 
severe colitis compared to litter mate control wild type mice. These findings were 
unexpected given the previously described role of Bcl-3 as a negative regulator of 
inflammatory gene expression [111] and the recent identification of reduced Bcl-3 
expression as a potential risk factor for Crohn’s disease [170]. However, the 
resistance of Bcl-3
-/-
 mice to experimentally induced colitis correlates with our 
analysis of Bcl-3 expression in the colon of IBD patients which was significantly 
increased when compared to healthy individuals. It is possible that the identified 
SNPs [170] may lead to increased Bcl-3 expression rather than decreased expression 
as predicted. Thus, our findings suggest that increased expression of Bcl-3 rather 
than reduced expression may be a potential risk factor for IBD. This study also 
identifies a novel role for Bcl-3 in regulating intestinal epithelial cell proliferation 
during DSS-induced colitis. 
DSS has shown differential sensitivity in different murine strains [203, 204]. 
Therefore we tested 1%, 2% and 2.5% DSS doses to determine the minimal dose of 
DSS required to induce colitis in Bcl-3
-/-
 and WT litter mate control mice. Analysis 
of DAI scoring revealed that the 2% dose was the minimal dose required to induce 
colitis in the WT littermate controls. Furthermore, this dose identified Bcl-3
-/- 
mice 
as less sensitive to DSS than their WT counterparts. This difference was not evident 
in the 2.5% DSS dose with both WT and Bcl-3
-/- 
mice demonstrating equivalent 
sensitivity towards DSS. In addition, the 1% DSS dose was not sufficient to induce 
intestinal inflammation in both groups. This data suggested that the higher dose of 
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DSS induced a powerful inflammatory response in both groups masking the role of 
Bcl-3 in regulating intestinal inflammation in this model. Thus, the 2% DSS dose 
was chosen for all downstream experiments. 
Analysis of cytokine expression during DSS-induced colitis in Bcl-3
-/-
 mice revealed 
a robust inflammatory response following DSS treatment characterised by 
significantly elevated levels of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β. 
The levels of these cytokines in Bcl-3
-/-
 mice were similar to WT mice indicating 
that Bcl-3 does not act as a negative regulator of TNF-α, IL-6 and IL-1β expression 
in the context of DSS-induced colonic inflammation. Histological analysis further 
supported this observation as significant oedema and leukocyte infiltration were 
present in Bcl-3
-/-
 colonic tissue sections and to a similar degree as that seen in WT 
mice. Furthermore, equivalent composition of cellular infiltrates was observed 
between WT and Bcl-3
-/-
 mice which demonstrated that the inflammation was 
qualitatively, as well as quantitatively, similar to WT mice. This data suggests that 
Bcl-3 may not play a significant role in the regulation of inflammation in the colon. 
Of note, gene expression analysis and histological analysis was performed at the 
experimental endpoint therefore there may have been increased inflammation after 
DSS treatment. Thus analysis of gene expression and cellular infiltration at an earlier 
time point during DSS treatment may give additional information of the role of Bcl-3 
in the induction of intestinal inflammation. 
Despite a robust inflammatory response following DSS treatment, the colonic tissue 
architecture in Bcl-3
-/-
 mice, in particular the epithelial features remain intact. 
Following DSS treatment intestinal epithelial cell proliferation in Bcl-3
-/-
 mice was 
significantly enhanced whereas in WT mice it was absent. The increased 
proliferation in Bcl-3
-/-
 mice correlates with the maintenance of tissue architecture 
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and structure and suggests that the resistance to DSS-induced colitis of Bcl-3
-/-
 mice 
results from increased regeneration of the epithelium. It is also noteworthy that Bcl-3 
acts a negative regulator of myeloid progenitor proliferation and differentiation, and 
is essential for limiting granulopoiesis under inflammatory conditions [109]. This 
study identifies a novel role for Bcl-3 in regulating intestinal epithelial cell 
proliferation under inflammatory but not homeostatic conditions. Our identification 
of Bcl-3 as a negative regulator of intestinal epithelial cell proliferation during colitis 
suggests additional physiological functions for Bcl-3 beyond its role as a negative 
regulator of pro-inflammatory gene expression. 
The dual role of NF-κB as a key mediator of inflammation and a critical driver of 
epithelial cell survival and proliferation has rendered it a complex and difficult 
therapeutic target in IBD. Transgenic mice in which NF-κB activity has been 
selectively inhibited in the intestinal epithelium develop spontaneous colitis due to 
failure of the epithelial barrier function while an increase in intestinal NF-κB activity 
also leads to severe inflammation [189]. The data obtained in this study however 
suggests that certain regulatory components of the NF-κB pathway such as Bcl-3 
may play a more important role in the epithelium rather than the immune system in 
the colon. We have previously demonstrated that Bcl-3 expression is induced by 
inflammation [111]. Given that the proliferation of intestinal epithelial cells is 
normal in Bcl-3
-/-
 mice it is likely that inflammation induced expression of Bcl-3 in 
the epithelium during colitis contributes to the development of disease. Thus, by 
targeting Bcl-3 it may be possible to enhance epithelial cell proliferation and 
regeneration without exacerbating inflammation in the intestine. The potential 
therapeutic benefits to IBD are highlighted by the reduced clinical score and lack of 
weight loss in DSS-treated Bcl-3
-/-
 mice. 
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In summary, we describe a novel function for Bcl-3 in regulating epithelial cell 
proliferation during DSS-induced colitis. The increased epithelial cell proliferation 
and regeneration in Bcl-3
-/-
 mice further supports a role for NF-κB in maintaining the 
integrity of the intestinal epithelium. This report suggests that targeting Bcl-3 in 
colitis may be therapeutically beneficial in IBD through increasing tissue 
regeneration and repair in the colon without exacerbating the inflammatory response. 
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4. Identification of a novel hybrid macrophage 
polarisation state following recovery from LPS 
tolerance 
4.1 Abstract 
Lipopolysaccharide (LPS) tolerance is an essential immune-homeostatic response 
towards repeated exposure to LPS which prevents excessive inflammatory responses. 
LPS tolerance induces a state of altered responsiveness in macrophages resulting in 
repression of pro-inflammatory gene expression and increased expression of factors 
which mediate the resolution of inflammation. In this study the transcriptional 
plasticity of macrophages was analysed following LPS tolerance using genome-wide 
transcriptional profiling. We demonstrate that LPS tolerance is a transient state and 
that the expression of pro-inflammatory genes is restored to levels comparable to the 
acute response to LPS. However, following recovery from LPS tolerance a number 
of genes remained locked in a tolerisable state including IL-33, CD86, IL-10 and 
NFIL3. Furthermore, we identify of a number of genes uniquely induced following 
recovery from LPS tolerance. Thus, macrophages adopt a unique transcriptional 
profile following recovery from LPS tolerance and have a distinct expression pattern 
of regulators of antigen presentation, antiviral responses and transcription factors. 
Our data suggests that recovery from LPS tolerance leads to a novel hybrid 
macrophage activation state which is pro-inflammatory and microbicidal in nature 
but which possesses a regulatory anti-inflammatory profile distinct from that of LPS 
tolerant and LPS activated (M1) macrophages.  
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4.2 Introduction 
Inflammation is a powerful, organised and complex immunological response towards 
infection and tissue damage. Toll-like receptors (TLR) are central to innate 
inflammatory responses and are key sensors of microbial presence and host damage 
[5]. Toll-like receptor 4 (TLR4) is the most extensively studied TLR which 
recognises lipopolysaccharide (LPS), an outer membrane cell wall component of 
gram negative bacteria. Ligation of TLR4 triggers intracellular signalling pathways 
culminating in the production of pro-inflammatory cytokines, chemokines and type 1 
interferons to effectively clear infection [5, 12, 13]. Chronic or repeated exposure of 
macrophages to LPS leads to a phenomenon termed LPS tolerance which represents 
a state of altered responsiveness towards additional LPS challenge. The most notable 
feature of LPS tolerance is the sharp reduction in pro-inflammatory cytokine 
expression in response to LPS stimulation, including TNF-α and IL-6. LPS tolerance 
is critical in limiting the innate response to infection in order to reduce host damage 
and promote the resolution of inflammation [36, 125, 205]. Failure to enforce LPS 
tolerance may have profound consequences including death due to excessive and 
uncontrolled cytokine production [36, 206].  
Recent transcriptional profiling of macrophages identified two classes of LPS 
induced genes; those that are suppressed during LPS tolerance, so-called tolerisable 
(class T) genes which include TNF-α and IL-6, and those genes whose expression is 
maintained or even increased during LPS tolerance, so called non-tolerisable genes 
(class NT) which include anti-microbial and anti-inflammatory genes. This study 
identified inducible chromatin modifications associated with LPS tolerance which 
promoted a global transcriptional switch in macrophage gene expression. This 
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unique transcriptional signature drives a phenotypic switch in macrophage 
polarisation from a pro-inflammatory to an anti-inflammatory pro-resolution state 
[75]. A number of negative regulators of TLR-induced responses have been 
identified which are critical in promoting LPS tolerance. These include regulators of 
TLR4 induced signal transduction such as IRAK-M, TOLLIP, SHIP, A20 and 
transcriptional regulators such as Bcl-3 [39, 43, 47, 49, 69, 111, 207, 208]. 
Macrophages display a spectrum of activation states which are broadly described as 
classical (M1), alternative (M2) and regulatory (M2-like/M2b) [127, 140]. M1 
macrophages are pro-inflammatory cytotoxic phagocytes and promote Th1 adaptive 
immune responses following TLR and IFN-γ challenge [127, 140]. In contrast, IL-4 
and IL-13 specifically polarise macrophages to an alternatively activated M2 state. 
These cells are anti-inflammatory, promote tissue remodelling and are important in 
mediating Th2 immunity towards fungal and parasitic infections in addition to 
mounting allergic responses [127, 144, 145]. Regulatory macrophages are immune 
regulatory cells that display both anti-inflammatory and pro-inflammatory features 
through suppression of some pro-inflammatory genes and increased production of 
IL-10, while maintaining antigen presenting capacity. Immune complexes in 
conjunction with TLR activation polarise macrophages into a regulatory state. In 
addition, other stimuli including glucocorticoids, prostaglandins and apoptotic cells 
have been implicated in regulatory macrophage polarisation. While regulatory 
macrophages are distinct from both M1 and M2 macrophages, these cells share some 
overlapping anti-inflammatory properties with M2 cells [127]. These three 
macrophage populations represent the main groups in the emerging spectrum of 
macrophage polarisation however many hybrid macrophage activation states exist 
owing to the large number of activation stimuli that macrophages encounter in vivo. 
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Tumour associated macrophages, intestinal macrophages and LPS tolerised 
macrophages are described as representing hybrid macrophage populations which 
share overlapping M1/M2 and regulatory properties while expressing distinct 
features unique to their polarisation state and the microenvironment they reside. 
[152-154].  
LPS tolerance polarises macrophages into an anti-inflammatory macrophage 
activation state [152-154]. Although transcriptomics analysis has been performed on 
LPS tolerance [42, 75, 153], the plasticity of this state has not been explored using 
the same approach. In this chapter the persistence of LPS tolerance was analysed 
using transcriptional profiling and bioinformatics analysis. We utilised a model of 
LPS activation of murine macrophages which generated naïve (N), LPS activated/ 
acute response to LPS (A = M1) and LPS tolerised (T) polarisation states. Our data 
demonstrates that LPS tolerance is a transient state in macrophages and that 
following LPS tolerance macrophages adopt a previously unreported hybrid 
activation state, which we here term recovered macrophage (RM) to reflect the 
recovery from LPS tolerance. Using transcriptional analysis we demonstrate that 
recovery from LPS tolerance, as defined by cytokine expression, is associated with a 
global change in the transcriptional profile of macrophages. Thus RM cells display 
increased expression of tolerisable genes such as TNF-α and IL-6 following LPS 
stimulation, equivalent to that of an LPS activated M1 polarised cell. However, a 
number of genes, including IL-33 remained locked in an LPS tolerisable state and do 
not recover from LPS tolerance a feature not typical of M1 cells. Furthermore, 
recovered macrophages express a subset of inducible genes not observed in M1 or 
the LPS tolerised states. In addition, RM cells display a distinct pattern of expression 
of regulators of antigen presenting and anti-viral responses. Our data suggests that 
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recovery from LPS tolerance leads to a novel hybrid macrophage activation state 
which is pro-inflammatory and cytotoxic in nature but which possesses a regulatory 
anti-inflammatory profile distinct from that of LPS tolerant and LPS activated (M1) 
macrophages.  
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4.3 Results 
4.3.1 LPS Tolerance Recovery Model 
A model of LPS tolerance was designed using murine bone marrow derived 
macrophages (BMDMs) based on previous studies of TLR tolerance in human 
monocytes and murine BMDMs [42, 75]. In addition to naïve (N), acute response to 
LPS – M1-like (A) and LPS tolerant (T) macrophages, we also analysed 
macrophages for up to four days following the induction of LPS tolerance (R). 
Briefly, LPS tolerance (T) was induced by stimulation with LPS (100ng/ml) for 8 
hours followed by washout of LPS with fresh culture medium. Cells were then rested 
for an additional 16 hours prior to re-stimulation with LPS (100ng/ml) for 4 hours. 
Recovery from LPS tolerance (R) was analysed following an additional resting 
period of three days prior to re-stimulation with LPS (100ng/ml) for 4 hours. 
Additional resting days (D2, D4) are specified within the text where appropriate. The 
acute response to LPS was measured in cells which received no pre-stimulation with 
LPS prior to stimulation with 100ng/ml LPS for 4 hours (A). Naïve macrophages (N) 
remained untreated (Figure 4.1).  
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Figure 4.1: LPS Tolerance Recovery model 
Four individual macrophage activation states were induced in the LPS tolerance recovery model; 
Naïve macrophage (N), Acute response to LPS/ M1 (A), LPS tolerant (T) and Recovered macrophage 
(R).  
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4.3.2 Confirmation of LPS tolerance induction 
To confirm suppression of pro-inflammatory gene expression and successful 
induction of an LPS tolerant state in macrophages, gene expression for a validated 
LPS tolerisable pro-inflammatory cytokine, IL-6 [75] was measured by qRT-PCR 
(Figure 4.2). LPS inducible IL-6 mRNA levels were suppressed in the tolerant group 
(T) when compared to the cells of the acute response to LPS (p<0.001) (A). In 
contrast, cells stimulated with LPS two to four days (D2 – D4) prior to re-stimulation 
(recovery) demonstrated inducible gene expression at all stages of recovery from 
LPS tolerance (D2, D3 and D4) when compared to the LPS tolerant group (p<0.001 
D2 and D3, p<0.05 D4). No difference in IL-6 gene expression was found between 
the day 2 and day 3 recovered groups and the acute response group (A) (Figure 4.2). 
Day 3 was found to represent the optimal time point of recovery from LPS tolerance 
with IL-6 gene expression returning to comparable expression levels as the acute 
response group (A). All subsequent experiments performed used day 3 (D3) as the 
time point of recovery from LPS tolerance. 
To investigate if recovery from LPS tolerance was specific to IL-6, gene expression 
of two additional LPS inducible tolerisable genes (T genes) [75, 111] was measured 
by qRT-PCR. The pro-inflammatory genes CXCL10 and TNF-α were induced in the 
recovered group (R) to comparable levels as the LPS activated group (A) (Figure 
4.3). In addition, gene expression for CXCL10 and TNF-α was measured in an 
independent macrophage population to determine if interferon priming of BMDM 
resulting from CSF-1 dependent induction of type 1 interferons was responsible for 
the responses we observed in each macrophage group (N, A, T and R) [209]. 
Thioglycollate elicited macrophages were treated as per the tolerance recovery 
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model and no difference in gene expression patterns for CXCL10 and TNF-α was 
found in these cells when compared with BMDMs (Figure 4.3). This data indicates 
that LPS tolerance is a transient macrophage activation state with recovery of pro-
inflammatory gene expression from LPS tolerance optimally achieved three days 
post LPS tolerance induction. 
 
 
Figure 4.2: Confirmation of LPS tolerance induction 
IL-6 gene expression was measured for each macrophage activation state in the LPS tolerance 
recovery model following 4 hours of re-stimulation by qRT-PCR. Differences between groups were 
measured by one-way ANOVA with Tukey’s post hoc test with p<0.05 (*), p<0.01 (**) and p<0.001 
(***). N = Naïve, A = acute response to LPS, T = LPS Tolerance and R = Recovery (D2 = 2 days 
rest, D3 = 3 days rest and D4 = 4 days rest). Data is representative of greater than four independent 
experiments and measured as relative mRNA as determined by the 2
-CT 
method.  
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Figure 4.3: Pro-inflammatory gene induction following recovery from LPS Tolerance 
Gene expression of CXCL10 and TNF-α was measured for each macrophage activation state in the 
LPS tolerance recovery model following 4 hours of re-stimulation by qRT-PCR. Differences between 
groups were measured by one-way ANOVA with Tukey’s post hoc test with p<0.05 (*), p<0.01 (**) 
and p<0.001 (***). N = Naïve, A = activated, T = LPS Tolerance and R = Recovery. Data is 
representative of greater than four independent experiments and measured as relative mRNA as 
determined by the 2
-CT 
method. BMDM (bone marrow derived macrophage), PM (thioglycollate 
elicited peritoneal macrophage). 
 
 
117 
 
4.3.3 Recovery from LPS Tolerance results in a global shift in the gene 
expression profile of macrophages 
To investigate the global gene expression profile of macrophages that recovered 
from LPS tolerance, microarray analysis was performed on all four macrophage 
groups (N, A, T and R). Initial K-means clustering analysis revealed a unique 
transcriptional signature for each macrophage treatment group with 10 unique gene 
clusters (Figure 4.4A-B). Cluster 1 contains genes that are specifically induced by 
LPS in the tolerant group (T) but not the acute response (A) or recovered groups (R).  
Interestingly, while a reduction in expression of these genes was measured in the 
recovered group compared to the LPS tolerant group (T), gene expression levels 
were increased when compared with the acute response group (A). In contrast, 
clusters 3 and 5 contain genes that were suppressed in the LPS tolerant group (T) but 
were inducible again following recovery from LPS tolerance. This data supports our 
initial pro-inflammatory inducible gene expression findings following recovery from 
LPS tolerance (Figure 4.2). Interestingly, cluster 5 genes were induced to a greater 
level in the recovered group relative to the acute response group (A) while cluster 3 
genes were induced to a lesser degree. Of note, cluster 6 contains genes that are 
highly induced following recovery from LPS tolerance when compared to all other 
groups, thus identifying a unique transcriptional signature for this group (Figure 
4.4A and B).  
Correspondence analysis (COA) identified a 30% (PC1) measure of variance 
between the different macrophage groups (Figure 4.5). This suggests that each 
macrophage group in our model represents a distinct macrophage state. The acute 
response (A) and recovered (R) macrophage populations clustered closely together 
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indicating overlapping transcriptional profiles between these groups. However, upon 
closer examination PC4 (8% variance between groups) measured differences 
between the acute response (A) and the recovered group (R) further supporting a 
unique gene expression profile in RM cells. This finding indicates a high degree of 
macrophage plasticity following the induction of LPS tolerance. Taken together, 
these initial bioinformatics findings confirm that LPS tolerance is a transient 
transcriptional macrophage state and that recovery from LPS tolerance involves a 
global change in the macrophage gene expression profile. This gene expression 
profile of macrophages following recovery from tolerance shares similarity to the 
profile of the acute response group (A) suggesting that recovery from tolerance 
polarises macrophages towards a pro-inflammatory classically activated like (M1-
like) state. 
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Figure 4.4: Recovery from LPS Tolerance results in a global shift in the transcriptional profile of macrophages (Figure legend –Next page)
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Figure 4.4: Recovery from LPS Tolerance results in a global shift in the transcriptional profile 
of macrophages 
(A) Microarray gene expression profiling was performed on Naive, Activated, Tolerant and 
Recovered macrophages (N, A, T and R). Transcriptional profiling was analysed using K-means 
clustering and identified 10 unique gene profile clusters. (B) Extrapolated individual gene clusters 
representing unique gene expression trends. Normalised expression values are represented in Log2. 
Statistical significance was determined using Benjamini Hochberg multiple correction testing. Data is 
represented as log2 fold change of ± 0.585 (1.5 fold) and p<0.05. N = Naïve, A = acute response to 
LPS, T = LPS Tolerance and R = Recovery. 
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Figure 4.5: Correspondence analysis (COA): Recovery from LPS Tolerance involves a global 
shift in the transcriptional profile of macrophages 
Correspondence analysis (COA) was performed on the LPS tolerance recovery microarray 
experiments.  PC1 identified 30% variance between individual groups (N, A, T and R). PC2 revealed 
13% variance between individual microarray replicate experiments. PC3 (11%) identified differences 
between the naïve (N) and tolerant (T) group with PC4 (8%) revealing differences between the acute 
response (A) and recovered (R) groups. N = Naïve, A = acute response to LPS, T = LPS Tolerance 
and R = Recovery. Statistical significance was determined using Benjamini Hochberg multiple 
correction testing (log2 fold change of ± 0.585 (1.5 fold) and p<0.05). 
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4.3.4 Differentially expressed genes and gene ontology enrichment  
To further characterise the gene expression signature of recovered macrophages (R), 
we identified differentially expressed genes in the recovered group relative to naïve 
(N), acute response (A) and tolerant (T) groups (± 1.5 fold change, p<0.05). 
Recovery from LPS tolerance resulted in induced expression of 3,536 genes with 
4,813 suppressed when compared with the naïve group. This gene list was visualised 
by hierarchical clustering analysis which revealed that a large proportion of LPS 
tolerisable genes (T genes) were re-induced following recovery from LPS tolerance 
to levels comparable with the LPS activated group (Figure 4.6A and B). Upon 
further examination the top 30 up-regulated and down regulated genes identified in 
the recovered group relative to the naïve group, revealed striking similarities with 
cells of the acute response group (Figure 4.6A and B, Table 4.1, Table 4.2). The pro-
inflammatory genes CXCL10, TNF-α, IL-27, CD40, CD69, SOCS3 and MX2 were 
all found to be within the top 30 inducible genes in the recovered group based on 
fold change relative to the naïve group (Figure 4.6B and Table 4.1). When 
expression levels of these seven pro-inflammatory genes were compared with the 
levels induced in LPS activated cells relative to naïve cells, no difference in gene 
induction was found (Table 4.3).  
Gene ontology analysis using the online bioinformatics tool DAVID [183] was then 
used to determine the biological significance of differentially expressed genes. 
Unsurprisingly, immune response, TLR signalling, antigen presentation, cytokine 
regulation, and defence response were found to be the most significantly enriched 
gene ontology terms from the genes up-regulated in the recovered group relative to 
the naïve group (Table 4.4 – Table 4.5). This data correlates with differentially 
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expressed genes and biological processes associated with macrophages of the acute 
response compared with untreated controls from this study (Figure 4.7, Table 4.6 and 
Table 4.7) Furthermore the gene ontology terms cell cycle, cell division and mitosis 
were the most significantly enriched biological processes found from the analysis of 
genes up-regulated in the recovered group (R) relative to the tolerant group (T) 
(Figure 4.8, Table 4.8 – Table 4.11). This data suggests that following recovery from 
LPS tolerance macrophages are pro-inflammatory cells with increased cellular 
proliferative capacity compared to anti-inflammatory tolerised cells. 
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Figure 4.6: Differentially expressed genes: Recovery (R) vs. Naïve (N)  
(A) Hierarchical clustering heatmap illustrating up-regulated (red) and down regulated (green) genes 
identified by pairwise comparisons between the recovered group (R) relative to the Naïve group (N). 
(B) Hierarchical clustering heatmap representing the top 30 (largest to smallest fold change) 
differentially expressed up-regulated and down-regulated genes in the recovered group (R) relative to 
the naïve group (N) (data extrapolated from total differential expressed genes - Figure 4.6A). 
Differentially expressed genes were identified using fold change ± 1.5 fold (0.585 Log2) and a P 
value of less than 0.05 (p<0.05). N = Naïve, A = Activated, T = LPS Tolerance and R = Recovery. T 
gene = toleriable gene, NT gene = non-tolerisable gene. 
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Table 4.1: Top 30 up-regulated genes – Recovery (R) vs. Naïve (N)  
Differentially expressed genes were identified using a 1.5 fold change and a P value of less than 0.05 
(p<0.05). Genes are ranked by largest to smallest fold change. 
Rank Gene Name Fold change P value 
1 Cxcl10 202.95 1.49E-02 
2 Irg1 162.80 1.76E-02 
3 Rsad2 155.63 2.21E-02 
4 Cmpk2 128.80 1.64E-02 
5 Cd40 125.45 2.56E-03 
6 TNF 108.53 2.92E-02 
7 Mnda 108.46 1.24E-02 
8 Mx1 103.18 1.07E-02 
9 Gbp2 101.76 1.27E-02 
10 AW112010 98.70 2.13E-02 
11 Clec4e 97.34 2.41E-02 
12 Ifit2 96.47 1.41E-02 
13 Socs3 96.40 6.12E-03 
14 Traf1 94.75 6.09E-03 
15 Cd69 93.38 8.39E-03 
16 LOC100044430 85.51 1.83E-02 
17 Wdr92 81.80 1.62E-02 
18 Mx2 81.01 1.01E-02 
19 Gm4902 79.62 1.16E-02 
20 Gbp3 79.18 9.70E-03 
21 Peci 78.74 1.34E-02 
22 Gm2563 76.48 2.90E-02 
23 Ccl2 76.37 3.51E-02 
24 Phf11 72.71 8.63E-03 
25 Ccl7 71.95 2.14E-02 
26 Saa1 69.60 4.67E-02 
27 Gm4951 68.45 3.55E-03 
28 LOC100039402 64.31 1.76E-02 
29 ENSMUST00000037976 63.78 9.80E-03 
30 Il27 60.46 8.89E-03 
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Table 4.2: Top 30 down-regulated genes – Recovery (R) vs. Naïve (N)  
Differentially expressed genes were identified using a 1.5 fold change and a P value of less than 0.05 
(p<0.05). Genes are ranked by largest to smallest fold change. 
Rank Gene Name Fold change P value 
1 Fam78a -31.41 4.67E-02 
2 BC031353 -28.09 2.50E-02 
3 6430548M08Rik -24.74 3.27E-02 
4 D8Ertd158e -22.90 2.34E-02 
5 Rab3il1 -21.10 6.12E-03 
6 Bmf -17.08 1.89E-02 
7 Snx30 -16.47 3.40E-03 
8 Il6ra -14.93 1.84E-04 
9 Asb2 -14.67 1.09E-04 
10 0610040J01Rik -14.66 1.73E-04 
11 Irf2bp2 -14.61 1.91E-04 
12 Cdca7 -13.73 3.57E-03 
13 Tsc22d3 -13.29 1.74E-02 
14 E2f2 -13.13 6.11E-03 
15 Ascl2 -12.28 1.40E-05 
16 Snx29 -12.25 1.13E-02 
17 Card11 -11.76 7.00E-06 
18 chr7:16633756-16634410_F -11.67 1.50E-05 
19 Arhgef4 -11.20 1.06E-03 
20 Zfp36l1 -11.17 1.41E-03 
21 Gpr146 -11.08 9.60E-05 
22 Raver2 -11.04 4.20E-05 
23 Engase -10.67 1.14E-04 
24 Cxcr4 -9.95 2.60E-05 
25 Lpin1 -9.84 1.22E-04 
26 ENSMUST00000103426 -9.58 1.90E-05 
27 AU022793 -9.55 1.02E-04 
28 Pgbd5 -9.49 1.82E-04 
29 Trib3 -9.34 3.21E-03 
30 Cd300lb -9.20 1.27E-03 
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Table 4.3: Inflammatory expression differences; Recovery (R) and acute 
response (A)  
Differentially expressed genes selected from the top 30 inducible gene lists (Table 4.1 and Table 4.6). 
Genes were identified using a 1.5 fold change and a P value of less than 0.05 (p<0.05) of either group 
relative to the naïve group (R vs. N, A vs. N). Genes are ranked by largest to smallest fold change. 
 
Acute response (A)  Recovered (R)  
Gene Name Fold change  P value Fold change P value 
 
    
CXCL10 209.82 5.48E-02 202.95 4.68E-02 
TNF 104.91 1.02E-02 108.53 2.93E-02 
IL27 56.65 4.07E-02 60.46 3.19E-02 
SOCS3 58.12 5.12E-02 96.40 2.48E-02 
CD69 129.61 2.65E-02 93.38 3.02E-02 
MX2 92.35 3.13E-02 81.01 3.55E-02 
CD40 88.59 2.35E-02 125.45 1.30E-02 
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Table 4.4: Gene Ontology – Recovery (R) vs. Naïve (N)  
Gene ontology terms were identified using DAVID based on differentially expressed inducible genes 
identified using a 1.5 fold change and a P value of less than 0.05 (p<0.05). 
Recovery vs. Naïve: Gene list up-regulated 
Term P-value 
 
 
immune response  2.30E-32 
phosphoprotein  5.10E-20 
Toll-like receptor signaling pathway  1.00E-13 
inflammatory response  2.00E-12 
antigen processing and presentation  2.70E-12 
regulation of cytokine production  4.50E-12 
Cytokine-cytokine receptor interaction  1.80E-11 
response to wounding  4.70E-11 
inflammatory response  5.10E-11 
defense response  2.00E-10 
positive regulation of cytokine production  2.60E-10 
cytokine  3.80E-10 
immune response  4.60E-10 
NOD-like receptor signaling pathway  1.70E-09 
cytokine activity  2.70E-09 
protein kinase cascade  3.00E-09 
cell death 5.50E-09 
death 8.70E-09 
positive regulation of immune system process  1.20E-08 
Type I diabetes mellitus  1.40E-08 
apoptosis 1.50E-08 
programmed cell death  1.60E-08 
positive regulation of response to stimulus  3.10E-08 
Graft-versus-host disease  6.10E-08 
Cytosolic DNA-sensing pathway  1.10E-07 
Apoptosis  1.40E-07 
regulation of apoptosis  2.00E-07 
regulation of immune effector process  2.10E-07 
Allograft rejection 3.10E-07 
MHC protein complex  3.20E-07 
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Table 4.5: Gene Ontology – Recovery (R) vs. Naïve (N)  
Gene ontology terms were identified using DAVID based on differentially expressed suppressed 
genes identified using a 1.5 fold change and a P value of less than 0.05 (p<0.05). 
Recovery vs. Naïve: Gene list down-regulated 
Term P-value 
 
 
phosphoprotein  3.10E-23 
zinc ion binding  9.40E-19 
transition metal ion binding  1.00E-15 
zinc 1.80E-15 
nucleus  1.80E-15 
Transcription 3.00E-15 
transcription  3.70E-15 
GTPase regulator activity  3.20E-13 
metal-binding  6.90E-13 
nucleoside-triphosphatase regulator activity  7.80E-13 
regulation of transcription  1.50E-12 
intracellular non-membrane-bounded organelle  1.10E-10 
non-membrane-bounded organelle  1.10E-10 
regulation of RNA metabolic process  3.40E-10 
regulation of transcription, DNA-dependent  7.50E-10 
alternative splicing  1.10E-09 
regulation of small GTPase mediated signal transduction  1.20E-09 
zinc-finger  1.40E-09 
cell cycle  2.20E-09 
GTPase activator activity  2.20E-09 
DNA binding  4.10E-09 
response to DNA damage stimulus  5.30E-09 
metal ion binding  7.50E-09 
small GTPase regulator activity  1.10E-08 
DNA metabolic process  1.10E-08 
cation binding  1.20E-08 
cell cycle  1.40E-08 
mitochondrion  1.60E-08 
enzyme activator activity 2.00E-08 
cellular response to stress  2.20E-08 
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Figure 4.7: Differentially expressed genes: Acute response (A) vs. Naïve (N)  
(A) Hierarchical clustering heatmap illustrating all up-regulated (red) and down regulated (green) 
genes identified by pairwise comparisons between the acute response group (A) relative to the Naïve 
(N) group. (B) Hierarchical clustering heatmap representing the top 30 (largest to smallest fold 
change) differentially expressed up-regulated and down-regulated genes in acute response group 
relative to the naïve group (data extrapolated from total differential expressed genes - Figure 4.7A). 
Differentially expressed genes were identified using fold change ± 1.5 fold (0.585 Log2) and a P 
value of less than 0.05 (p<0.05). N = Naïve, A = Activated, T = LPS Tolerance and R = Recovery. 
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Table 4.6: Top 30 up-regulated genes – Acute response (A) vs. Naive (N) 
Differentially expressed genes were identified using a 1.5 fold change and a P value of less than 0.05 
(p<0.05). Genes are ranked by largest to smallest fold change. 
Rank Gene Name Fold change P value 
1 Cd69 129.61 2.63E-02 
2 Ifit2 123.13 4.31E-02 
3 Gbp2 108.91 4.69E-02 
4 Mx1 101.97 4.52E-02 
5 Gm3651 95.87 2.90E-02 
6 Cxcl9 94.75 1.56E-03 
7 Mx2 92.35 3.75E-02 
8 Cd40 88.59 2.36E-02 
9 Gbp3 85.98 3.83E-02 
10 Il12b 73.52 1.80E-05 
11 Batf2 69.74 3.55E-02 
12 Fam26f 68.36 2.65E-02 
13 AK152967 65.25 5.51E-03 
14 Ccl12 64.85 3.92E-02 
15 Serpina3g 63.08 6.39E-03 
16 Isg20 62.99 4.07E-02 
17 Sdc4 58.44 2.75E-02 
18 Gm3430 56.85 4.20E-02 
19 Il27 56.65 4.08E-02 
20 Gm2371 54.83 4.79E-02 
21 A530032D15Rik 54.76 2.02E-02 
22 Abtb2 53.89 1.46E-02 
23 chr16:84708695-84708806_F 51.63 7.47E-03 
24 Gm4499 51.59 3.33E-02 
25 Irf7 50.60 3.26E-02 
26 Il15 50.46 1.77E-02 
27 Gm8995 47.67 4.56E-02 
28 Gm4080 47.54 2.97E-02 
29 Gm4951 44.72 3.42E-02 
30 A_55_P2020538 44.02 3.43E-02 
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Table 4.7: Gene ontology - Acute response to LPS (A) vs. Naive (N) 
Gene ontology terms were identified using DAVID based on differentially expressed inducible genes 
identified using a 1.5 fold change and a P value of less than 0.05 (p<0.05). 
Acute response to LPS vs. Naïve: Gene list up-regulated 
Term P value 
  
phosphoprotein 1.40E-17 
immune response 5.40E-07 
nucleus 4.10E-07 
Toll-like receptor signalling pathway 6.70E-07 
nucleotide binding 1.30E-05 
zinc-finger 3.70E-06 
transcription regulation 5.40E-06 
purine ribonucleotide binding 2.10E-05 
ribonucleotide binding 2.10E-05 
Cytosolic DNA-sensing pathway 5.80E-06 
regulation of apoptosis 9.70E-05 
regulation of programmed cell death 1.00E-04 
regulation of cell death 8.90E-05 
purine nucleotide binding 5.30E-05 
RIG-I-like receptor signalling pathway 1.30E-05 
regulation of cytokine production 1.30E-04 
death 1.30E-04 
apoptosis 1.20E-04 
cell death 1.10E-04 
programmed cell death 1.60E-04 
activation of innate immune response 4.10E-04 
Apoptosis 7.00E-05 
cytoplasm 1.70E-04 
NOD-like receptor signalling pathway 7.70E-05 
Transcription 1.80E-04 
response to peptidoglycan 1.10E-03 
alternative splicing 2.90E-04 
domain:PARP catalytic 1.50E-02 
Apoptosis 3.30E-04 
DNA binding 1.20E-03 
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Figure 4.8 (A-B): Differentially expressed genes: Recovery (R) vs. LPS tolerant (T)  
(A) Hierarchical clustering heatmap illustrating all up-regulated (red) and down regulated (green) 
genes identified by pairwise comparisons between the recovered group (R) relative to the LPS tolerant 
group (T). (B) Hierarchical clustering heatmap representing the top 30 (largest to smallest fold 
change) differentially expressed up-regulated and down-regulated genes in recovered group relative to 
the LPS tolerant group (data extrapolated from total differential expressed genes - Figure 4.8A). 
Differentially expressed genes were identified using fold change ± 1.5 fold (0.585 Log2) and a P 
value of less than 0.05 (p<0.05). N = Naïve, A = Activated, T = LPS Tolerance and R = Recovery. 
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Table 4.8: Top 30 up-regulated genes – Recovery (R) vs. LPS Tolerant (T)  
Differentially expressed genes were identified using a 1.5 fold change and a P value of less than 0.05 
(p<0.05). Genes are ranked by largest to smallest fold change. 
Rank Gene Name Fold change P value 
1 Mamdc2 9.05 1.10E-03 
2 Hopx 7.33 2.52E-03 
3 Mrc1 7.05 1.52E-04 
4 Mycl1 6.22 8.02E-04 
5 Inhbb 6.20 2.49E-04 
6 Kalrn 5.29 2.59E-04 
7 Mgll 5.26 1.53E-04 
8 Cfh 5.25 9.36E-04 
9 Klf8 5.20 1.96E-04 
10 Arid5a 5.16 1.75E-02 
11 Pax4 5.01 6.30E-04 
12 Tnfsf10 4.96 3.32E-03 
13 Ifnb1 4.90 3.80E-02 
14 Tnfsf15 4.73 1.41E-03 
15 Gm10419 4.69 1.10E-05 
16 Dll1 4.66 4.48E-04 
17 1700031F10Rik 4.63 3.41E-02 
18 Lck 4.58 7.84E-04 
19 Otud1 4.53 4.19E-04 
20 Il19 4.48 4.07E-03 
21 Serpina3f 4.41 5.01E-03 
22 Nrcam 4.39 7.58E-04 
23 Ppm1k 4.29 3.76E-02 
24 Rnd3 4.28 1.51E-04 
25 Fn1 4.15 3.53E-02 
26 Gprc5c 4.10 1.50E-03 
27 Ifng 4.08 1.35E-03 
28 chr7:13533925-13544525_F 4.07 1.48E-03 
29 Pcp4l1 4.01 2.64E-04 
30 Larp1b 4.00 6.10E-05 
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Table 4.9: Top 30 down-regulated genes – Recovery (R) vs. LPS Tolerant (T)  
Differentially expressed genes were identified using a 1.5 fold change and a P value of less than 0.05 
(p<0.05). Genes are ranked by largest to smallest fold change. 
Rank Gene Name Fold change P value 
1 LOC100044439 -8.56 4.50E-04 
2 Cyp4f18 -7.26 1.14E-04 
3 ENSMUST00000105034 -6.40 1.14E-04 
4 Tgfbi -6.33 4.31E-02 
5 Spib -6.22 2.90E-04 
6 Pdgfb -6.02 9.44E-04 
7 Sema7a -5.97 6.36E-03 
8 Ankrd37 -5.85 1.82E-03 
9 4930583H14Rik -5.84 2.95E-04 
10 Enpp2 -5.79 1.19E-02 
11 ENSMUST00000108773 -5.65 4.75E-04 
12 Cd209f -5.59 4.53E-03 
13 Derl3 5.58 7.25E-03 
14 Rims3 -5.54 4.23E-04 
15 Slc6a13 -5.48 3.10E-04 
16 LOC676974 -5.37 1.53E-03 
17 Treml4 -5.36 1.79E-04 
18 Raver2 -5.30 2.95E-03 
19 Irf2bp2 -5.29 1.65E-02 
20 Pbxip1 -5.21 3.18E-04 
21 Fut7 -5.19 7.51E-04 
22 D430040L24Rik -5.18 1.38E-04 
23 Klf10 -5.16 8.30E-05 
24 Trem3 -5.05 2.69E-03 
25 Kif21b -4.97 4.38E-04 
26 Gpr56 -4.96 1.40E-03 
27 Vgf -4.83 1.67E-03 
28 Esrrg -4.82 8.77E-03 
29 Cd209g -4.66 4.61E-03 
30 Cdkn2b -4.57 4.45E-04 
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Table 4.10: Gene Ontology – Recovery (R) vs. LPS Tolerant (T)  
Gene ontology terms were identified using DAVID based on differentially expressed inducible genes 
identified using a 1.5 fold change and a P value of less than 0.05 (p<0.05). 
Recovery vs. LPS Tolerance: Gene list up-regulated 
Term P-value 
 
 
phosphoprotein  1.90E-16 
cell cycle  5.10E-11 
cell cycle process  7.30E-08 
regulation of cytokine production  1.00E-07 
cell cycle  5.50E-07 
nuclear division  7.00E-07 
mitosis  7.00E-07 
M phase  8.90E-07 
M phase of mitotic cell cycle  1.10E-06 
mitotic cell cycle  1.10E-06 
intracellular signaling cascade  1.30E-06 
chromatin  1.50E-06 
organelle fission  1.50E-06 
mitosis  2.20E-06 
cell cycle phase  2.70E-06 
positive regulation of cytokine production  4.20E-06 
chromosome  6.80E-06 
transferase activity, transferring pentosyl groups  7.80E-06 
positive regulation of biosynthetic process  1.00E-05 
cell division  1.10E-05 
response to wounding  1.10E-05 
cell division  1.20E-05 
regulation of cell proliferation  1.40E-05 
NAD+ ADP-ribosyltransferase activity  1.40E-05 
chromosomal part  1.40E-05 
positive regulation of cellular biosynthetic process  1.50E-05 
heart development  2.10E-05 
regulation of immune effector process  2.50E-05 
domain:PARP catalytic 3.10E-05 
ubl conjugation  3.30E-05 
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Table 4.11: Gene Ontology – Recovery (R) vs. LPS Tolerant (T)  
Gene ontology terms were identified using DAVID based on differentially expressed suppressed 
genes identified using a 1.5 fold change and a P value of less than 0.05 (p<0.05). 
Recovery vs. LPS Tolerance: Gene list down-regulated 
Term P-value 
 
 
mitochondrion  1.80E-16 
zinc ion binding  6.50E-14 
transcription  2.10E-13 
Transcription 3.40E-13 
zinc 5.30E-13 
metal-binding  9.90E-13 
transition metal ion binding  1.80E-12 
regulation of transcription  1.30E-10 
Glycolysis / Gluconeogenesis  1.10E-09 
metal ion binding  1.40E-09 
cation binding  5.00E-09 
mitochondrial part  9.60E-09 
ion binding  1.90E-08 
phosphoprotein  5.50E-08 
regulation of RNA metabolic process  6.30E-08 
regulation of transcription, DNA-dependent  8.40E-08 
nucleus  9.60E-08 
membrane-enclosed lumen  1.70E-07 
organelle lumen  2.10E-07 
intracellular organelle lumen  3.20E-07 
mitochondrion  3.40E-07 
zinc finger region:C2H2-type 7 3.50E-07 
monosaccharide catabolic process  5.50E-07 
glycolysis 6.10E-07 
mitochondrial membrane  1.40E-06 
glucose catabolic process  1.50E-06 
hexose catabolic process  1.50E-06 
glycolysis 1.70E-06 
alcohol catabolic process  2.60E-06 
cellular carbohydrate catabolic process  3.10E-06 
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4.3.5 Recovery from LPS tolerance induces a unique transcriptional signature 
Although COA analysis (PC1) revealed similar transcriptional profiles between the 
acute LPS response and re-stimulation of cells following recovery from LPS 
tolerance, clear differences in the expression of distinct groups of genes can be found 
(PC4). In support of this finding re-stimulation of macrophages with LPS following 
recovery from tolerance induced the expression of 310 genes not induced during the 
initial acute LPS response. Conversely 332 genes were found to be no longer 
induced by LPS following recovery from tolerance. The chemokine receptor 
CX3CR1, often used to distinguish between inflammatory and resident 
monocytes/macrophage lineages [128, 131, 132, 134, 210], was found to be one of 
the most significantly induced genes in the recovered group (R) not found in the 
acute LPS response group (A). Similarly the chemokine receptor CCR5, the folate 
receptor FOLR2, CCR3 and IFN-γ were specifically induced in the recovered group 
(R) (Figure 4.9, Figure 4.10, Table 4.12). The most significantly suppressed 
differentially expressed gene in the recovered group relative to the acute response 
group was the alarmin and pro-inflammatory gene IL-33. IL-33 is suppressed during 
LPS tolerance and remains “locked” in a tolerisable gene expression state following 
recovery from LPS tolerance (Figure 4.9, Figure 4.10 and Table 4.13). 
Unsurprisingly, GO analysis of the 310 up-regulated differentially expressed genes 
in the recovered group relative to the acute response group were found to be enriched 
with numerous immune related processes and pathways. These included immune 
response, response to wounding and inflammatory response (Table 4.14). Of note, 
the most significant biological terms identified from the down-regulated 
differentially expressed genes were antiviral response and response to virus and 
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included the IFNA4, IFNA12, IFNA13, IFNA2, IFNA5 and IFNA7 genes (Figure 
4.10) This was followed by cytokine activity, immune system development and 
cytosolic DNA-sensing pathways (Table 4.15) and included the anti-inflammatory 
cytokine IL-10 and the transcription factor NFIL3 (Figure 4.10). To validate these 
microarray findings gene expression of markers of RM cells was independently 
measured by qRT-PCR and by flow cytometry for the chemokine receptor CCR3 
(Figure 4.11 and Figure 4.12).  
Taken together, the transcriptional profile of the recovered group reflects many 
features of the LPS activated group however this data confirms recovery from LPS 
tolerance does not polarise macrophages strictly into an activated M1 pro-
inflammatory macrophage. Importantly macrophages that recover from LPS 
tolerance have a unique transcriptional signature that identifies them as a novel 
macrophage activation state with altered expression of regulators of the anti-viral 
responses in addition to suppression of selective genes such as IL-33, an amplifier of 
LPS induced responses. 
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Figure 4.9 (A-B): Differentially expressed genes: Recovery (R) vs. activated (A)  
(A) Hierarchical clustering heatmap illustrating all 310 up-regulated (red) and 332 down regulated 
(green) genes identified by pairwise comparisons between the recovered group (R) relative to the 
acute response group (A). (B) Hierarchical clustering heatmap representing the top 30 (largest to 
smallest fold change) differentially expressed up-regulated and down-regulated genes in recovered 
group (R) relative to the acute response group (A) (data extrapolated from total differential expressed 
genes - Figure 4.9A). Differentially expressed genes were identified using fold change ± 1.5 fold 
(0.585 Log2) and a P value of less than 0.05 (p<0.05). N = Naïve, A = Activated, T = LPS Tolerance 
and R = Recovery. 
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Table 4.12: Top 30 up-regulated genes – Recovery (R) vs. LPS activated (A)  
Differentially expressed genes were identified using a 1.5 fold change and a P value of less than 0.05 
(p<0.05). Genes are ranked by largest to smallest fold change. 
Rank Gene Name Fold change P value 
1 LOC100048875 7.38 1.79E-02 
2 Ctla2a 6.32 3.08E-02 
3 Cx3cr1 6.06 2.54E-02 
4 Ccr5 5.84 1.41E-02 
5 Hdac7 4.54 2.80E-02 
6 chrX:120300373-120302404_F 4.40 4.70E-02 
7 Lad1 4.19 4.90E-02 
8 BC055004 4.15 5.54E-03 
9 Antxr1 4.09 2.59E-03 
10 Ifng 3.84 1.82E-02 
11 AW060742 3.82 4.48E-02 
12 Dmwd 3.73 1.89E-02 
13 Folr2 3.58 5.66E-03 
14 Bdh2 3.56 1.37E-02 
15 Pf4 3.39 4.12E-02 
16 Thbs1 3.36 3.04E-02 
17 Nrcam 3.30 2.41E-02 
18 Arhgef10l 3.22 6.89E-03 
19 Lrrc4 3.08 2.00E-02 
20 Col18a1 3.06 1.10E-02 
21 2310046A06Rik 3.06 2.64E-02 
22 chr14:78924115-78938125_R 3.06 4.83E-02 
23 Rdh1 3.05 4.24E-02 
24 chr14:78214602-78225827_F 2.93 3.32E-02 
25 LOC100048011 2.88 1.10E-02 
26 9030619P08Rik 2.81 3.96E-02 
27 Adam8 2.81 1.73E-03 
28 Plxdc2 2.81 2.00E-02 
29 Ralgps1 2.78 4.16E-02 
30 D2Bwg0886e 2.77 3.00E-02 
 
 
 
 
142 
 
Table 4.13: Top 30 down-regulated genes – Recovery (R) vs. LPS activated (A)  
Differentially expressed genes were identified using a 1.5 fold change and a P value of less than 0.05 
(p<0.05). Genes are ranked by largest to smallest fold change. 
 
 
 
 
Rank Gene Name Fold change P value 
1 Il33 -7.18 2.88E-02 
2 LOC545005 -6.84 3.17E-02 
3 Raver2 -6.55 1.44E-02 
4 ENSMUSG00000068790 -5.83 2.61E-02 
5 Cdkn1c -5.76 2.57E-02 
6 BE288493 -5.70 3.18E-02 
7 Mmp9 -5.02 2.92E-02 
8 Gm10406 -5.02 3.18E-02 
9 ENSMUST00000103426 -4.86 1.29E-02 
10 Gm16525 -4.85 1.89E-02 
11 Cbr2 -4.60 1.49E-03 
12 Gm10021 -4.42 3.04E-02 
13 Scd1 -4.33 4.97E-02 
14 Gm3411 -4.08 3.18E-02 
15 1700003M07Rik -4.00 3.18E-02 
16 Gm3115 -3.86 2.80E-02 
17 Igsf9 -3.81 2.00E-02 
18 Abcg1 -3.80 1.49E-03 
19 Il2ra -3.62 3.85E-02 
20 Sez6l2 -3.61 7.13E-03 
21 C920021L13Rik -3.59 1.01E-02 
22 Ndrg1 -3.53 4.03E-02 
23 Gp9 -3.51 2.33E-02 
24 Cnksr3 -3.49 2.36E-02 
25 Cd79b -3.45 2.00E-02 
26 Uts2d -3.43 2.92E-02 
27 Gm5797 -3.40 4.24E-02 
28 Myo15b -3.37 1.51E-02 
29 Pcolce -3.34 1.87E-02 
30 Htra4 -3.26 3.73E-02 
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Table 4.14: Gene Ontology – Recovery (R) vs. LPS activated (A)  
Gene ontology terms were identified using DAVID based on differentially expressed inducible genes 
identified using a 1.5 fold change and a P value of less than 0.05 (p<0.05). 
Recovery vs. LPS activation: Gene list up-regulated 
Term P-value 
 
 
disulfide bond  2.10E-07 
disulfide bond 2.40E-06 
glycoprotein 1.30E-05 
signal 1.60E-05 
immune response  2.30E-05 
Systemic lupus erythematosus  3.40E-05 
response to wounding  3.70E-05 
signal peptide 3.80E-05 
inflammatory response  4.80E-05 
hydroxylation  8.90E-05 
glycosylation site:N-linked (GlcNAc...) 1.20E-04 
membrane  1.30E-04 
defense response  1.60E-04 
positive regulation of response to stimulus  2.60E-04 
adaptive immune response  3.60E-04 
adaptive immune response based on somatic recombination  3.60E-04 
positive regulation of immune system process  5.40E-04 
B cell mediated immunity  8.10E-04 
positive regulation of immune response  8.70E-04 
monoamine transport  1.00E-03 
extracellular region part  1.20E-03 
lymphocyte mediated immunity  1.60E-03 
innate immunity  1.70E-03 
blood vessel morphogenesis  1.80E-03 
negative regulation of angiogenesis  1.80E-03 
vasculature development  2.10E-03 
topological domain:Cytoplasmic 2.10E-03 
acute inflammatory response  2.20E-03 
collagen 2.80E-03 
activation of immune response  2.80E-03 
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Table 4.15: Gene Ontology – Recovery (R) vs. LPS activated (A)  
Gene ontology terms were identified using DAVID based on differentially expressed suppressed 
genes identified using a 1.5 fold change and a P value of less than 0.05 (p<0.05). 
Recovery vs. LPS activation: Gene list down-regulated 
Term P-value 
 
 
Antiviral defense  3.70E-05 
response to virus  3.40E-04 
cytokine  1.60E-03 
cytokine activity  2.40E-03 
immune system development  3.50E-03 
phosphoprotein  4.30E-03 
atp-binding  4.70E-03 
Natural killer cell mediated cytotoxicity  5.70E-03 
Cytosolic DNA-sensing pathway  6.10E-03 
kinase  6.70E-03 
hemopoietic or lymphoid organ development  8.00E-03 
allosteric enzyme  9.80E-03 
extracellular space  9.90E-03 
Regulation of autophagy  1.00E-02 
transferase  1.20E-02 
hemopoiesis  1.20E-02 
regulation of I-kappaB kinase/NF-kappaB cascade  1.30E-02 
Jak-STAT signaling pathway  1.60E-02 
Focal adhesion  1.60E-02 
Lectin  1.70E-02 
ATP binding  1.90E-02 
One carbon pool by folate  1.90E-02 
adenyl ribonucleotide binding  2.20E-02 
carbohydrate binding  2.20E-02 
defense response  2.30E-02 
negative regulation of cell morphogenesis involved in differentiation  2.40E-02 
amino-acid biosynthesis  2.70E-02 
negative regulation of cellular component organization  2.80E-02 
nucleotide-binding  2.90E-02 
basolateral plasma membrane  2.90E-02 
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Figure 4.10: Recovery from LPS tolerance results in a unique transcriptional signature 
Hierarchical clustering analysis of unique gene markers of the recovered group (R) (up-regulated 
(red) and down regulated (green) genes) identified by pairwise comparisons between the recovered 
group (R) relative to the acute response group (A). Differentially expressed genes were identified 
using fold change ± 1.5 fold (0.585 Log2) and a P value of less than 0.05 (p<0.05). N = Naïve, A = 
Activated, T = LPS Tolerance and R = Recovery. 
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Figure 4.11: Recovered macrophages: Validated expression markers 
Microarray intensities (A) and qRT-PCR (B) gene expression confirmation. Data is represented as 
relative mRNA or relative intensity (normalised microarray expression intensity). (C) CCR3 surface 
expression for all macrophage polarisation groups. Data is representative of three independent 
experiments with fluorescence minus one (FMO) and isotype controls. Data is represented as 
percentage gated cells and mean fluorescence intensity (MFI). N = Naïve, A = LPS activated, T = 
LPS Tolerance and R = Recovery. Differences between groups were determined using one-way 
ANOVA with Tukey’s post hoc test with p<0.001 (***), p<0.01 (**) and p<0.05(*). 
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Figure 4.12: Recovered macrophages: Validated expression markers 
Microarray intensities (A) and qRT-PCR (B) gene expression confirmation. Data is represented as 
relative mRNA or relative intensity (normalised microarray expression intensity) Differences between 
groups were determined using one-way ANOVA with Tukey’s post hoc test with p<0.001 (***), 
p<0.01 (**) and p<0.05(*). N = Naïve, A = LPS activated, T = LPS Tolerance and R = Recovery. 
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4.3.6 Recovery from LPS tolerance induces a hybrid macrophage activation 
state, RM. 
Antigen presentation is a classical feature of M1 macrophages while M2 anti-
inflammatory macrophages display reduced capacity to present antigens to adaptive 
immune cells [127, 136]. LPS inducible CD86 mRNA levels were suppressed in 
both the LPS tolerant and recovered groups (Figure 4.13A-B) similar to IL-33, IL-
10, NFIL3 and type 1 interferon gene expression (Figure 4.12). In addition we 
identified a large increase in the number of CD86 (46%) and CD80 (20.7%) F4/80 
double positive cells following acute activation with LPS (Figure 4.13C). CD86 
surface expression was suppressed during LPS tolerance (10.7%) and was not further 
inducible following recovery from LPS tolerance (9.8%). Similarly, LPS inducible 
CD80 surface expression was suppressed in the LPS tolerant group and was not 
inducible following recovery from LPS tolerance in a similar pattern to CD86 
(Figure 4.13C). In contrast to suppression of co-stimulatory molecule expression, 
microbicidal activity and phagocytic capacity remained intact in the recovered 
group. NOS2 gene expression and nitrite production (greiss assay) was increased in 
the recovered group relative to the tolerant group confirming that recovery from LPS 
tolerance restores cytotoxic capacity in macrophages (Figure 4.14A-E). 
In order to further define this inducible macrophage hybrid which we termed an RM 
macrophage state, we analysed M1 and M2 polarising markers from the microarray 
dataset. Using hierarchical clustering analysis we identified an overlap in M1 and 
M2 associated genes expressed following recovery from tolerance (Figure 4.15, 
Table 4.16, Table 4.17 and Table 4.18). The M1 polarisation markers IL-6, NOS2 
and IL-12B [127, 136, 140] were significantly induced by LPS following recovery 
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from tolerance similar to the acute LPS response. In contrast, a number of M2 
associated polarisation markers such as CCL17 and CCL24 [135] were found to be 
significantly induced following recovery from tolerance. Furthermore an increase in 
expression of the M2 polarisation markers mannose receptor (MRC1) and chitinase-
3 like (chi3l3), [127, 135] were induced following recovery from tolerance (Figure 
4.15, Table 4.16, Table 4.17 and Table 4.18). This data suggests that recovery from 
LPS tolerance may alter macrophage antigen presentation capacity and subsequent 
activation of the adaptive immune response. Our finding that following recovery 
from tolerance LPS may robustly induce iNOS gene expression suggests that these 
cells retain their cytotoxic microbicidal function. In addition, the expression of both 
M1 and M2 associated genes further emphasises that recovery from LPS tolerance 
induces a hybrid macrophage state with a unique transcriptional signature. 
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Figure 4.13: RM cells display alterations in regulators of antigen presentation 
(A-B) Microarray and qRT-PCR validation of CD86 gene expression. Microarray gene expression is 
represented as relative intensity with qRT-PCR gene expression is represented as relative mRNA. (C) 
Surface staining for CD80 and CD86 co-stimulatory markers on each F4/80 positive group in the LPS 
tolerance recovery model (% Gated cells and mean fluorescence intensity – MFI). Data is 
representative of greater than three independent experiments. Flow cytometry data is normalised to 
fluorescence minus one (FMO) and isotype controls. Differences between groups determined by one 
way ANOVA with Tukey’s post hoc test p<0.001 (***), p<0.01 (**) and p<0.05 (*).   N = Naïve, A = 
LPS activated, T = LPS Tolerance, R = Recovery. 
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Figure 4.14: RM cells display intact phagocytic and cytotoxic capacity (Figure legend – Next page) 
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Figure 4.14: RM cells display intact phagocytic and cytotoxic capacity 
(A-B) Microarray and qRT-PCR validation of NOS2 gene expression. Microarray gene expression is 
represented as relative intensity with qRT-PCR gene expression is represented as relative mRNA. 
Data is representative of greater than four independent experiments. (C-D) Measurement of nitric 
oxide production was measured using Greiss reagent. (C) NO production 24hr LPS re-stimulation. 
(D) NO production 24hr LPS re-stimulation (fresh media change prior to re-stimulation) (E) 
Phagocytosis capacity was determined by uptake of pHrodo particles. Ingested particles were 
measured by flow cytometry. Differences between groups determined by one way ANOVA with 
Tukey’s post hoc test p<0.001 (***), p<0.01 (**) and p<0.05 (*).  N = Naïve, A = LPS activated, T = 
LPS Tolerance and R = Recovery, NO = nitric oxide. 
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Figure 4.15: RM cells display a hybrid macrophage phenotype 
Hierarchical clustering heatmap analysis of statistically significant M1 and M2 associated genes. 
Statistical significance was determined by log2 fold change ± 0.585 (1.5 fold) and p<0.05. N = Naïve, 
A = LPS activated, T = LPS Tolerance and R = Recovery. 
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Table 4.16: Differentially expressed macrophage polarisation genes – acute 
response (A) vs. Naïve (N) 
Differentially expressed genes were identified using a 1.5 fold change and an 
adjusted P value of less than 0.05 (p<0.05). Differential expression corresponds to 
hierarchical clustering heatmap analysis of macrophage polarisation markers (Figure 
4.15) 
Gene Name Fold change  P value 
Mrc1 -1.02 9.73E-01 
CCL17 1.71 2.64E-02 
CCL22 1.20 4.69E-01 
IL12B 47.21 1.80E-05 
TNFSF4 4.57 7.41E-03 
Ptgs2 21.32 2.29E-03 
IL6 26.63 1.99E-03 
Chi3L3 1.69 1.39E-01 
NOS2 43.32 5.74E-02 
IL10 2.95 7.58E-03 
IL33 12.68 1.65E-03 
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Table 4.17 : Differentially expressed macrophage polarisation genes - LPS 
Tolerant (T) vs. Naïve (N) 
Differentially expressed genes were identified using a 1.5 fold change and an 
adjusted P value of less than 0.05 (p<0.05). Differential expression corresponds to 
hierarchical clustering heatmap analysis of macrophage polarisation markers (Figure 
4.15) 
Gene Name Fold change  P value 
Mrc1 -3.95 4.99E-03 
CCL17 2.38 3.27E-03 
CCL22 1.85 1.51E-02 
IL12B 11.66 2.71E-04 
TNFSF4 2.36 1.32E-01 
Ptgs2 12.53 1.19E-02 
IL6 7.18 4.83E-02 
Chi3L3 2.20 3.86E-02 
NOS2 18.06 1.80E-01 
IL10 0.73 5.02E-01 
IL33 0.91 9.36E-01 
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Table 4.18: Differentially expressed macrophage polarisation genes - Recovered 
(R) vs. Naïve (N) 
Differentially expressed genes were identified using a 1.5 fold change and an 
adjusted P value of less than 0.05 (p<0.05). Differential expression corresponds to 
hierarchical clustering heatmap analysis of macrophage polarisation markers (Figure 
4.15) 
Gene Name Fold change  P value 
Mrc1 1.78 4.58E-02 
CCL17 2.39 2.31E-03 
CCL22 1.93 2.04E-03 
IL12B 25.65 1.00E-06 
TNFSF4 7.93 1.65E-04 
Ptgs2 27.59 6.00E-06 
IL6 31.30 2.19E-02 
Chi3L3 2.39 7.54E-03 
NOS2 49.45 1.36E-02 
IL10 1.73 1.10E-01 
IL33 1.77 3.73E-01 
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4.3.7 Recovery from LPS tolerance is associated with a unique signalling and 
transcription factor profile in macrophages. 
Macrophage polarisation is regulated by a number of transcription factors including 
the NF-κB, STAT and IRF families in addition to MAP kinase signalling. In order to 
assess the role of NF-κB in shaping macrophage responses following recovery from 
LPS tolerance we initially assessed the expression of NF-κB subunits by 
immunoblot. The levels of RelB, c-ReL and p65 subunits following recovery from 
tolerance were similar to those of the acute response group (Figure 4.16A-C). In 
contrast, LPS tolerised cells demonstrated elevated levels of RelB, c-ReL and p50 
protein (Figure 4.16A) Interestingly, p50 levels remained elevated during recovery 
from LPS as demonstrated by both total and nuclear protein at 60 minutes of re-
stimulation with LPS (Figure 4.16A-B). In addition, a re-stimulation step was 
important for movement of NF-κB into the nucleus with minimal detection of NF-κB 
subunits measured without LPS re-stimulation (Figure 4.16B).  Furthermore, we 
observed no difference in total LPS-induced NF-κB binding activity following 
recovery from tolerance and the acute response group as shown by electrophoretic 
mobility shift assay (EMSA) (Figure 4.16C). 
To assess LPS-induced signal transduction following recovery from LPS tolerance 
we measured ERK1/2 and p38 activation at 0, 15, 30 and 60 minutes following LPS 
stimulation using phospho-specific antibodies (Figure 4.17A). Following recovery 
from tolerance ERK1/2 was activated to levels comparable with the LPS activated 
group. Interestingly, p38 phosphorylation was increased following recovery from 
tolerance relative to the acute LPS response. p38 and ERK phosphorylation was 
suppressed in the tolerised group at 30 minutes in agreement with previous studies 
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[211] (Figure 4.17A). We next measured  STAT1 and STAT3 in addition to IRF4 
and IRF5 protein levels both of which have been previously been associated with 
macrophage polarisation [141, 149]. Interesting elevated phosphorylated STAT1 and 
STAT3 was measured in the LPS tolerant and recovered groups with IRF4 protein 
levels reduced in RM cells. No differences were observed in IRF5 protein (Figure 
4.17B and C).  
Interestingly hierarchical clustering analysis of transcription factor mRNA levels 
identified no significant difference in the expression of NF-κB and STAT proteins 
following recovery from tolerance (R) when compared to the acute LPS response 
group (A) (Figure 4.18, Table 4.19, Table 4.20 and Table 4.21). However, we did 
observe differences in the levels of the transcription factors NFIL3 and IRF8, a 
member of the IRF family of transcription factors. Both LPS inducible NFIL3 and 
IRF8 genes were suppressed following recovery from tolerance in a similar pattern 
to IL-33, IL-10 and type I interferon genes (Figure 4.10 and Figure 4.12). This data 
suggests that although no differences were observed in NF-κB protein levels, 
suppression of IRF4, IRF8 and NFIL3 may play a role in defining the transcriptional 
signature following recovery from LPS tolerance. Taken together, recovery from 
LPS tolerance induces a novel hybrid macrophage activation state with a unique 
transcriptional signature. 
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Figure 4.16: Recovery from LPS tolerance is reliant on NF-κB activation (Figure legend – Next page) 
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Figure 4.16: Recovery from LPS tolerance is reliant on NF-κB activation 
(A-B) Immunoblot of total and nuclear NF-κB members during recovery from LPS tolerance. Nuclear 
and total protein was normalised to HDAC1 and β-actin loading controls respectively. (C) EMSA 
measurement of NF-κB binding in each macrophage group (N, A, T and R). N = Naïve, A = LPS 
activated, T = LPS Tolerance, R = Recovery (D2 = day 2, D3 = day 3, D4 = day 4). Data is 
representative of greater than three independent experiments. 
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Figure 4.17: Recovery from LPS tolerance induces a unique signalling and transcription factor profile in macrophages (Figure legend – Next page) 
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Figure 4.17: Recovery from LPS tolerance induces a unique signalling and transcription factor 
profile in macrophages 
(A-B) Immunoblot analysis of pp38, p38, ERK and pERK from whole cell lysates at 0, 15, 30 and 60 
minutes of re-stimulation. Total protein was normalised to the β-actin loading control. (C) 
Immunoblot analysis for IRF4 and IRF5 protein from whole cell lysates. Total protein was normalised 
to the β-actin loading control. N = Naïve, A = LPS activated, T = LPS Tolerance, R = Recovery (D2 = 
day 2, D3 = day 3, D4 = day 4). Data is representative of greater than three independent experiments. 
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Figure 4.18: Recovery from LPS tolerance induces a unique signalling and transcription factor 
profile in macrophages 
Hierarchical clustering analysis with complete linkage of transcription factor genes during LPS 
tolerance recovery. Statistical significance was determined by a Log2 fold change ±0.585 (1.5 fold) 
and a p<0.05. N = Naïve, A = LPS activated, T = LPS Tolerance, R = Recovery (D2 = day 2, D3 = 
day 3, D4 = day 4). 
 
 
 
 
 
 
164 
 
Table 4.19: Differential expressed transcription factor genes - Acute response 
(A) vs. Naïve (N) 
Differentially expressed genes were identified using a 1.5 fold change and an 
adjusted P value of less than 0.05 (p<0.05). Differential expression corresponds to 
hierarchical clustering heatmap analysis of transcription factors (Figure 4.18) 
Gene Name Fold change P value 
Irf6 1.42 4.97E-02 
Nfil3 2.03 2.99E-02 
Irf8 2.29 8.28E-04 
Irf1 3.85 8.50E-05 
Irf7 50.60 3.26E-02 
Stat1 3.03 1.02E-04 
Nfkb1 4.61 2.20E-05 
Stat2 4.63 2.60E-05 
Nfkb2 5.98 5.30E-05 
Stat5a 3.71 1.10E-04 
Rela 1.70 6.21E-04 
Relb 2.53 3.30E-05 
Nfix 1.77 3.63E-03 
Stat3 3.15 2.60E-05 
Rel 5.15 1.12E-04 
Irf2 3.34 4.90E-05 
Irf5 2.13 1.14E-04 
Irf9 1.64 1.26E-03 
Cebpa 0.12 9.60E-05 
Cebpg 0.84 4.93E-01 
Jun 0.74 1.60E-01 
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Table 4.20: Differential expressed transcription factor genes - LPS tolerance (T) 
vs. Naïve (N) 
Differentially expressed genes were identified using a 1.5 fold change and an 
adjusted P value of less than 0.05 (p<0.05). Differential expression corresponds to 
hierarchical clustering heatmap analysis of transcription factors (Figure 4.18) 
Gene Name Fold change  P value 
Irf6 -1.24 2.82E-01 
Nfil3 -1.61 1.73E-01 
Irf8 -1.63 2.89E-02 
Irf1 1.48 1.22E-01 
Irf7 66.35 3.30E-02 
Stat1 2.23 1.90E-03 
Nfkb1 2.54 9.15E-04 
Stat2 3.03 4.43E-04 
Nfkb2 5.37 2.70E-04 
Stat5a 2.30 4.22E-03 
Rela 1.48 7.81E-03 
Relb 2.61 1.23E-04 
Nfix 1.14 5.14E-01 
Stat3 1.49 4.83E-02 
Rel 1.88 4.96E-02 
Irf2 1.17 4.86E-01 
Irf5 1.12 5.02E-01 
Irf9 1.23 1.33E-01 
Cebpa 0.43 3.99E-02 
Cebpg 0.60 3.34E-02 
Jun 0.45 2.50E-03 
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Table 4.21: Differential expressed transcription factor genes - Recovered (R) vs. 
Naïve (N) 
Differentially expressed genes were identified using a 1.5 fold change and an 
adjusted P value of less than 0.05 (p<0.05). Differential expression corresponds to 
hierarchical clustering heatmap analysis of transcription factors (Figure 4.18) 
Gene Name Fold change  P value 
Irf6 1.51 2.35E-02 
Nfil3 -1.23 4.92E-01 
Irf8 -1.10 8.05E-01 
Irf1 3.50 6.00E-06 
Irf7 55.41 5.84E-03 
Stat1 3.03 1.40E-05 
Nfkb1 5.29 2.35E-04 
Stat2 4.11 1.00E-06 
Nfkb2 6.44 1.00E-06 
Stat5a 3.32 1.10E-05 
Rela 2.01 1.10E-05 
Relb 2.85 1.00E-06 
Nfix 2.49 5.00E-05 
Stat3 2.68 1.30E-05 
Rel 4.57 1.30E-05 
Irf2 2.72 7.00E-06 
Irf5 1.98 4.04E-04 
Irf9 1.53 5.43E-04 
Cebpa -4.98 3.67E-03 
Cebpg -1.44 5.51E-02 
Jun -2.32 1.58E-04 
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4.4 Discussion 
The acute response towards LPS or endotoxin is one of the most extensively studied 
immune processes owing to its powerful effect on host immunity and disease. In this 
study we utilised a transcriptomics approach to characterise the transcriptional 
signature of macrophages post LPS tolerance induction. We identified that recovery 
from LPS tolerance induced a novel macrophage activation state (RM) resulting 
from a global transcriptional shift from an anti-inflammatory profile to a M1-M2 
hybrid macrophage state. While a large proportion of tolerisable pro-inflammatory 
gene expression (IL-6, TNF-α and CXCL10) was restored, a number of pro-
inflammatory (IL-33, type 1 interferons), anti-inflammatory (IL-10) and immune 
regulatory genes (NFIL3, CD86) remained locked in a tolerisable state thus failing to 
recover from LPS tolerance. In addition, RM cells expressed a number of unique 
markers not expressed in the other macrophage groups. Taken together this data 
confirms that recovery from LPS tolerance does not polarise macrophages back into 
a pro-inflammatory M1 activation state, but rather a hybrid macrophage state with a 
unique transcriptional signature. 
Macrophages are key components of the innate immune response and central 
mediators of inflammation and defence. These cells also play important 
physiological roles involving tissue repair and remodelling, phagocytosis of cellular 
debris and apoptotic cells in addition to having important metabolic functions [127]. 
This range of biological roles is reflected in an increasingly recognised spectrum of 
macrophage activation states largely focused around the M1 pro-inflammatory /M2 
anti-inflammatory classification system. M1 macrophages are mainly recruited under 
inflammatory conditions such as bacterial or viral infections. These cells are highly 
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cytotoxic, produce significant quantities of pro-inflammatory cytokines and are 
powerful activators of Th1 adaptive immune responses. On the contrary, M2 
macrophages are important in wound healing, tissue remodelling and parasitic 
infections and polarised by IL-4 and IL-13 [127, 135, 136, 140, 212]. Many 
additional stimuli can be found in vivo including glucocorticoids, IL-10, TGF-β, 
parasitic infections, immune complexes and TLR engagement. Therefore 
macrophages are heterogeneous cells with many hybrid polarisation states existing in 
the emerging spectrum of macrophage polarisation [127, 135]. In addition, many 
resident macrophage populations adopt a hybrid anti-inflammatory-like state 
dependent on the local microenvironment. These include liver Kupffer cells, 
intestinal macrophages, placental macrophages, LPS tolerant macrophages and 
tumour associated macrophages [131, 135, 153-155, 157, 163]. 
In this study, we identified a novel macrophage activation state that shares many 
properties of both M1 and M2 macrophage populations. Recovered macrophages 
(RM) express highly inducible levels of pro-inflammatory cytokines and have 
cytotoxic capacity as illustrated by inducible iNOS expression and nitrite production 
suggesting that these cells are more pro-inflammatory M1-like. However, the 
expression of markers of M2 activation (CCL17, CCL22) in addition to the reduced 
expression of co-stimulatory molecules (CD80, CD86) following recovery from LPS 
tolerance would suggest that RM display features of both M1 and M2 polarisation 
states. Importantly, RM cells expressed reduced levels of two associated M2 
polarising markers (IL-33, IRF4) which may be critical to promoting this novel 
hybrid state. IL-33 is a pro-inflammatory cytokine, alarmin and amplifier of LPS 
activation [213-217]. The lack of IL-33 expression in RM may be important in 
limiting the amplification of LPS responses and M2 polarisation through paracrine 
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signalling. Reduced expression of the M2 polarising transcription factor IRF4 [73, 
149] may play a role in facilitating recovery from LPS tolerance by limiting the 
potential for maintenance of an M2-like macrophage polarisation state. In addition, 
we found increased expression of CX3CR1 in both RM and LPS tolerant cells. 
CX3CR1 is expressed on some resident macrophage populations and has been 
implicated in cellular survival. Thus, increased expression of CX3CR1 in RM cells 
may regulate survival post inflammatory challenge [218, 219]. While reduced 
expression of a number of type 1 interferons in RM cells may render macrophages 
more susceptible to viral infections, suppression of these genes may be important to 
limit their unnecessary production post bacterial inflammatory challenge. Taken 
together our data suggests that RM cells are distinct from LPS tolerised macrophages 
and represent a unique macrophage population primed to respond to new 
inflammatory challenges under strict environmental conditions. 
The plasticity of macrophages can have both positive and negative outcomes 
depending on the local environmental requirements and activation stimuli that 
macrophages encounter. While an endotoxin tolerant state may limit potentially 
devastating consequences of excessive inflammation, prolonged tolerance can have 
harmful effects. Monocytes isolated from patients with sepsis or cystic fibrosis 
display reduced responsiveness towards ex vivo challenges with LPS as determined 
by pro-inflammatory cytokine production [159]. These cells remained locked in a 
tolerant state which coincided with patient mortality due to inability to produce a 
robust inflammatory response to secondary infections. Interestingly, patients who 
recovered from sepsis are responsive towards LPS upon LPS challenge ex vivo [159, 
160]. This suggests that recovery from endotoxin tolerance may be a critical 
physiological response to maintain host protection to invading microbial challenges. 
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On the contrary, under normal homeostatic conditions, intestinal macrophages adopt 
a regulatory tolerant-like state towards the local environmental microbial 
community. This environment is rich in the cytokines IL-10 and TGF-β which 
contribute to generating an anti-inflammatory tolerant environment in the gut [131]. 
In addition, the resident macrophage population (Kupffer cells) in the liver adopt an 
anti-inflammatory tolerised-like phenotype specific to the liver microenvironment 
where they are exposed to a vast array of gut derived and environmental toxins under 
the normal physiologic conditions [163-165]. These two macrophage populations 
represent environments where prolonged tolerance is a physiological protection 
mechanism. The loss of this normal tolerance state is associated with alcoholic liver 
disease, HCV viral infections and IBD [158, 167]. Of note, deficiencies in IL-10 and 
the transcription factor NFIL3 have been associated with chronic inflammation in the 
gut [220], two genes that are locked in a tolerised state in RM cells. In addition, 
CD14+ lamina propria mononuclear cells from Crohn’s disease and ulcerative colitis 
patients showed reduced NFIL3 gene expression in comparison to non-inflamed cells 
[220]. NFIL3 is a regulator of IL-12B expression with IL-10 acting as a co-factor in 
NFIL3 induction in macrophages. Although we measured no difference in IL12B 
gene expression in RM cells, suppression of both IL-10 and NFIL3 in RM cells may 
facilitate the recovery from LPS tolerance. Thus this data suggests that a recovery 
from LPS tolerance is central to restoring normal physiological responses following 
microbial infections. Importantly recovery from this tolerant state may be 
environment specific due to the positive and negative effects a loss of tolerance can 
have on host immunity. 
In summary, we have identified a novel transcriptional signature following recovery 
from LPS tolerance which has both pro-inflammatory and anti-inflammatory 
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characteristics. Recovery from LPS tolerance may represent a physiological response 
of macrophages following microbial infection which is important to controlling and 
limiting excessive inflammation. Macrophages that are in an LPS tolerance state 
could be more susceptible towards new microbial challenges due to reduced iNOS 
activity and antigen presentation capability. Macrophages remaining locked in this 
tolerised state would likely have deleterious consequences to the host upon new 
microbial challenges. Recovery from LPS tolerance may therefore allow 
macrophages to be primed towards mounting an effective immune response towards 
new microbial challenges while still maintaining a level of tolerance that protects 
against unnecessary over-activation of the inflammatory response. 
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5. Regulation of cytokine secretion following 
recovery from LPS Tolerance 
5.1 Abstract 
Cytokines and chemokines play a fundamental role in orchestrating the inflammatory 
response through recruitment and expansion of immune cell populations in addition 
to modulating the immunological functions of these cells. Excessive or uncontrolled 
cytokine and chemokine production can have both pathological and immune 
suppressive consequences; therefore their production is tightly controlled 
transcriptionally through induction of TLR tolerance under normal homeostatic 
conditions. In this chapter functional analysis of cytokine and chemokine production 
was performed by fluorescent microscopy and ELISA to investigate the regulation of 
cytokine secretion following recovery from LPS tolerance. We demonstrate a novel 
mechanism of TLR tolerance in macrophages at the level of protein secretion 
through degradation of pro-inflammatory cytokine protein. We identify that pro-
inflammatory cytokine (IL-6, TNF-α and IL-12) and anti-inflammatory cytokine (IL-
10) secretion is selectively suppressed in RM cells despite inducible mRNA and total 
intracellular protein levels measured in these cells. Furthermore, we identified that 
TNF-α cytokine secretion is regulated in a lysosomal dependent process, 
independent of autophagy and acidic protease, calpain and cathepsin dependent 
degradative processes. In addition, we identify that a second independent 
inflammatory signal including IL-1β can restore TNF-α secretion thereby restoring 
immune competency in RM cells. Our data describes a unique mechanism of 
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regulation of TLR tolerance post transcriptionally through degradation of translated 
cytokine protein. 
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5.2 Introduction 
Cytokines and chemokines belong to a diverse family of proteins that play a 
fundamental role in shaping the inflammatory response following recognition of 
pathogen and tissue injury signals. These glycoproteins display a range of pleiotropic 
effects which can function in an autocrine, feedback or synergistic network to tailor 
appropriate inflammatory responses towards specific microbial and host derived 
stimuli. Cytokine and chemokine families largely mediate recruitment of immune 
effector cells such as inflammatory monocytes and neutrophils from circulation to 
sites of infections. In addition, secretion of these proteins by immune cells such as 
macrophages, leads to priming and activation of other innate and adaptive immune 
cell functions including cytotoxicity and antigen presentation in addition to 
promoting the expansion of Th1, Th2, Th17 and B cell populations and their cellular 
responses [3, 221]. 
Microbial recognition by PRRs such as TLR4 leads to rapid production and secretion 
of pro-inflammatory cytokines and chemokines including TNF-α, IL-6, IL-12 and 
RANTES in addition to type 1 interferons and anti-microbial peptides [1]. Induction 
of these pro-inflammatory proteins is associated with a powerful cytotoxic 
macrophage state promoting TH1 immune responses. Cytokine and chemokine 
secretion is regulated transcriptionally during LPS tolerance. Expression of multiple 
negative regulators of TLR signalling and TLR induced transcription such as IRAK-
M, A20, ST2 and Bcl-3 are central to promoting an anti-inflammatory regulatory 
state in macrophages in addition to transcriptional suppression of pro-inflammatory 
cytokine and chemokine production [35, 39, 47, 49, 111]. While induction of a pro-
inflammatory state is essential in order to mount effective immunity against 
microbial infection, excessive and dysregulated production of immune modulators 
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underlies the pathology of a number of chronic inflammatory conditions ranging 
from IBD, chronic obstructive pulmonary disease (COPD), asthma, obesity and 
cancer [222-224]. In contrast, prolonged suppression of these immuno-modulatory 
proteins can lead to a state of immunosuppression rendering the host more 
susceptible to developing opportunistic secondary infections [36, 160, 225].  
Recently suppression of TNF-α secretion has been observed in macrophages isolated 
from Crohn’s disease (CD) patients [226]. TNF-α protein was found within CD 
macrophages despite suppressed TNF-α secretion. It was proposed that lysosomal 
degradation was implicated in suppressing cytokine secretion in CD macrophages 
[226]. This study provides physiological evidence of a disconnect between mRNA 
and protein secretion in macrophages suggesting that post transcriptional regulation 
of cytokine secretion may play a role in the pathogenesis of CD. Importantly whether 
suppressed cytokine secretion is a pathophysiological consequence of CD remains to 
be determined. On the contrary, colonic macrophages under normal environmental 
conditions have been associated with a hyporesponsive state with reduced production 
of pro-inflammatory cytokines including TNF-α despite inducible mRNA and 
intracellular protein measured in these cells [162, 227]. In addition a recent study has 
demonstrated that secretion of the pro-inflammatory cytokine IL-1β by intestinal 
macrophages is controlled by NLRC4 inflammasome activation [228]. In this study, 
colonic macrophages demonstrate a hyporesponsive state through suppressed TNF-α 
and IL-6 production. Furthermore, these cells were shown to contain high levels of 
pro-IL-1β however the mature cytokine was not secreted. Secretion of mature IL-1β 
was dependent on activation of the NLRC4 inflammasome upon pathogenic 
infection as a result of NLRC4 activation of caspase 1 and subsequent cleavage of 
pro-IL-1β. Interestingly, this study demonstrates discrimination between pathogenic 
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and commensal bacteria is dependent on the NLRC4 inflammasome with mature IL-
β not produced in response to commensal bacteria exposure [228]. These studies 
further emphasise a disconnect between mRNA and protein secretion in a 
macrophage population that reside in the unique tolerant environment of the gut. 
These studies highlight that cytokine secretion is regulated post transcriptionally. 
Thus performing transcriptional profiling alone of macrophages that recover from 
LPS tolerance as described in chapter 4 is not sufficient to determine the global 
activation status of RM cells. Therefore in this chapter we performed functional 
analysis of cytokine secretion in RM cells to complement our transcriptional 
profiling data to determine the global impact of recovery from LPS tolerance on the 
activation status of macrophage. 
As described in Chapter 4, recovery from LPS tolerance induces a global switch in 
the gene expression profile of macrophages resulting in a novel macrophage 
activation state with a unique transcriptional signature (RM). Transcriptional 
suppression of many pro-inflammatory genes was alleviated following recovery 
from LPS tolerance, as assessed by microarray profiling however post transcriptional 
analysis of pro-inflammatory cytokine and chemokine expression remained to be 
elucidated in RM cells. In this chapter we used a functional approach to analyse the 
regulation of cytokine production following recovery from LPS tolerance. Similarly 
to transcriptional profiling experiments, we utilised the model of LPS activation of 
murine macrophages to generate naïve (N), LPS activated/ acute response (A = M1), 
LPS tolerised (T) and recovered (R = RM) polarisation states. Our data demonstrates 
that while recovery from LPS tolerance restores transcription of many pro-
inflammatory genes, secretion of pro-inflammatory cytokines and chemokines 
remains suppressed in RM cells despite pro-inflammatory cytokine mRNA actively 
177 
 
being translated into protein. This chapter illustrates a novel mechanism of 
regulation of TLR tolerance through regulation of cytokine secretion in RM cells. 
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5.3 Results 
5.3.1 Recovery from LPS tolerance restores cytokine and chemokine gene 
transcription in RM cells 
Using the designed ex vivo model of recovery from LPS tolerance as previously 
outlined in Chapter 4, the cytokine and chemokine expression profile was analysed 
in RM cells. As previously discussed, LPS tolerance (T) was induced by stimulation 
of BMDMs with LPS (100ng/ml) for 8 hours followed by washout and resting of 
cells for an additional 16 hours prior to re-stimulation with LPS (100ng/ml).  
Recovery from LPS tolerance (R) was induced in macrophages by extending the rest 
period to 3 days following LPS washout. The acute response to LPS (A) was 
measured in cells which received no pre-stimulation with LPS prior to stimulation 
with 100ng/ml LPS (A). The duration of LPS re-stimulation was dependent on the 
experimental endpoint. Messenger RNA levels were measured following 4 hours 
LPS re-stimulation. TNF-α protein was measured following 1.5 hours LPS re-
stimulation for fluorescent microscopy experiments. Intracellular cytokine protein 
was measured at 8 hours post LPS re-stimulation for both immunoblotting and 
intracellular staining by flow cytometry. Cytokine and chemokine secreted protein 
was measured in supernatants removed from cells following 8 and 24 hours LPS re-
stimulation. Naive macrophages (N) remained untreated (Figure 5.1).  
Gene expression of LPS inducible cytokines and chemokines was measured by 
microarray profiling and visualised by hierarchical clustering analysis in all groups 
(N, A, T and R). Gene expression profiling revealed a robust increase in cytokine 
and chemokine mRNA levels following a single stimulation with LPS (A) as 
determined using a 1.5 fold change difference and p value cut off of 0.05. These 
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included pro-inflammatory cytokines and chemokines such as IL-6, CXCL10, IL-12 
and RANTES. A large number of these genes were suppressed following LPS 
tolerance induction (T) and re-inducible upon recovery from LPS tolerance (R) to 
levels comparable with the acute response group (A). In addition a number of non-
tolerisable cytokines and chemokines including RANTES remained inducible 
following recovery from LPS tolerance (Figure 5.2). In support of these findings, 
qRT-PCR validation of cytokine and chemokine gene expression (IL-6, CXCL10, 
CXCL1, TNF-α, RANTES and CXCL2) revealed a robust increase in mRNA levels 
following recovery from LPS tolerance (R) confirming the microarray gene 
expression findings (Figure 5.3).  
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Figure 5.1: LPS Tolerance Recovery Model 
Ex-vivo model of recovery from LPS tolerance using murine BMDM. Briefly, four unique 
macrophage polarisation groups were induced. N = Naïve, A = acute response to LPS, T = LPS 
Tolerance and R = Recovery (RM). 
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Figure 5.2: Cytokine and chemokine transcriptional profile 
Hierarchical clustering analysis of cytokine and chemokine microarray gene expression. Statistical 
significance was determined using Benjamini Hochberg multiple correction testing and with a fold 
change of ± 1.5 fold (0.585 Log2) and a P value cut off of less than 0.05 (p<0.05). Normalised 
expression data is represented in Log2. Up-regulated (up) and down-regulated (down) genes are 
represented in red and green respectively. N = Naïve, A = acute response to LPS, T = LPS Tolerance 
and R = Recovery. 
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Figure 5.3: qRT-PCR validation of cytokine and chemokine gene expression 
Gene expression of CXCL10, IL-6, CXCL1, RANTES, CXCL2 and TNF-α was analysed by qRT-
PCR. Differences between groups were measured by one-way ANOVA with Tukey’s post hoc test 
with p<0.05 (*), p<0.01 (**) and p<0.001 (***). Data is representative of greater than four 
independent experiments and measured as relative mRNA as determined by the 2
-CT 
method. N = 
Naïve, A = acute response to LPS, T = LPS Tolerance and R = Recovery. 
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5.3.2 Recovery from LPS Tolerance restores intracellular TNF-α protein 
To confirm restoration of cytokine and chemokine protein expression following 
recovery from LPS tolerance, intracellular TNF-α protein expression was measured 
by flow cytometry and immunoblot analysis following 8 hours LPS re-stimulation in 
the presence or absence of the protein secretion inhibitor Brefeldin A (1μg/106 cells)  
(Figure 5.4A and B). TNF-α was highly inducible following an initial stimulation 
with LPS (A) with 62% of cells staining double positive for TNF-α and F4/80. In 
contrast only 10.6% of F4/80 positive cells contained TNF-α protein in the LPS 
tolerant group (T). In agreement with the gene expression results, TNF-α protein 
expression was induced in the recovered group (R) (57.8%) to levels comparable 
with the acute response group (A) as determined by intracellular staining and 
immunoblotting analysis (Figure 5.4A and B). This data confirms that suppression of 
pro-inflammatory cytokines and chemokines during LPS tolerance is a transient and 
temporary transcriptional event with both gene expression and intracellular cytokine 
protein restored in RM cells as determined by TNF-α expression. 
184 
 
 
Figure 5.4: Recovery from LPS Tolerance restores intracellular TNF-α protein expression 
(A) Intracellular TNF-α protein was measured in F4/80 positive cells from each group ± brefeldin A 
(1μg/106 cells – BD Golgi Plug). Data was controlled for with isotype specific and FMO controls. (B) 
Immunoblot measurement of total TNF-α protein ± brefeldin A. TNF-α protein was normalised to β-
actin control protein. Data is representative of greater than four independent experiments with protein 
expression measured 8 hours post LPS re-stimulation. N = Naïve, A = acute response to LPS, T = 
LPS Tolerance and R = Recovery. 
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5.3.3 Suppression of pro-inflammatory cytokine secretion following recovery 
from LPS tolerance 
We next analysed cytokine secretion in each macrophage group (N, A, T and R) by 
ELISA. Unexpectedly we were unable to detect significant levels of TNF-α, IL-6, 
IL-10 and IL-12p70 when compared with the acute response group (A) (Figure 
5.5A). These cytokines remained suppressed in a LPS tolerisable state despite 
inducible intracellular TNF-α protein expression measured by intracellular staining 
and immunoblot analysis in the presence or absence of brefeldin A (1μg/106 cells) 
for 8 hours during LPS re-stimulation (Figure 5.4A and B).  
To further analyse the secretion of cytokines and chemokines in the recovered group 
(R) we used an independent method involving an antibody membrane array. We 
screened a panel of thirty two cytokines including IL-6, IL-12p70, IL-12p40/p70, 
RANTES, CXCL1, CXCL2 and CCL3 (Appendix 1  and Appendix 2). Cells from 
each macrophage group (N, A, T and R) were treated as described in the LPS 
tolerance recovery model with cells re-stimulated with LPS for 24 hours. 
Supernatants removed from these cells were incubated with individual cytokine 
antibody membrane arrays for each group (N, A, T and R). This was followed by 
incubation of the membrane with a cocktail of biotinylated antibodies and 
subsequent labelling with streptavidin HRP. The membrane was visualised using a 
chemiluminescence imaging system. Using densitometric analysis we confirmed that 
IL-6, IL-12p70, CCL3 and IL-12p40/p70 secretion remained suppressed in the 
recovered group (R) with levels similar to that of the tolerant group (T) when 
compared with the acute response group (A). No significant difference in the 
secretion of the chemokines CXCL1, RANTES and CXCL2 was found between the 
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groups (A, T and R) (Figure 5.5B and Appendix 1). This data demonstrates that 
cytokine secretion is a regulated process and that cytokine synthesis does not lead to 
cytokine secretion in RM cells. In addition, this data suggests that cytokine secretion 
is regulated post transcriptionally through selective inhibition of pro-inflammatory 
cytokine secretion following recovery from LPS tolerance.  
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Figure 5.5: Suppression of pro-inflammatory cytokine secretion following recovery from LPS 
tolerance 
(A) Pro-inflammatory cytokine secretion is measured by ELISA (pg/ml); TNF-α (8 hours), IL-6, IL-
12p70, IL-10 (24 hours). (B) Pro-inflammatory cytokine and chemokine secretion (24 hours LPS re-
stimulation); cytokine membrane array. Data is represented as relative intensity with all groups 
compared to the Naïve group (N) as determined by densitometric analysis. Densitometric analysis was 
performed using Image J software. Data is representative of greater than four independent 
experiments. N = Naïve, A = acute response to LPS, T = LPS Tolerance and R = Recovery. 
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5.3.4 TNF-α cytokine secretion is regulated through a bafilomycin A sensitive 
compartment 
TNF-α translated protein is trafficked through a classical secretory route via the 
golgi intracellular compartment to recycling endosomes before delivery to the cell 
surface via the phagocytic cup for enzymatic cleavage and release of mature protein 
[229]. To investigate the disconnect between cytokine transcription and translation 
with that of cytokine secretion in RM cells, we measured TNF-α intracellular protein 
levels during the early stages in TNF-α cytokine trafficking through the Golgi. 
Intracellular TNF-α trafficking within each macrophage group (N, A, T and R) was 
analysed by fluorescence microscopy using antibodies against TNF-α and a marker 
of the Golgi intracellular apparatus, GM130. Trafficking of TNF-α through the Golgi 
was measured by analysis of GM130 and TNF-α co-localisation within cells and 
quantified by measuring the percentage co-localisation of GM130/TNF-α per field of 
view at 100X magnification. We identified that 1.5 hours of LPS re-stimulation was 
the optimal time point for analysis of GM130/TNF-α co-localisation in each 
macrophage group. This time point identified a disconnect in TNF-α intracellular 
protein trafficking through the Golgi between cells of the acute response (A) and RM 
cells (Figure 5.6 - Figure 5.12). This disconnect in TNF-α trafficking through the 
Golgi compartment was not evident at later time points as determined by 
GM130/TNF-α co-localisation.  
Upon acute exposure to LPS (A) (1.5 hours), 60% of cells of the acute LPS response 
(A) were found to contain TNF-α co-localising with the Golgi compartment as 
determined by co-localisation with the Golgi marker GM130. In contrast, reduced 
TNF-α protein was measured within the Golgi in the LPS tolerant group (T) with 
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less than 10% of cells containing TNF-α protein co-localising with the Golgi marker 
GM130. This data is in agreement with reduced intracellular TNF-α expression 
levels as measured by flow cytometry and immunoblotting in addition to TNF-α 
transcriptional suppression demonstrated by qRT-PCR in the tolerant group (T) 
(Figure 5.3 and Figure 5.4). Despite inducible mRNA levels of TNF-α in RM cells to 
a level equal to the acute response group (A) (Figure 5.3), an average of 20% of RM 
cells were found to contain TNF-α protein co-localising with the Golgi compartment 
as determined by GM130/TNF-α co-localisation. Importantly a two fold significant 
difference was identified in the level of TNF-α co-localising within the Golgi 
compartment between cells of the acute LPS response (A) and RM cells (p<0.001) 
(Figure 5.6B, Figure 5.7B, Figure 5.8B and Figure 5.9B). This data correlated with 
the previous finding of suppressed cytokine secretion in RM cells at 8 hours post 
LPS re-stimulation (Figure 5.5).  
Reduced TNF-α co-localisation within the Golgi compartment in RM cells despite 
inducible mRNA and total intracellular TNF-α protein (Figure 5.3 and Figure 5.4) 
suggests that TNF-α cytokine secretion is a regulated process. The lack of secretion 
of TNF-α is accompanied by increased total intracellular levels of TNF-α in RM 
cells suggesting that the synthesised protein is being degraded intracellularly. To test 
this hypothesis a panel of inhibitors used to target intracellular proteases (pepstatin 
A), calcium dependent proteases (MDL28170 - calpain III inhibitor) and cathepsin B 
(ca074me) to investigate if these enzymes were involved in degrading TNF-α protein 
in RM cells. Macrophages from each group were re-stimulated for 1.5 hours with 
LPS in the presence of absence of individual inhibitors (pepstatin A - 10μM, 
ca074me – 10μM and MDL28170 - 10μM). TNF-α protein trafficking through the 
golgi was measured by fluorescence microscopy in each macrophage group (N, A, T 
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and R) and represented as percentage GM130/TNF-α co-localisation per field of 
view at 100X magnification. 
Treatment of macrophages from each group with the cathepsin B inhibitor ca074me 
or pepstatin A did not affect TNF-α co-localisation within the Golgi or restore 
cytokine secretion in RM cells despite cathepsin B previously being shown to be 
involved in post-transcriptional processing of TNF-α (Figure 5.6 and Figure 5.7) 
[230]. Although treatment with the calpain inhibitor MDL28170 led to an increase in 
GM130/TNF-α co-localisation in RM cells, a significant difference (p<0.001) 
remained in GM130/TNF-α co-localisation between the acute LPS response group 
(A) and RM cells (Figure 5.8A and B). In addition, while MDL28170 treatment lead 
to increased TNF-α secretion in both the acute LPS response (A) and RM cells, 
MDL28170 treatment did not restore TNF-α secretion in RM cells to levels 
comparable with the acute LPS response groups (A) as determined by ELISA 
(Figure 5.8C).  
We next treated all macrophage groups with bafilomycin A, a vacuolar type H
+ 
ATPase, an inhibitor of intracellular organelle acidification and an inhibitor of the 
late stages of autophagy through inhibition of autophagosome and lysosome fusion, 
to determine if TNF-α protein was being degraded intracellularly in RM cells. Re-
stimulation of groups A, T and R with LPS in the presence or absence of 
bafilomycin A (1μM) for 1.5 hours (including the naïve group) resulted in increased 
levels of intracellular TNF-α protein co-localising within the Golgi compartment in 
both the acute response (A) and recovered groups (R) (Figure 5.9A and B). An 
increase in GM130/TNF-α co-localisation was measured in the acute response group 
(A) treated with bafilomycin A with roughly 80% of cells of the acute response (A) 
co-localising within the Golgi compartment when compared with non bafilomycin A 
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treated acute response cells (A). However a significantly larger fold increase (2 fold) 
in GM130/TNF-α co-localisation was measured following recovery from LPS 
tolerance with 60% of RM cells containing TNF-α co-localising within the Golgi in 
the presence of bafilomycin A when compared with non bafilomycin A treated RM 
cells. In contrast GM130/TNF-α co-localisation was found to be relatively 
unchanged in the LPS tolerant group (T) upon treatment with bafilomycin A (Figure 
5.9A and B). Bafilomycin A treatment during LPS re-stimulation of cells  for 8 
hours led to a 4.5 fold increase (p<0.001) in TNF-α secretion in the acute response 
group (A) when compared with non bafilomycin A treated cells (Figure 5.9C). 
Importantly, treatment of RM cells with bafilomycin A led to a 10 fold increase in 
TNF-α secretion following 8 hours of LPS re-stimulation when compared with RM 
cells without bafilomycin treatment (p<0.001) (Figure 5.9C). Furthermore, 
bafilomycin A treatment led to restoration of TNF-α secretion in RM cells to levels 
comparable with the acute response group (A) (Figure 5.9C). A statistically 
significant increase in TNF-α mRNA levels was measured in RM cells however this 
increase in gene expression is not biologically significant when compared with the 
10 fold increase in secreted TNF-α protein in RM cells treated with bafilomycin A 
(Figure 5.9D). This data demonstrates that a bafilomycin sensitive compartment is 
involved in the regulation of TNF-α cytokine secretion following recovery from LPS 
tolerance. 
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Figure 5.6: Pepstatin A inhibition does not restore TNF-α protein levels in RM cells (Figure legend – Next page)
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Figure 5.6: Pepstatin A inhibition does not restore TNF-α protein levels in RM cells  
(A) GM130/TNF-α co-localisation following 1.5 hour LPS re-stimulation ± protease inhibitor 
pepstatin A (10μM). Immunofluorescence images are representative of individual fields of view (10 
fields of view analysed at 100X). (B) Quantification of GM130/TNF-α co-localisation (% co-
localisation). Quantification was performed on greater than 10 fields of view at 100X magnification 
from greater than two independent experiments. (C) TNF-α secretion ± pepstatin A (8 hours LPS re-
stimulation) Differences between groups were measured by one-way ANOVA with Tukey’s post hoc 
test; p<0.001 (***), p<0.01 (**) p<0.05 (*). N = Naïve, A = acute response to LPS, T = LPS 
Tolerance and R = Recovery. 
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Figure 5.7: Cathepsin B inhibition does not restore TNF-α protein levels in RM cells (Figure legend – Next page) 
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Figure 5.7: Cathepsin B inhibition does not restore TNF-α protein levels in RM cells  
(A) GM130/TNF-α co-localisation following 1.5 hour LPS re-stimulation ± cathepsin inhibitor 
ca074me (10μM). Immunofluorescence images are representative of individual fields of view (10 
fields of view analysed at 100X). (B) Quantification of GM130/TNF-α co-localisation (% co-
localisation). Quantification was performed on greater than 10 fields of view at 100X magnification 
from greater than two independent experiments. (C) TNF-α secretion ± ca074me (8 hours LPS re-
stimulation) Differences between groups were measured by one-way ANOVA with Tukey’s post hoc 
test; p<0.001 (***), p<0.01 (**) p<0.05 (*). N = Naïve, A = acute response to LPS, T = LPS 
Tolerance and R = Recovery. 
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Figure 5.8: Calpain inhibition does not restore TNF-α protein levels in RM cells (Figure legend – Next page)
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Figure 5.8: Calpain inhibition does not restore TNF-α protein levels in RM cells 
(A) GM130/TNF-α co-localisation following 1.5 hour LPS re-stimulation ± calpain III inhibitor 
MDL28170 (10μM). Immunofluorescence images are representative of individual fields of view (10 
fields of view analysed at 100X). (B) Quantification of GM130/TNF-α co-localisation (% co-
localisation). Quantification was performed on greater than 10 fields of view at 100X magnification 
from greater than two independent experiments. (C) TNF-α secretion ± MDL28170 (8 hours LPS re-
stimulation) Differences between groups were measured by one-way ANOVA with Tukey’s post hoc 
test; p<0.001 (***), p<0.01 (**) p<0.05 (*). N = Naïve, A = acute response to LPS, T = LPS 
Tolerance and R = Recovery. 
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Figure 5.9: TNF-α secretion is regulated through a Bafilomycin A sensitive compartment in RM cells 
(A) GM130/TNF-α co-localisation following 1.5 hour LPS re-stimulation ± bafilomycin A (1μM). Immunofluorescence images are representative of total 
field of view at 100X magnification. 
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Figure 5.9: TNF-α secretion is regulated through a Bafilomycin A sensitive compartment in RM cells 
(B) Quantification of GM130/TNF-α co-localisation (% co-localisation) following 1.5 hour LPS re-stimulation ± bafilomycin A (1μM) at 100X 
magnification.  (C) TNF-α secretion (pg/ml) ± bafilomycin A (8 hours). (D) TNF-α gene expression ± bafilomycin A represented as relative mRNA. 
Differences between groups were measured by one-way ANOVA with Tukey’s post hoc test; p<0.001 (***), p<0.01 (**) p<0.05 (*). Quantification of 
GM130/TNF-α co-localisation was measured from greater than 10 fields of view at 100X magnification. Data is representative of greater than three 
independent experiments. N = Naïve, A = acute response to LPS, T = LPS Tolerance and R = Recovery. 
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5.3.5 Loss of Atg16L1 does not restore TNF-α secretion in RM cells 
Autophagy is an evolutionarily conserved process important in maintaining cell and 
tissue homeostasis through removal of cellular proteins and organelles by targeting 
them for degradation within lysosomes while recycling cellular energy and nutrients 
[231, 232]. Autophagy is a physiological host response and has also been shown to 
be important in controlling cytokine secretion by regulating inflammasome 
activation targeting pro-IL-1β for cleavage by caspase 1[231, 233]. In addition, 
autophagy has been shown to be important in regulating IL-23 secretion through the 
regulation of IL-1 family of cytokines [232, 234]. Atg16L1 is an important 
component of the autophagy apparatus with Atg16L1 deficiency leading to defective 
recruitment of the Atg12-Atg5 complex resulting in inhibition of autophagosome 
formation [235]. Furthermore Atg16L1 has been identified as a Crohn’s disease 
susceptibility gene [236] in addition to being important in regulating LPS induced 
IL-1β secretion in BMDMs [72]. Therefore to investigate if suppressed cytokine 
secretion in RM cells was controlled by an autophagy dependent degradative 
process, we tested if TNF-α secretion could be restored in RM cells to levels 
comparable to cells of the acute response (A) in the absence of Atg16L1 using 
Atg16L1 deficient BMDMs.  
WT and Atg16L1 deficient BMDMs were treated as described in the LPS tolerance 
recovery model (Figure 5.1). No difference in TNF-α gene expression was measured 
between WT and Atg16L1
-/- 
cells following 4 hours re-stimulation of macrophage 
groups (A, T and R) with LPS (Figure 5.10A). Similarly no difference in total 
intracellular TNF-α protein was found between WT and Atg16L1-/- cells as 
determined by immunoblot and intracellular staining by flow cytometry following 8 
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hours LPS re-stimulation in the presence or absence of brefeldin A (1μg/106 cells) 
(Figure 5.10B and C). 
We next measured TNF-α trafficking through the Golgi compartment by measuring 
the percentage of cells containing TNF-α co-localising with the Golgi marker 
GM130 following 1.5 hours LPS re-stimulation. A 2 fold significant increase was 
measured in the number of Atg16L1
-/- 
RM cells containing TNF-α co-localising 
within the Golgi (GM130/TNF-α co-localisation) in comparison to that of wild type 
RM cells (Figure 5.11A and B). However this did not fully restore GM130/TNF-α 
co-localisation in Atg16L1 deficient RM cells to levels comparable with Atg16L1 
deficient cells of the acute response (A) as determined quantitatively by measuring 
the percentage of GM130/TNF-α positive cells (Figure 5.11A and B). These data 
correlate with treatment of RM cells with bafilomycin A, which led to an increase in 
TNF-α co-localising within the Golgi compartment when compared with non 
bafilomycin treated RM cells (Figure 5.9B). Importantly, despite Atg16L1 
deficiency in RM cells leading to a 2 fold increase GM130/TNF-α co-localisation 
similar to bafilomycin treatment of RM cells, Atg16L1 deficiency did not restore 
TNF-α secretion in RM cells when compared with Atg16L1 deficient acute LPS 
response cells (A) (Figure 5.11C). This data is in contrast to the ability of 
bafilomycin A treatment of RM cells to induce a 10 fold increase in TNF-α secretion 
in comparison to non bafilomycin A treated RM cells Figure 5.9C). Taken together 
this data suggests that a bafilomycin A dependent cellular process through inhibition 
of organelle acidification other than autophagy may be involved in regulation of 
TNF-α secretion in RM cells. 
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Figure 5.10: Atg16L1 deficiency does not affect TNF-α transcription and translation following 
recovery from LPS tolerance 
Wild type (WT) and Atg16L1
-/- 
BMDMs (A) TNF-α gene transcription (relative mRNA) following 4 
hours LPS re-stimulation. (B) Immunoblot of total TNF-α protein ± brefeldin A (8 hours LPS re-
stimulation) normalised to β-actin control protein. (C) Intracellular TNF-α protein was measured in 
F4/80 positive cells from each group (N, A, T and R) ± brefeldin A (8 hours LPS re-stimulation). 
Data was controlled for with isotype specific and FMO controls. Differences between groups were 
measured by one-way ANOVA with Tukey’s post hoc test; p<0.001 (***), p<0.01 (**) p<0.05 (*). 
Data is representative of greater than three independent experiments. N = Naïve, A = acute response 
to LPS, T = LPS Tolerance and R = Recovery. 
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Figure 5.11: TNF-α secretion in RM cells is not regulated by autophagy (Figure legend – Next page) 
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Figure 5.11: TNF-α secretion in RM cells is not regulated by autophagy 
WT and Atg16L1
-/- 
BMDMs (A) TNF-α/GM130 co-localisation following 1.5 hour LPS re-
stimulation. Immunofluorescence images are representative of total field of view at 100X 
magnification. (B) Quantification of TNF-α/GM130 co-localisation (% co-localisation) was measured 
from greater than 10 fields of view at 100X magnification. (C) TNF-α secretion (pg/ml) was 
measured at 8 hours post re-stimulation. Differences between groups were measured by one-way 
ANOVA with Tukey’s post hoc test; p<0.001 (***), p<0.01 (**) p<0.05 (*). Data is representative of 
greater than three independent experiments. N = Naïve, A = acute response to LPS, T = LPS 
Tolerance and R = Recovery. 
 
 
 
 
 
 
 
 
 
 
 
 
205 
 
5.3.6 TNF-α co-localisation within the Golgi is restored in RM cells upon 
treatment with monensin 
To further investigate the consequences of blocking acidification of intracellular 
organelle compartments, GM130 co-localisation with TNF-α was measured in the 
presence or absence of the monovalent ionophore monensin. Monensin treatment 
raises the pH of acidic intracellular compartments such as lysosomes by facilitating 
the exchange of sodium ions for protons. In a similar pattern to bafilomycin A 
treatment of cells (Figure 5.9), monensin (2μM) treatment for 1.5 hours during LPS 
re-stimulation led to a significant increase in GM130/TNF-α co-localisation in RM 
cells comparable with cells of the acute LPS response (A) (Figure 5.12A and B). 
Despite alterations in Golgi structure associated with treatment with monensin or 
brefeldin A [237], co-localisation of TNF-α within this fragmented compartment was 
easily measured. Monensin treatment of cells of the acute LPS response (A) led to a 
small increase in intracellular TNF-α co-localising within the Golgi however 
monensin treatment completely restored GM130/TNF-α co-localisation (90%) in 
RM cells to levels comparable with cells of the acute response group. Collectively, 
this data suggests that TNF-α is directed towards acidic intracellular compartments 
such as lysosomes for degradation in RM cells rather than being trafficked to the cell 
surface for cleavage and subsequent secretion of mature TNF-α protein. 
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Figure 5.12: TNF-α secretion may be regulated in a lysosomal dependent process 
(A) TNF-α/GM130 co-localisation following 1.5 hour LPS re-stimulation ± monensin. Immunofluorescence images are representative of total field of view 
at 100X magnification. (B) Quantification of TNF-α/GM130 co-localisation (% co-localisation) was measured from greater than 10 fields of view at 100X 
magnification. Differences between groups were measured by one-way ANOVA with Tukey’s post hoc test; p<0.001 (***), p<0.01 (**) p<0.05 (*). Data is 
representative of greater than three independent experiments. N = Naïve, A = acute response to LPS, T = LPS Tolerance and R = Recovery. 
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5.3.7 Restoration of cytokine secretion in RM cells upon stimulation with a 
second independent signal  
Suppression of cytokine secretion despite intact total intracellular cytokine protein 
expression (Figure 5.4) levels in RM cells would appear to be a wasteful use of 
cellular energy resources. In addition, inhibition of cytokine secretion in RM cells 
may render the host more susceptible to secondary opportunistic infections due to the 
inability to recruit other innate immune cells including neutrophils and monocytes 
mediated by cytokines and chemokines. In addition induction of cytotoxicity, 
antigen presentation activities and expansion of Th1, Th2, Th17 and B cell 
populations and their cellular responses are all key functions of cytokines and 
chemokines which would be reduced if cytokine secretion is inhibited. Therefore to 
investigate the ability of RM cells to mount an effective immune response towards 
secondary infections, cytokine secretion was measured in RM cells upon challenge 
with a second independent inflammatory signal.  
Macrophages from each group were treated as described in the LPS tolerance 
recovery model prior to re-stimulation (Figure 5.1). Macrophages were then re-
stimulated with a combination of LPS and an additional inflammatory signal such as 
IL-1β (10ng/ml) or a TLR2 agonist Pam3CSK4 (100ng/ml) or the TLR9 agonist 
CpG (1μM) or IFN-γ (50ng/ml) or CD40L (10μg/ml) for 8 hours (TNF-α secretion) 
and 24 hours (IL-6 secretion). Supernatants were removed from each group (N, A, T 
and R) that were re-stimulated with different combinations of ligands described. 
Cytokine secretion was analysed by ELISA. TNF-α cytokine secretion was restored 
in RM cells to levels comparable to the acute response group (A) upon combined re-
stimulation with LPS and IL-1β. The LPS and IL-1β combined stimulation resulted 
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in a 2 fold increase in TNF-α secretion in RM cells. Treatment of group A, T and R 
with LPS and Pam3CSK4 or LPS and CpG resulted in a robust increase in cytokine 
secretion in all groups. Treatment of RM cells with LPS and Pam3CSK4 resulted in 
a 20 fold increase in TNF-α secretion while LPS and CpG co-treatment of RM cells 
resulted in an 18 fold increase in TNF-α secretion (Figure 5.13). Interestingly this 
coincided with increased mRNA levels of TNF-α in the macrophage groups (A, T 
and R) upon Pam3CSK4 and CpG challenge but not that of IL-1β challenge. 
Importantly increased mRNA levels in RM cells did not account for restoration of 
secretion of TNF-α as no difference in mRNA levels were found between the acute 
LPS response group (A) and RM cells following co-treatment with LPS and IL-1β or 
LPS and Pam3CSK4 or LPS and CpG (Figure 5.13). Importantly, re-stimulation of 
tolerant cells (T) with LPS and IL-1β, or LPS and Pam3CSK4, or LPS and CpG did 
not alter TNF-α secretion with TNF-α secretion and gene expression remaining 
suppressed when compared with the acute response group (A) (Figure 5.13).  
The restoration of TNF-α cytokine secretion was found to be stimulus dependent 
with combined LPS stimulation with IFN-γ or LPS and CD40L, two powerful 
activators of inflammation, failing to restore TNF-α secretion in RM cells when 
compared with the acute LPS response group (A). TNF-α secretion levels were 
found be comparable to the LPS tolerant group (T) (Figure 5.14). Furthermore 
restoration of cytokine secretion was specific to TNF-α with secretion of IL-6 
remaining suppressed upon re-stimulation with LPS and IL-1β or LPS and 
Pam3CSK4 or LPS and CpG when compared with the acute response group (A) 
(Figure 5.15). Taken together this data suggests that RM cells are primed to respond 
and secrete TNF-α upon independent inflammatory signals such IL-1β. Furthermore 
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this highlights that restoration of pro-inflammatory cytokine secretion is tightly 
regulated in a stimulus dependent manner.  
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Figure 5.13: An independent inflammatory stimulus restores TNF-α secretion in RM cells 
TNF-α secretion (pg/ml) and TNF-α gene expression was measured post re-stimulation with LPS ± 
Pam3CSK4 (100ng/ml), CpG (1μM) or IL-1β (10ng/ml). Secretion and gene expression were 
measured 8 and 4 hours post re-stimulation respectively. Gene expression is measured as relative 
mRNA. Differences between groups were measured by one-way ANOVA with Tukey’s post hoc test; 
p<0.001 (***), p<0.01 (**) p<0.05 (*). Data is representative of greater than three independent 
experiments. N = Naïve, A = acute response to LPS, T = LPS Tolerance and R = Recovery.  
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Figure 5.14:  Restoration of TNF-α secretion in RM cells is stimulus specific 
TNF-α secretion (pg/ml) was measured post re-stimulation with LPS ± IFN-γ (50ng/ml) or CD40L 
(10μg/ml). Secretion was measured 8 post re-stimulation. Differences between groups were measured 
by one-way ANOVA with Tukey’s post hoc test; p<0.001 (***), p<0.01 (**) p<0.05 (*). Data is 
representative of greater than three independent experiments. N = Naïve, A = acute response to LPS, 
T = LPS Tolerance and R = Recovery.  
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Figure 5.15: Pam3CSK4, CpG and IL-1β does not restore IL-6 secretion in RM cells 
IL-6 secretion (pg/ml) and IL-6 gene expression were measured post re-stimulation with LPS ± 
Pam3CSK4 (100ng/ml), CpG (1μM) or IL-1β (10ng/ml). Secretion and gene expression were 
measured 24 hours and 4 hours post re-stimulation respectively. Gene expression is measured as 
relative mRNA. Differences between groups were measured by one-way ANOVA with Tukey’s post 
hoc test; p<0.001 (***), p<0.01 (**) p<0.05 (*). Data is representative of greater than three 
independent experiments. N = Naïve, A = acute response to LPS, T = LPS Tolerance and R = 
Recovery.  
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5.4 Discussion 
TLR induced inflammation is a highly orchestrated and tightly regulated 
immunological response to infection and injury. While extensive research has been 
undertaken to elucidate the regulation of TLR immune responses, much of this focus 
has been largely centred on the TLR signalling pathway and transcriptional 
regulation of TLR responses [2, 3, 30, 75]. Here we illustrate a novel mechanism of 
regulation of TLR inflammatory responses post translationally at the level of 
cytokine secretion. Using the model of acute response to LPS, regulation of cytokine 
protein was analysed in Naïve (N), acute LPS response (A), LPS tolerant (T) and 
RM recovered cells (R = RM). Transcriptomic analysis revealed that gene 
expression of interleukin, CXCL and CCL pro-inflammatory cytokine and 
chemokine families were inducible upon recovery from LPS tolerance. Tolerisable 
cytokines including TNF-α, CXCL10, CXCL1 and IL-6 were induced in RM cells to 
levels comparable with that of the acute response to LPS (A). Furthermore non-
tolerisable cytokine and chemokine genes including RANTES, CCL17, CCL9 and 
CCL22 remained inducible in RM cells. In agreement with these findings, 
intracellular levels of TNF-α were measured following recovery from LPS tolerance 
(R) confirming that TNF-α mRNA was translated and not inhibited through post 
transcriptional regulatory events [238]. In contrast, secretion of TNF-α in addition to 
IL-6, IL-10, CXCL10, CCL3, and IL-12p70 was dramatically reduced in RM cells. 
Furthermore we identified that a second independent specific stimulus may 
selectively restore cytokine secretion upon recovery from LPS tolerance. 
Cytokine and chemokine secretion during infection or injury is fundamental to 
mounting an effective and tailored immunological response to specific inflammatory 
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stimuli. These key immune-modulatory proteins initiate immune cell recruitment in 
addition to modulating immune cellular functions and expansion of adaptive immune 
cell populations to fight and clear infection, thus restoring immune and tissue 
homeostasis [3]. Despite playing a fundamental protective immunological role, 
excessive production of cytokines and chemokines underlie the pathology of many 
chronic inflammatory and autoimmune diseases. Cytokines produced from multiple 
cellular sources including macrophages play a central role in the pathogenesis of 
rheumatoid arthritis (RA) [222]. Although numerous cytokines and chemokines have 
been implicated in RA, TNF-α is widely found in synovial membranes of these 
patients. Over-expression studies in mice with TNF-α demonstrated the ability to 
develop spontaneous arthritis [222]. Similarly, excessive cytokine production has 
been a central component of the pathogenesis of inflammatory bowel disease [239]. 
Of note, neutralising TNF-α protein with TNF-α targeting antibodies (infliximab and 
adalimuab) are widely used in the clinic as part of the treatment and management of 
both RA and IBD [222, 239]. The development of therapeutics targeting cytokines 
specifically highlights the central role cytokines play in the pathology of these 
diseases. 
Tissue resident macrophages that are found in healthy non-obese adipose tissue have 
an anti-inflammatory like phenotype dependent on the local adipokine 
microenvironment to perform tissue specific regulatory functions. During obesity 
this metabolic environment is disrupted as a result of increased levels of pre-
adipocytes. Increased levels of these cells can lead to increased production of pro-
inflammatory cytokines and induction of unnecessary inflammation. Increased 
production of TNF-α and IL-6 has been implicated in the development of insulin 
resistance and type 2 diabetes [127]. Furthermore, excessive and uncontrolled 
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cytokine and chemokine production has been implicated in asthma and lung diseases 
including COPD [223]. Similarly, extensive vascular inflammation has been 
associated with the pro-inflammatory environment created within atherosclerotic 
plaques [240]. On the contrary, dysregulation of cytokine production has been 
implicated in immunosuppressive states including sepsis [117, 159, 225]. Prolonged 
and unregulated suppression of pro-inflammatory cytokine production by monocytes 
mirrors a state of endotoxin tolerance in sepsis patients [36]. Furthermore, 
monocytes isolated from cystic fibrosis patients demonstrate a similar tolerant-like 
profile [42, 113, 241]. Additionally, inability to regulate cytokine production 
correlates with increased susceptibility to secondary opportunistic infections and 
subsequent patient mortality [160]. 
The variety of chronic inflammatory and immunosuppressive conditions associated 
with dysregulated cytokine and chemokine production demonstrates the importance 
for tight regulation of cytokine secretion following acute inflammatory responses. 
This study suggests that inflammation is regulated post translationally through 
modulation of cytokine secretion following recovery from LPS tolerance. To 
decipher the regulatory mechanism involved in inhibiting TNF-α secretion, RM cells 
were treated with bafilomycin A, a known inhibitor of autophagy and vacuolar type 
H
+
ATPase which inhibits acidification of cellular compartments including lysosomes 
and endosomes. Restoration of TNF-α secretion and increased levels of TNF-α co-
localising within the Golgi in RM cells upon bafilomycin A treatment suggested that 
translated TNF-α may be alternatively trafficked within RM cells towards lysosomal 
compartments to prevent secretion. Treatment with additional inhibitors of 
intracellular proteases including pepstatin A, in addition to a calpain inhibitor and 
cathepsin B inhibitor did not have the same effect as bafilomycin A in restoring 
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TNF-α secretion in RM cells suggesting that an alternative intracellular compartment 
that is bafilomycin A sensitive is involved in TNF-protein degradation. Additionally, 
RM cells deficient in Atg16L1, an autophagy protein involved in recruitment of the 
Atg12-Atg5 complex which is involved in autophagosome formation in the 
autophagy pathway [235] did not demonstrate restored TNF-α secretion despite 
defects in the autophagy pathway implicated in the alterations in IL-1β production 
[72, 231, 232, 234]. This suggests that an alternative bafilomycin sensitive 
compartment may be involved in the regulation of cytokine secretion in RM cells. In 
support of bafilomycin A restoration of TNF-α secretion in RM cells, treatment of 
cells with an additional inhibitor of lysosomal acidification, monensin, led to 
increased levels of TNF-α protein co-localising within the Golgi compartment 
thereby preventing trafficking of TNF-α towards these intracellular acidic 
compartments. Collectively this data suggests that recovery from LPS tolerance 
regulates inflammation through altering TNF-α trafficking towards a degradative 
pathway that is independent of autophagy and intracellular acidic proteases, calpain 
and cathepsin B enzyme degradation.  
Interestingly, suppression of TNF-α secretion has been observed in macrophages 
isolated from Crohn’s disease (CD) patients [226]. Smith et al found intracellular 
TNF-α protein within CD macrophages despite reduced protein secretion. Smith et al 
proposed that lysosomal degradation was implicated in suppressing cytokine 
secretion in CD macrophages [226]. This study provides solid evidence for post 
translational regulation of cytokine secretion as a mechanism for regulating 
macrophage responses to TLRs. Whether suppressed cytokine secretion is a 
consequence of CD pathology remains to be determined.  
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In light of this work we propose that TLR tolerance is not only regulated at the 
mRNA level, but also at the level of secretion. In chapter 4 transcriptional profiling 
identified LPS tolerance as a transient state with transcriptional repression of pro-
inflammatory mRNA alleviated following recovery from this state. In this chapter 
measurement of total intracellular TNF-α protein further highlighted restoration of 
inflammatory potential post LPS tolerance. Furthermore, this confirmed that post 
transcriptional regulatory events involving mRNA stability were not implicated in 
suppressing cytokine secretion [238]. Reduced TNF-α secretion following recovery 
from LPS tolerance suggests that RM cells do not restore full pro-inflammatory 
potential similar to macrophages of the acute response to LPS. Requirement of a 
secondary independent signal highlighted that macrophages post LPS tolerance 
adopt an immune primed phenotype that is regulated through cytokine secretion. 
This level of regulation of inflammation suggests that following recovery from LPS 
tolerance, macrophages may retain a memory of a prior inflammatory response. Thus 
these cells are able to respond rapidly upon additional specific infections, in 
environments where maintaince of a tolerant state is critical to maintain tissue 
homeostasis such as in the gut or that of adipose tissue.  
Recent studies have demonstrated a role for the multiprotein inflammasome complex 
in the regulation of inflammatory responses in intestinal phagocytes through NLRC4 
driven IL-β production [228]. Franchi et al demonstrated that CD11b positive 
intestinal phagocytes (iMPs) were anergic to TLR stimulation however produced 
high levels of pro-IL-1β [228]. Upon pathogenic infection with Salmonella or 
Pseudomonas species NLRC4 drives mature IL-1β production which in turn 
orchestrates the inflammatory response to these infections in the intestine [228]. 
Interestingly, we identified that IL-1β co-stimulation with LPS restored TNF-α 
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secretion in RM cells suggesting that activation of the inflammasome complex may 
play a role in the regulation of cytokine secretion following recovery from LPS 
tolerance.  
Ueda et al demonstrated that colonic macrophages are hyporesponsive towards TLR 
stimulation with IL-10 production central to controlling secretion of inflammatory 
cytokines including IL-6 and TNF-α [162]. In addition, this study demonstrated that 
STAT3 or IL-10 deficient mice were hyperresponsive to LPS with increased TNF-α 
and IL-6 secretion measured in colonic macrophages [162]. In chapter 4 we 
measured increased phosphorylated STAT1 and STAT3 in both LPS tolerant (T) and 
RM cells (Figure 4.17) suggesting that these transcription factors may play a role 
regulation of cytokine secretion in RM cells. A recent study has characterised 
colonic macrophage populations under steady state and inflammatory conditions 
[227]. This study demonstrated that resident colonic macrophages were responsive 
toward TLR challenge with mRNA and intracellular TNF-α protein increased in 
these cells [227]. While TNF-α secretion was not measured in these cells, previous 
studies by Franchi et al [228] and Ueda et al [162] did not detect secretion of TNF-α 
or IL-6  upon TLR stimulation. These two studies isolated colonic macrophages 
using CD11b MACS separation or CD11b flow cytometry cell sorting, however 
Bain et al describe a novel isolation protocol for resident colonic macrophages using 
a panel of colonic macrophage specific markers [227]. As a result, it would be 
important to measure cytokine production from these cells upon TLR challenge to 
confirm the suppressed cytokine secretion identified in the previous studies. Taken 
together these studies correlate with the suppressed cytokine secretion findings in 
RMs of this study suggesting that TLR tolerance may also be regulated at the level 
of cytokine secretion under physiological conditions in the intestine. 
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These three studies also highlight the importance of measuring both cytokine 
secretion and mRNA levels to determine the activation status of cells. LPS tolerance 
results from transcriptional repression of pro-inflammatory gene expression and 
subsequent suppression of cytokine synthesis and secretion [75]. Measurement of 
restored mRNA levels of tolerisable cytokines including TNF-α alone would suggest 
that recovery from LPS tolerance restored inflammatory potential of macrophage to 
levels comparable with LPS M1 macrophages. Measurement of cytokine secretion 
by ELISA alone would suggest that RM cells remain in a LPS tolerisable state which 
does not fit the profile of RM cells that we describe here. Therefore analysis of gene 
expression cytokine synthesis and cytokine secretion is critical to identifying the full 
activation status of RM cells. Taken together this approach has identified a novel 
mechanism of regulating TLR tolerance at the level of secretion with RM cells 
retaining the ability to restore immune competency through regulation of cytokine 
secretion upon appropriate inflammatory challenge. 
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6. General Discussion 
The mammalian immune system comprises a complex network of innate and 
adaptive components including mucosal barriers, soluble factors and specialised 
immune cells that recognise noxious stimuli and mount powerful immune responses. 
While these responses are fundamental to host defence and protection, dysregulation 
of the inflammatory response is the central hallmark of immune deficient, 
autoimmune and chronic inflammatory conditions. Due to the costly pathological 
consequences of uncontrolled inflammation, TLR tolerance is pivotal in regulating 
TLR induced inflammation by preventing excessive and uncontrolled inflammation 
while also promoting the resolution of inflammation [2, 75, 242].  
Extensive research has been carried out in deciphering the regulation of TLR 
responses [29, 30, 32, 75] however the plasticity of this state has not been explored. 
Therefore the aims of this thesis were to investigate the regulation of TLR tolerance 
using two models of inflammation. Firstly, utilising a murine model of intestinal 
inflammation, the role of the negative regulator of TLR responses Bcl-3 was 
investigated to decipher its role in the regulation of microbial tolerance in the gut in 
addition to its contribution to the pathogenesis of intestinal inflammatory diseases. 
Secondly, a transcriptomics approach was employed to analyse the transcriptional 
plasticity of LPS tolerance in macrophages upon additional TLR exposure. 
Simultaneously, functional analysis of TLR tolerance plasticity led to the discovery 
of a novel mechanism regulating TLR responses involving inhibition of cytokine 
secretion through intracellular degradation.  
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Chapter 3 describes an in vivo study of intestinal inflammation utilising the DSS 
induced colitis model in mice deficient in Bcl-3. Bcl-3 is a nuclear member of the 
IκB family which binds only homodimers of the p50 or p52 NF-κB subunits. Since 
these subunits lack a transactivation domain they are associated with repression of 
NF-κB transcription [90]. Bcl-3 was originally identified in a subset of chronic 
lymphocytic leukaemia (B-CLL) patients containing a recurring t(14:19) 
chromosomal translocation [91, 92]. As a result Bcl-3 has since been implicated in 
cell survival and tumorigenesis [93-96]. Bcl-3 deficient T cells showed reduced 
survival while over-expression of Bcl-3 increased T cell survival [100-102]. Bcl-3 is 
a regulator of cyclin D1 and is important in cell cycle regulation. Over-expression of 
Bcl-3 has been shown to shorten the G1 phase of cell cycle in breast cancer epithelial 
cells which coincided with elevated cyclin D1 expression levels [96]. Furthermore, 
Bcl-3 also regulates HDM2, an inhibitor of p53 induced apoptosis by promoting its 
expression [103]. Bcl-3 plays a critical role in immunological development via 
negative regulation of autoreactive thymocytes in addition to altering T cell 
responses [104-106]. Recently Bcl-3 has been identified as a negative regulator of 
essential TLR induced responses [111] with Bcl-3
-/- 
cells and mice
 
demonstrating 
hyper-responsiveness to TLR stimulation. Additionally Bcl-3
-/-
 mice have 
demonstrated increased susceptibility to microbial infections with Klebsiella 
pneumoniae, Streptococcus pneumoniae and Listeria monocytogenes [68, 108, 111, 
112]. Importantly Bcl-3
-/- 
macrophages and mice show a lack of lipopolysaccharide 
(LPS) tolerance induction and increased susceptibility to LPS toxicity [111].  
Maintenance of a tolerant co-existence between the intestinal microbial community 
and the underlying mucosal immune cellular network is essential to promote tissue 
homeostasis. Preventing excessive and uncontrolled inflammation is critical in this 
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unique environment as unnecessary inflammation can lead to the development of 
severe chronic inflammatory conditions including Crohn’s disease and ulcerative 
colitis [131, 243]. Recently, a single nucleotide polymorphism (SNP) associated with 
reduced Bcl-3 gene expression has been identified as a potential risk factor for 
Crohn’s disease [170]. However, the role of Bcl-3 in regulation of intestinal 
inflammation and inflammatory bowel disease has not been investigated to date. 
Therefore we hypothesised that Bcl-3 may play a role in contributing to the 
regulation of the host immune and intestinal microbial interactions through 
maintaining a level of microbial tolerance between both groups. 
The study presented in chapter 3 identifies Bcl-3 as a negative regulator of intestinal 
epithelial cell proliferation during intestinal colitis which suggests additional 
physiological functions for Bcl-3 beyond its role as a negative regulator of pro-
inflammatory gene expression. Interestingly Bcl-3 deficient mice developed milder 
colitis than their WT litter mate control mice as determined by daily disease activity 
scoring. However upon further examination, we measured no differences in 
inflammatory scores between both WT and Bcl-3
-/- 
mice. Histological observations 
of significant oedema and leukocyte infiltration correlated with quantification of 
infiltrating leukocytes and pro-inflammatory mucosal gene expression which 
revealed equivalent inflammatory scores between both Bcl-3
-/-
 and WT groups. Of 
note, gene expression and histological analysis was performed at the experimental 
endpoint on day 8, a time point where WT mice demonstrated a more severe colitis 
phenotype than Bcl-3
-/-
 mice as determined by DAI scores. At this time point mice 
had stopped DSS treatment and the barrier of WT mice was severely disrupted as 
demonstrated by DAI scoring and histological analysis of distal colon tissue. 
However during DSS treatment up to day 6, DAI scores demonstrated that both WT 
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and Bcl-3
-/- 
mice displayed similar levels of inflammation, therefore there may have 
been increased inflammation during DSS treatment at an earlier time point that led to 
significant infiltration of leukocytes and cytokine production in Bcl-3
-/- 
mice. Thus 
analysis of gene expression and cellular infiltration at an earlier time point during 
DSS treatment would give additional information of the role of Bcl-3 in the 
induction of intestinal inflammation.  
These findings of reduced severity of DSS induced colitis in Bcl-3
-/- 
mice are in 
contrast to previous studies examining the role of additional TLR signalling negative 
regulators in DSS induced colitis. Both IRAK-M
-/- 
and SOC1
+/-
 mice revealed severe 
colitis induction in comparison to their WT counterparts [244, 245]. In addition 
microbial models of infection revealed a hyperresponsive state in Bcl-3 deficient 
mice [108, 112]. Klebsiella pneumoniae lung infection in Bcl-3
-/- 
mice resulted in 
increased lung damage, reduced bacterial clearance and subsequent dissemination of 
bacteria into the bloodstream. This study highlights the importance of Bcl-3 in 
regulation of lung inflammation through clearance of Gram negative bacteria [112]. 
Similarly, Schwarz et al demonstrated the importance of Bcl-3 in the clearance of 
Listeria monocytogenes infection with Bcl-3
-/- 
mice demonstrating a 2 fold enhanced 
bacterial load in their spleens when compared with their WT counterparts. 
Furthermore, this study showed that Bcl-3
-/- 
were highly susceptible to Streptococcus 
pneumoniae infection as a result of the lack of a competent humoral immune 
response required to fight and clear this Gram positive pathogen. As a result of a 
deficiency in Bcl-3, survival of mice was severely affected in comparison to WT 
infected mice [108]. 
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In support of our findings, the resistance of Bcl-3
-/-
 mice to experimentally induced 
colitis correlates with our analysis of Bcl-3 expression in the colon of IBD patients 
which was significantly increased when compared to healthy individuals. 
Histological analysis revealed intact epithelial structures within the colonic tissue 
architecture of Bcl-3
-/-
 mice. This corresponded with a significant enhancement in 
epithelial cell proliferation as determined by Ki67 immunofluorescence staining and 
suggests that the resistance of Bcl-3
-/- 
mice to DSS-induced colitis results from 
increased regeneration of the epithelium. Therefore it is possible that the identified 
SNPs [170] implicating reduced Bcl-3 levels as a potential IBD risk factor may lead 
to increased Bcl-3 expression rather than decreased expression as predicted. Thus, 
our findings suggest that increased expression of Bcl-3 rather than reduced 
expression may be a potential risk factor for IBD. Given that the proliferation of 
intestinal epithelial cells is normal in Bcl-3
-/-
 mice, it is likely that inflammation 
induced expression of Bcl-3 in the epithelium during colitis contributes to the 
development of disease. Furthermore, our data suggests that increased expression of 
Bcl-3 leads to reduced epithelial regenerative capacity and therefore may contribute 
to the development of IBD. Thus, by targeting Bcl-3 it may be possible to enhance 
epithelial cell proliferation and regeneration without exacerbating inflammation in 
the intestine. The potential therapeutic benefits to IBD are highlighted by the 
reduced clinical score and lack of weight loss in DSS-treated Bcl-3
-/-
 mice.  
This report suggests that targeting Bcl-3 in colitis may be therapeutically beneficial 
in IBD through increasing tissue regeneration and repair in the colon without 
exacerbating the inflammatory response. Therefore it would be interesting to further 
investigate the role of Bcl-3 in the pathogenesis of murine colitis using additional 
models of colitis. The model of DSS induced colitis was utilised in our study as this 
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model mimics intestinal inflammation in ulcerative colitis. Furthermore 
administration of DSS is of short duration and is technically straightforward with 
induction of colitis being highly reproducible. However human IBD is a 
heterogeneous disease and modelling IBD is complex in the mouse as no one model 
replicates that of human IBD. However the variety of genetic, chemical, T cell 
mediated and spontaneously induced colitis models provide significant insight into 
the different factors involved in the pathogenesis of IBD [65, 171, 172, 174].  
DSS induced colitis is a chemical model mediating destruction of the 
mucosal/epithelial barrier driving intestinal inflammation [173, 174]. However this 
model may not encompass important features of murine colitis and human IBD 
including bacterial induced colitis and T cell mediated intestinal inflammation. 
These important feature are studied in additional murine models of IBD including, 
TNBS and oxazolone induced colitis in addition to Citrobacter rodentium induced 
colitis [246, 247]. Therefore analysis of Bcl-3 deficiency in a bacterial induced 
colitis model such as Citrobacter rodentium or Salmonella typhimurium would 
provide significant insight into the role of Bcl-3 in response to pathogenic infections 
in the gut mediating intestinal inflammation. Furthermore a T cell model of murine 
colitis would provide additional insight into the role of Bcl-3 in the pathogenesis of 
IBD particularly when Bcl-3 has previously been shown to be involved in T cell 
responses [106]. We analysed Bcl-3 deficiency in an acute model of DSS induced 
colitis hence examination of epithelium regeneration and immunological responses 
during the chronic regenerative phase of DSS induced colitis would be important. 
This phase of the DSS induced colitis model represents a longer duration of 
intestinal inflammation and repair. This phase also consists of a different cellular 
population  infiltrating the colon with a change from that of a macrophage heavy 
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load during the acute phase to an T cell load from day 12 to 25 of the chronic phase 
of DSS induced colitis [172]. Therefore, owing to the role Bcl-3 plays in T cell 
responses [101, 106], examination of Bcl-3
-/- 
mice immune responses during the 
chronic DSS induced colitis phase would be of interest particularly due to the new 
role for Bcl-3 we identified in the regulation of epithelial cell proliferation in the 
colon. In addition, due to the importance of an intact epithelial barrier in the 
regulation of inflammation in the gut, a study of barrier function by measuring serum 
FITC levels of Bcl-3
-/- 
mice fed with FITC dextran [178] and Ki67 staining of the 
intestinal epithelium throughout the study duration would be important. Furthermore 
analysis of barrier function using these strategies in additional chemical models of 
colitis including TNBS and Oxazolone induced colitis which result in intestinal 
epithelial destruction, in addition to bacterial models of colonic hyperplasia induced 
in the Citrobacter rodentium induced colitis model would be important to provide 
further insight into the role of Bcl-3 in the regulation of epithelial regeneration 
during intestinal inflammation [246, 248]. Importantly, investigation of the 
molecular mechanisms involved in regulation of intestinal epithelial cells by Bcl-3 is 
merited. Bcl-3 is a multifaceted member of the atypical IκB family of regulators of 
NF-κB activation therefore, Bcl-3 may transcriptionally repress NF-κB target genes 
involved in resolution of inflammation to prevent regeneration of the intestinal 
epithelium during colitis or in human IBD. 
In this study we identified Bcl-3 as a negative regulator of intestinal epithelial cell 
proliferation. Given that Bcl-3 is a putative oncogene and a regulator of cyclin D1 
[92, 96, 196], we were surprised that Bcl-3 deficiency resulted in increased epithelial 
cell proliferation. In support of our findings Bcl-3 expression has been associated 
with colorectal cancer [249]. Furthermore enhanced epithelial cell proliferation in 
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the colon has been shown to be protective against colitis associated cancer [250]. 
However given the role of Bcl-3 in tumorigenesis [91, 95, 97], further studies to 
investigate the implications of Bcl-3 deficiency in the development of colitis 
associated cancer are merited. Collectively, we have shown that increased Bcl-3 is a 
potential risk factor in IBD which may be involved in regulating regeneration of the 
epithelium. Thus future studies will provide a significant opportunity to target Bcl-3 
therapeutically. 
The work carried out in chapter 4 and 5 of this thesis represents an ex vivo study of 
TLR tolerance using LPS to investigate the plasticity of TLR tolerance in 
macrophages. Macrophages are professional phagocytes with important 
physiological and metabolic roles however these cells are also essential mediators of 
inflammation and central to host defence. [127]. This range of biological roles is 
reflected in an emerging spectrum of macrophage activation states largely focused 
around the M1 pro-inflammatory /M2 anti-inflammatory classification system. M1 
macrophages are mainly recruited under inflammatory conditions such as bacterial or 
viral infections. These cells are highly cytotoxic, produce high levels of pro-
inflammatory cytokines and are powerful activators of Th1 adaptive immune 
responses. In contrast, M2 macrophages are anti-inflammatory cells important in 
wound healing, tissue remodelling and parasitic infections [127, 135, 136, 140, 212]. 
Regulatory macrophages are immune regulatory cells that display both anti-
inflammatory and pro-inflammatory features through suppression of some pro-
inflammatory genes and increased production of IL-10, while maintaining antigen 
presenting capacity. Immune complexes in conjunction with TLR activation in 
addition to other stimuli including glucocorticoids, prostaglandins and apoptotic 
cells have been implicated in regulatory macrophage polarisation. While regulatory 
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macrophages are distinct from both M1 and M2 macrophages, these cells share some 
overlapping anti-inflammatory properties with M2 cells [127]. These three 
macrophage populations represent the main groups in the emerging spectrum of 
macrophage polarisation however many hybrid macrophage activation states exist 
owing to the large number of activation stimuli that macrophages encounter in vivo. 
Tumour associated macrophages, intestinal macrophages, liver Kupffer cells, 
placental macrophages and LPS tolerised macrophages are described as representing 
hybrid macrophage populations which share overlapping M1/M2 and regulatory 
properties while expressing distinct features unique to their polarisation state and the 
microenvironment where they reside. [127, 135, 152-155, 163]. 
Using a model of acute LPS responses in murine BMDMs, we demonstrated that 
LPS tolerance is a transient transcriptional immunological state with recovery from 
LPS tolerance promoting a global switch in the gene expression profile of 
macrophages. Bioinformatics analysis revealed a large shift in macrophage gene 
expression with correspondence analysis (COA) initially revealing transcriptional 
overlap between macrophages of the acute LPS response (A) and RM cells. The 
expression of many pro-inflammatory genes in RM cells was inducible at levels 
comparable to the acute response group (A). However further examination of 
correspondence analysis data (PC4) revealed that the acute response group (A) did 
not fully overlap with RM cells which confirmed a unique transcriptional profile in 
RM cells. In addition RM cells displayed some transcriptional features of LPS 
tolerant cells. These included suppression of co-stimulatory molecules and genes 
involved in regulation of antiviral responses despite restoration of cytotoxic capacity 
in RM cells as determined by NOS2, CD86 and type 1 interferon expression. 
Importantly this data emphasised that LPS tolerance is a plastic transcriptional state 
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in macrophages resulting in induction of a previously un-described hybrid 
macrophage activation state with a unique transcriptional signature distinct from M1 
and M2 polarisation states.  
M1 and M2 classification of macrophage polarisation is largely based upon in vitro 
studies and therefore does not aptly describe the physiological polarisation states of 
macrophages. Tissue resident macrophage polarisation is largely influenced by the 
specific microenvironment they reside in and therefore these physiological 
phagocytes adopt a hybrid phenotype. In addition inflammatory macrophages 
recruited to sites of infection are also polarised into different activation states 
dependent on the specific environmental stimulus, largely focused around M1 and 
M2 states however many overlapping hybrid states exist [127]. Therefore re-
addressing macrophage polarisation states under physiological conditions is merited. 
Our data demonstrates that LPS tolerance is a transcriptionally regulated plastic state 
in macrophages with recovery from this state polarising macrophage into a unique 
immune primed hybrid state which may mimic a macrophage phenotype post 
microbial infection in vivo.  
Secretion of cytokines and chemokines during infection or injury is fundamental to 
mounting an effective and tailored immunological response [2, 221]. These key 
immuno modulatory proteins initiate immune cell recruitment in addition to 
modulating immune cellular functions and expansion of adaptive immune cell 
populations to fight and clear infection thereby restoring immune and tissue 
homeostasis [2, 3]. Despite these proteins playing a fundamental protective 
immunological role, excessive production of cytokines and chemokines underlies the 
pathology of many chronic inflammatory and autoimmune diseases ranging from 
rheumatoid arthritis to IBD [221-224, 251]. During LPS tolerance the potentially 
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deleterious effects of pro-inflammatory cytokine secretion are suppressed 
transcriptionally through induction of negative regulators of TLR signalling and 
TLR induced gene transcription in addition to epigenetic chromatin modelling [30, 
32, 75]. As described in chapter 4 recovery from LPS tolerance restored gene 
expression of a large proportion of tolerisable genes including pro-inflammatory 
cytokine and chemokines.  
The data presented in chapter 5 re-enforces the highly plastic nature of macrophage 
transcriptional responses with RM cells displaying inducible mRNA levels of these 
cytokines including TNF-α, IL-6 and CXCL10. Further examination revealed 
however that TNF-α secretion was un-coupled from protein synthesis. We measured 
increased intracellular TNF-α in RM cells which confirmed that the protein was 
actively translated and TNF-α was not subject to post transcriptional regulation of its 
mRNA through ARE (adenine/uridine rich elements) dependent regulation of mRNA  
stability [238]. In contrast cytokine secretion remained suppressed in RM cells 
suggesting that TNF-α was being alternatively trafficked within the cell towards a 
storage or degradative compartment. To decipher the regulatory mechanism involved 
in inhibiting TNF-α secretion, RM cells were treated with a panel of intracellular 
enzyme inhibitors to investigate if TNF-α was being degraded by a particular 
enzyme family. Treatment with inhibitors of intracellular proteases including 
pepstatin A, in addition to a calpain inhibitor and cathepsin B inhibitor did not 
restore TNF-α secretion in RM cells. However, treatment of RM cells with 
bafilomycin A, a known inhibitor of autophagy and vacuolar type H
+
ATPase which 
inhibits acidification of cellular compartments including lysosomes and endosomes 
led to increased TNF-α protein trafficking through the Golgi compartment and 
restoration of TNF-α secretion in RM cells. Bafilomycin A restoration of TNF-α 
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secretion confirmed that TNF-α protein was being trafficking to a bafilomycin A 
sensitive compartment where it was potentially being degraded in an autophagy 
dependent manner.  
Autophagy is an evolutionarily conserved process important in maintaining cell and 
tissue homeostasis through removal of cellular proteins and organelles by targeting 
them for degradation within lysosomes while recycling cellular energy and nutrients 
[231, 232]. Autophagy is a physiological host response and has also been shown to 
be important in controlling cytokine secretion by regulating inflammasome 
activation targeting pro-IL-1β for caspase 1 cleavage and subsequent production of 
mature IL-1β protein [231, 233]. In addition, autophagy has been shown to be 
important in regulating IL-23 secretion through the regulation of the IL-1 family of 
cytokines [232, 234]. Atg16L1 is an important component of the autophagy 
apparatus with Atg16L1 deficiency demonstrating defective recruitment of the 
Atg12-Atg5 complex resulting in inhibition of autophagosome formation [235]. 
Atg16L1 has also been shown to being important in regulating LPS induced IL-1β 
secretion in BMDMs [72].  
Regulation of IL-1β cytokine secretion has previously been shown to be regulated in 
an autophagy dependent manner with cleavage of pro-IL-1β occurring within the 
autophagosome intracellular compartment [233]. While regulation of TNF-α 
secretion under normal classical TLR induced inflammation is distinct from that of 
inflammasome regulated secretion of IL-1β [231, 233, 252], we postulated that the 
suppressed cytokine secretion profile in RM cells may be regulated in an autophagy 
dependent manner, independent of the classical secretory route for TNF-α via the 
trans Golgi network to the cell surface via the phagocytic cup [253-256]. Based upon 
this hypothesis and our findings that bafilomycin A restored TNF-α secretion in RM 
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cells, we measured TNF-α secretion in Atg16L1-/- BMDMs [175]. Despite a robust 
increase in TNF-α mRNA and protein levels within macrophages in all LPS 
stimulated groups (A, T and R), this did not restore TNF-α secretion in RM cells. 
This data suggested that the block in TNF-α cytokine secretion in RM cells is 
independent of autophagy but dependent on a bafilomycin sensitive degradative 
process. This was further supported by treatment of RM cells with monensin, an 
inhibitor of endosomal and lysosomal acidification [257] which demonstrated 
increased levels of TNF-α detected within the Golgi in RM cells, similar to 
bafilomycin A treatment of RM cells. This data demonstrates that cytokine secretion 
is a regulated process and that cytokine synthesis does not lead to cytokine secretion 
in RM cells. Collectively this data suggests that recovery from LPS tolerance 
regulates inflammation through altering TNF-α trafficking towards a lysosomal 
degradative pathway that is independent of autophagy and intracellular acidic 
proteases, calpain and cathepsin B enzyme degradation.  
A recent study has demonstrated the plasticity of dendritic cells to respond to an 
independent inflammatory signal despite developing reduced responsiveness towards 
LPS as measured by suppressed pro-inflammatory cytokine secretion [258]. Abdi et 
al revealed that these “exhausted” (LPS tolerised) dendritic cells retained 
responsiveness toward specific inflammatory signals such as activated T cells 
including CD40L. This study demonstrated that LPS tolerised dendritic cells were 
primed to respond to an adaptive immune signal suggesting that that TLR tolerance 
is a plastic state in dendritic cells [258].  Based upon this theory, we hypothesised 
that regulation of cytokine secretion in RM cells may be controlled by an 
independent secondary signal including a secondary opportunistic microbial 
infection or activation of the inflammasome complex. Treatment of RM cells with an 
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additional independent inflammatory signal including IL-1β and additional TLR 
ligands (Pam3CSK4 and CpG) restored cytokine secretion in RM cells. In contrast to 
the study performed by Abdi and colleagues [258], CD40L co-stimulation with LPS 
of RM cells did not restore TNF-α secretion suggesting that restoration of cytokine 
secretion is stimulus specific in RM cells. This data implies that RM cells are primed 
to respond to secondary signals but require an additional activation signal to restore 
full activation capacity.  
Recent studies have demonstrated a role for the multiprotein inflammasome complex 
in the regulation of inflammatory responses in intestinal phagocytes through NLRC4 
driven IL-1β production [228]. Franchi et al demonstrated that CD11b positive 
intestinal phagocytes (iMPs) were anergic to TLR stimulation as determined by IL-6 
and TNF-α secretion however these cells produced high levels of pro-IL-1β [228]. 
Upon pathogenic infection with Salmonella or Pseudomonas species NLRC4 drives 
mature IL-1β production which in turn orchestrates the inflammatory response to 
these infections in the intestine [228]. Interestingly, we identified that IL-1β co-
stimulation with LPS restored TNF-α secretion in RM cells suggesting that 
activation of the inflammasome complex may switch TNF-α trafficking within RM 
cells from that from a lysosomal compartment to directly trafficking to the cell 
surface for enzymatic cleavage and subsequent secretion. Discrimination between 
pathogenic and commensal bacteria is regulated by the NLRC4 inflammasome 
[228], thus inflammasome activation in RM cells upon exposure to specific 
pathogenic stimuli in vivo may represent a potential mechanism for restoring 
cytokine secretion through increased production of IL-1β by RM cells.  
IL-1β signalling is a potent activator of pro-inflammatory cytokine and chemokine 
transcription and subsequent secretion in response to inflammatory stimuli. TNF-α 
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protein is trafficked in macrophages through a classical secretory route through the 
Golgi and trans-Golgi network where it is then delivered to recycling endosomes and 
subsequently to the phagocytic cup at the cell surface where it is cleaved into its 
mature form by the enzyme TACE [229, 253-256]. IL-1β autocrine signalling 
resulting from inflammasome activation in RM cells may drive TNF-α protein 
trafficking in RM cells back to the classical secretory route as described above. 
Investigation of the potential mechanism of IL-1β modulating TNF-α trafficking 
from an alternative degradative route to the classical secretory route is essential and 
requires functional trafficking analysis of TNF-α protein which is beyond the scope 
of this thesis. However, inflammasome activation of IL-1β production may play an 
important role in the regulation of cytokine secretion following recovery from LPS 
tolerance particularly when a similar observation was described in intestinal 
phagocytes capacity to discriminate between pathogenic and commensal bacteria.   
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Figure 6. 1: Proposed mechanism of regulation of TNF-α secretion in RM cells 
(A) Classical intracellular trafficking of TNF-α from gene transcription to protein synthesis and 
delivery to the cell surface for enzymatic cleavage within the phagocytic cup. (B) Proposed 
alternative trafficking of TNF-α protein from the golgi to lysosomes for degradation of protein in RM 
cells. (C) Proposed mechanism of restored TNF-α secretion in RM cell upon IL-1β and LPS co-
stimulation following inflammasome activation and cleavage of pro-IL-1β. Co-stimulation of RM 
cells with LPS and IL-1β restores TNF-α secretion through directing TNF-α trafficking back towards 
the classical TNF-α trafficking route to the cell surface. RM = recovered macrophage, M1 = acute 
response to LPS. Arrow represents the direction of TNF-α trafficking within cells. 
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The variety of chronic inflammatory and immunosuppressive conditions associated 
with dysregulated cytokine and chemokine production demonstrates the importance 
of tight regulation of cytokine secretion following acute inflammatory responses. 
Recently suppression of TNF-α secretion has been observed in macrophages isolated 
from Crohn’s disease (CD) patients [226]. Interestingly, Smith et al demonstrated 
similar findings to the TNF-α secretion data in RM cells with translated TNF-α 
protein found within CD macrophages despite reduced protein secretion. Lysosomal 
degradation of cytokines was implicated in suppressing cytokine secretion in CD 
macrophages [226]. This study provides patho-physiological evidence for post 
translational regulation of cytokine secretion however whether suppressed cytokine 
secretion is a pathophysiological consequence of CD remains to be determined. 
Suppression of secreted TNF-α through neutralising of secreted protein with TNF-α 
targeting antibodies (infliximab and adalimuab) is a widely utilised therapeutic 
strategy used in the treatment and management of inflammation in RA and IBD 
patients [221, 222, 259, 260]. Therapeutic strategies mediating suppression of 
cytokine responses further indicates that suppression of cytokine secretion in RM 
cells under non chronic inflammatory pathologies may represent a physiological 
immune response post microbial tolerance induction with secretion restored upon 
specific inflammatory signals such as pathogenic infections. This is further 
supported by reduced secretion of pro-inflammatory cytokines in lamina propria 
macrophages under normal physiological conditions where they are constantly 
exposed to the intestinal microbial community. Furthermore, germ free mice have 
been shown to secrete increased levels of pro-inflammatory cytokines upon 
inflammatory challenge suggesting that suppressed secretion of cytokines regulates a 
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level of tolerance between the intestinal commensal microbial community and the 
underlying immune cellular network [162, 228]. 
Septic shock results from dysregulation of inflammatory responses mediated through 
an initial inflammatory phase followed by an immunosuppressive state in patients. 
This immunosuppressive phenotype observed in sepsis renders these patients more 
susceptible to developing secondary opportunistic infections which can have a 
significant effect on patient morbidity and mortality. In contrast to non-survival 
cases of septic shock, monocytes isolated from patients that recovered from this 
immunosuppressive septic state demonstrated restoration of cytokine secretion upon 
LPS challenge [117, 159] suggesting that survival may be attributed to restoration of 
immune competency. Our observations of restored immune competency in RM cells 
through restoration of cytokine secretion upon IL-1β or TLR treatment supports our 
hypothesis that regulation of cytokine secretion post tolerance is a important 
physiological response in the regulation of inflammation. This further suggests that 
cytokine suppression following inflammatory insult and post microbial tolerance 
may represent a unique level of regulation of inflammation.  
Chapter 4 and chapter 5 demonstrate the highly plastic nature of LPS tolerance with 
recovery from such state important in restoring immune competency which is 
regulated post translationally through modulation of cytokine secretion. This may 
represent an important physiological response in macrophages not only in response 
to LPS but to microbial infection. Therefore it would be beneficial to apply this 
model of recovery from LPS tolerance to additional inducers of TLR-induced 
inflammation including ligands representing Gram positive bacteria including 
peptidoglycan and Pam3CSK4. It would be particularly interesting to investigate the 
polarisation profile of RM macrophages following stimulation with viral associated 
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ligands in addition to viral infection of RM cells as these cells display alterations in 
regulators of anti-viral responses. 
Macrophages perform a diverse range of fundamental physiological and 
immunological roles to maintain tissue homeostasis therefore analysis of some of 
these functions in RM cells merits further investigation. Firstly, alterations in the 
patterns of expression of regulators involved in interaction with T cells e.g CD86 
suggested that interaction with adaptive immune cells is suppressed in RM cells 
similar to that observed during LPS tolerance. Therefore functional analysis of 
antigen presenting capacity would be interesting to measure in vivo by performing a 
mixed lymphocytic reaction. Recently, macrophage polarisation was shown to 
influence natural killer cell responses with endotoxin tolerant macrophage unable to 
induce NK cell activation [261]. Thus, it would be particularly be interesting to study 
the functional outcomes of NK cell polarisation by RM cells.  
Finally analysis of TLR tolerance plasticity needs to be investigated further in vivo to 
gain a greater understanding of the physiological relevance of this state under both 
homeostatic and pathophysiological conditions. Ueda el at demonstrated that colonic 
macrophages are hyporesponsive towards TLR stimulation with IL-10 production 
central to controlling reduced secretion of inflammatory cytokines including IL-6 
and TNF-α [162]. In addition, this study demonstrated that STAT3 and IL-10 
deficient mice were hyperresponsive to LPS with increased TNF-α and IL-6 
secretion measured in colonic macrophages [162]. In Chapter 4 we measured 
increased phosphorylated STAT1 and STAT3 in both LPS tolerant (T) and RM cells 
suggesting that these transcription factors may play a role in regulation of cytokine 
secretion in RM cells. A recent study has characterised colonic macrophage 
populations under steady state and inflammatory conditions [227]. This study 
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demonstrated that resident colonic macrophages were responsive toward TLR 
challenge with mRNA and intracellular TNF-α protein increased in these cells [227]. 
While TNF-α secretion was not measured in these cells, previous studies by Franchi 
et al [228] and Ueda et al [162] measured no secretion of TNF-α or IL-6  upon TLR 
stimulation. These two studies isolated colonic macrophages using CD11b MACS 
separation or CD11b flow cytometry cell sorting. However, Bain et al describe a 
novel isolation protocol for resident colonic macrophages using a panel of colonic 
macrophage specific markers [227]. As a result, it would be important to measure 
cytokine production from these cells upon TLR challenge to confirm suppressed 
cytokine secretion identified in these previous studies. Taken together these studies 
correlate with the suppressed cytokine secretion findings in RMs of this study 
suggesting that TLR tolerance may also be regulated at the level of cytokine 
secretion under physiological conditions such as that of the intestine. Based on 
functional analysis of cytokine secretion in RM cells, lysosomal degradation of 
intracellular TNF-α protein may represent a potential mechanism suppressing 
cytokine secretion in colonic macrophage populations under physiological conditions 
in response to the intestinal microbiota.  
These studies highlight the importance of measuring both cytokine secretion and 
mRNA levels to determine the activation status of cells. LPS tolerance results from 
transcriptional repression of pro-inflammatory gene expression and subsequent 
suppression of cytokine synthesis and secretion [75]. Measurement of restored 
mRNA levels of tolerisable cytokines including TNF-α alone would suggest that 
recovery from LPS tolerance restored inflammatory potential of macrophage to 
levels comparable with LPS M1 macrophages. Measurement of cytokine secretion 
by ELISA alone would suggest that RM cells remain in a LPS tolerisable state which 
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does not fit the profile of RM cells that we describe here. Thus, analysis of gene 
expression, cytokine synthesis and cytokine secretion is central to identifying the 
activation status of RM cells. Furthermore, using this strategy we identified a novel 
mechanism of regulation of TLR tolerance independent of mRNA regulation, 
through lysosomal degradation of synthesised TNF-α protein resulting in inhibition 
of TNF-α secretion. 
The findings of this thesis demonstrate that LPS tolerance is a highly plastic 
physiological response towards microbial challenge. We have identified a novel 
physiological role for Bcl-3 as a negative regulator of intestinal epithelial cell 
proliferation during intestinal colitis distinct from its essential role in the negative 
regulation of TLR induced inflammatory responses. Furthermore, the plasticity of 
the LPS tolerant state resulted in polarisation of macrophages to a distinct activation 
state with a unique transcriptional signature. In addition identification of this unique 
macrophage population led to a novel insight into the regulation of inflammation at 
the level of cytokine secretion. Collectively this thesis provides significant insight 
into the plasticity and regulation of TLR tolerance which provides solid groundwork 
for downstream physiological analysis and subsequent understanding of the 
pathophysiology of chronic inflammatory diseases. 
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Appendix 1 
Cytokine antibody Array 
 
 
 
 
 
 
 
 
 
264 
 
Appendix 2  
Cytokine antibody array layout 
 
 
 
 
